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With an increasingly ageing population, the prevalence of neurodegenerative 
diseases (NDDs) is set to rise. Diagnosis is still currently limited to clinical 
assessment and treatment options remain ineffective. Iron is thought to play a role 
in the progression of NDDs due to increased levels being discovered in the brain 
regions most affected by the specific disorders and exacerbating the loss of 
neurons, likely through oxidative stress mechanisms. Therefore, this research 
investigates magnetic resonance imaging (MRI) relaxometry methods to non-
invasively and accurately, detect and quantify iron during neurodegeneration and 
to understand the role of iron-induced toxicity for neuronal death. This work is the 
first to link iron assessment using MRI in an in vitro model with ex vivo post-mortem 
tissue and in vivo assessment of iron, as well as providing further validation of 
inconclusive and conflicting studies evaluating differences in iron content in 
neurodegenerative disease pathology. 
The accuracy of iron content measured using MRI relaxometry was assessed using a 
variety of model systems; ranging from the use of agarose standards, post-mortem 
human brain samples, and an in vivo animal model of iron-toxicity. Agarose 
standards containing different concentrations of iron demonstrated that iron 
linearly correlated to R1, R2 and R2*. This was the case for both ferrous and ferric 
iron forms, however ferric iron had a greater effect than ferrous iron. Human post-
mortem brain tissue from the medial temporal gyrus (MTG) was then taken from 
control and Alzheimer’s disease (AD) subjects and assessed by MRI relaxometry. 
The MTG is one of the brain regions affected in AD and contains both white (WM) 
3 
 
and grey matter (GM). Iron content was determined using synchrotron radiation X-
ray fluorescence (SR-XRF) elemental mapping, a quantitative measure of iron 
content rather than using Perl’s stain, a qualitative method of iron localisation. R2* 
correlation to iron content was strongest in both control and AD tissue, and was 
more sensitive within GM than in WM. Subsequent myelin assessment of brain 
samples using luxol fast blue demonstrated the effect of myelin content on iron-
relaxometry correlations.  Myelin was detectably lower in AD WM than control WM 
tissue, and contributed to an improved correlation of iron content to R2* 
measurements in AD samples. Finally, validation of iron content correlation to MRI 
relaxometry measurement was performed in vivo using a novel animal model by 
direct injection of ferric citrate into the mouse hippocampus. R2* and R2’ provided 
the best method for detection of injected iron ex vivo, however no changes were 
observed in vivo after 10 days recovery due to conflicting signals from iron content 
and oedema. Greater levels of neuronal cell death and neuroinflammation were 
associated with the presence of iron in the brain, confirming the contribution of 
iron to toxicity.  
Overall, this work improves our understanding of the relationship of iron to 
relaxometry measurement and the impact of myelin on such measurements. The 
work also confirms that the presence of high amounts of iron in the brain can lead 
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The World Health Organisation (WHO) recently reported that 36.5 million people 
worldwide currently have dementia, the most common manifestation of 
neurodegeneration (WHO, 2012). With globally ageing populations, especially in 
developing countries (Alzheimer's Disease International, 2013), neurodegenerative 
diseases represent a growing health and economic challenge, with approximately 
7.7 million new cases each year (WHO, 2012). It is expected that the number of 
patients with dementia will double to 65.7 million by 2030 and triple to 115.4 
million by 2050 (WHO, 2012). In the UK, over 800,000 people have been diagnosed 
with dementia and by 2051, this figure is set to exceed 2 million patients 
(Alzheimer's Society, 2014a). 
Not only are there huge numbers of patients and families that will be affected by 
the debilitating features of dementia and neurodegenerative diseases, but huge 
economic burdens are placed on countries to deal with dementia sufferers, with 
economic impact at £26.3 billion annually in the UK alone (Alzheimer's Society, 
2014a). This is equivalent to approximately £30,000 annually per patient, with only 
one third of these costs coming from the government (Alzheimer's Society, 2014a). 
The total cost of care for neurodegenerative diseases globally in 2010 was around 
$604 billion (Alzheimer's Disease International, 2010). 
Furthermore, these diseases have huge emotional and financial effects on the 
family members and caregivers of those with dementia, as they have limited 
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support to help provide sufferers with continued good quality of life (Alzheimer's 
Society, 2014b).  
No therapeutics currently exist that have been demonstrated to either prevent or 
cure neurodegenerative disorders, which include certain forms of dementia, let 
alone to recover lost capabilities (Alzheimer's Association, 2014). Treatment 
strategies currently in place are predominantly aimed towards alleviating symptoms 
(see section 1.2.6). More concerning, is the lack of understanding of the precise 
cellular and molecular causes of neuronal cell death that occur in 
neurodegenerative diseases. In part, this limited understanding of disease 
progression, has led to inaccurate assessments and biomarkers for the diagnosis of 
patients with dementia, such as Alzheimer’s disease (AD), with pre-symptomatic 
diagnosis of patients still not currently possible. Moreover, with patients only being 
diagnosed towards the end stages of disease, with greater levels of 
neurodegeneration, the window for successful therapeutic intervention is 
substantially reduced. As such, there is a pressing need to identify and stratify at-
risk individuals earlier during disease progression, prior to the memory impairments 
characteristic of disease, as well as gaining a greater understanding of the precise 
molecular changes occurring in order to develop effective therapeutics. 
My own interests lie in gaining both an understanding of the causative roles of 
neurodegeneration across multiple disorders and in the validation of methods for 
detecting and predicting their appearances within the population earlier during 
disease progression. Assessment of potential causative changes between normal 
and neurodegenerative disease patients may lead to the identification of certain 
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characteristics that may not only play roles in the underlying pathology, but may be 
directly measureable as an early diagnostic biomarker. 
The basis of this thesis therefore revolves around the hypotheses that there is a 
consistent, causative change in multiple neurodegenerative diseases due to metal 
ion dyshomeostasis, such as iron, in the brain. A role for iron during 
neurodegenerative diseases has been hypothesised since the 1950s when it was 
discovered that non-haem iron content increases in the brain during the normal 
ageing process. An increase in iron is found in the cortex, globus pallidus, putamen 
and substantia nigra up to approximately 40 years of age, at which point, the levels 
plateau (Hallgren and Sourander, 1958). Whilst there is a plateau in iron content 
during normal ageing, it was identified that this non-haem iron content was further 
increased in certain cell types within regions of the cortex of Alzheimer’s disease 
patients (Goodman, 1953, Hallgren and Sourander, 1960). Since then, it has also 
been demonstrated that increased iron content can be detected in the substantia 
nigra of Parkinson’s disease (PD) patients above that of healthy controls (Dexter et 
al., 1987, Dexter et al., 1989, Hirsch et al., 1991). Subsequently, studies of other 
neurodegenerative diseases have shown changes in iron content related to 
pathology. These diseases include Multiple Sclerosis (MS) (Craelius et al., 1982, 
Adams, 1988, LeVine, 1997), Huntington’s Disease (HD) (Dexter et al., 1991, 
Bartzokis et al., 2007b, Chen et al., 2013), as well as Amyotrophic Lateral Sclerosis 
(ALS) (Kasarskis et al., 1995). Given that the localisation of iron content changes in 
the brain seems to be regionally and pathologically relevant to each of the specific 
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diseases, iron, along with other trace metals have been hypothesised to play 
causative roles during neurodegeneration. 
With the non-invasive assessment of iron being possible using magnetic resonance 
imaging (MRI) methods, this thesis specifically focusses on the possibility for the 
quantitative detection of iron using MRI for potential clinical diagnosis during AD. 
Furthermore, the role of iron during neurodegeneration is also evaluated within the 
work of this thesis. 
 
1.2. Alzheimer’s Disease 
1.2.1. AD pathology 
Alzheimer’s disease (AD), first described in 1907 by Alois Alzheimer (Alzheimer, 
1907), involves the gradual loss of neurons throughout the brain, especially within 
the cortical and hippocampal regions. This loss of neurons causes a gradual decline 
in cognitive functioning, leading to semantic and spatial memory loss (Hodges and 
Patterson, 1995, de Toledo-Morrell et al., 2000), as well as mood and anxiety 
alterations (Chen et al., 2000). 
AD progression can be broadly characterised into three stages (WHO, 2012). In the 
first and earliest stage, patients become forgetful of things that have just 
happened, can get lost in familiar places and can show mood changes with lower 
motivation and activity levels (WHO, 2006). This is largely due to pathology 
affecting neurons in hippocampus (Hyman et al., 1984, Ball et al., 1985), amygdala 
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(Emre et al., 1993) and in the entorhinal cortex (Van Hoesen et al., 1991). In the 
middle stage of disease, pathology becomes clearer to identify, with patients 
becoming very forgetful of recent events and names, and becoming lost at home or 
in familiar places (WHO, 2006). Some speech and language difficulties can occur, 
signifying greater atrophy of the medial temporal lobe (Smith et al., 1986, Krasuski 
et al., 1998), which is involved in semantic and language functions. Furthermore, 
continued degeneration of the hippocampus, amygdala and entorhinal cortex 
occurs. The final stage requires full time care of patients, with almost complete loss 
of awareness and aggressive mood changes (WHO, 2006). 
A prodromal stage between normal ageing and Alzheimer’s disease has recently 
been conceptualised identifying patients with Mild Cognitive Impairment (MCI), 
where patients exhibit a greater degree of memory loss than in normal ageing, but 
not yet to the point for clinical diagnosis of dementia (Petersen, 2004, Gauthier et 
al., 2006, Petersen et al., 2009). MCI has been described as a precursor stage 
towards AD, due to the high propensity of patients that progress from MCI to AD 
later in life (Bozoki et al., 2001). However, conversion to AD will not occur in all 
patients or within the same timeframes (Morris et al., 2001). Furthermore, similar 
pathological hallmarks are found in post mortem tissue of MCI patients as with AD, 
with increased β-amyloid and tau protein deposits compared with control patients 
(see section 1.2.2), and cognition correlating to neurofibrillary tangle (NFT) burden 
(Guillozet et al., 2003). However, this is still to a lesser extent than AD itself 
(Petersen et al., 2006). 
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Whilst there are limitations in understanding the causative processes and time 
scales for MCI conversion to AD, ultimately, this period represents an important 
interval to treat patients with novel therapeutic strategies or to evaluate novel 
biomarkers for assessment of the conversion into AD, given that MCI may be the 
earliest identifiable indicator of dementia. 
Whilst the brain regions showing greatest atrophy during AD progression have been 
elucidated, (as described above) along with a growing understanding of some of the 
molecular processes that occur during pathology; namely that of the two major 
hallmarks of AD, β-amyloid plaques and tau neurofibrillary tangles, (see section 
1.2.2.1 and 1.2.2.2), the fundamental cause of neuronal cell death in AD, or any 
other neurodegenerative disease, has yet to be elucidated. There are two main 
hypotheses for the cause of neurodegeneration in AD, focussed on accumulation of 
β-amyloid and tau neurofibrillary tangles (see section 1.2.2), and the relatively 
recent hypothesis focussed on metal dysregulation (see section 1.2.3). These 
hypotheses however, are mechanistically not exclusive, and demonstrate 
considerable overlap.  
 
1.2.2. Protein accumulation 
Many of the most common neurodegenerative diseases involve accumulation of 
protein aggregates either intra- or extra-cellularly, as the major hallmarks of 
pathology on post-mortem examination of brain tissue (see review by Ross (Ross 
and Poirier, 2004)). In AD, extracellular senile plaques and intracellular 
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neurofibrillary tangles (NFT) are detected, comprised of β-amyloid and tau proteins 
respectively (see review by Selkoe (Selkoe, 2004)). Similarly, Parkinson’s disease 
patients display α-synuclein aggregates (Baba et al., 1998, Spillantini et al., 1998), 
Huntington’s disease patients display Huntingtin aggregates (Scherzinger et al., 
1997) and Creutzfeldt-Jakob disease (CJD) patients develop prion protein 
aggregates (Prusiner et al., 1998). Whilst the causes behind these protein 
aggregations are yet to be fully understood, all have been implicated with 
enhanced neuronal cell death. 
 
1.2.2.1. β-amyloid plaques 
β-amyloid plaques are one of the primary hallmarks of AD pathology. The protein 
itself, as well as the regulatory processes surrounding its expression, has been the 
predominant focus of research efforts to date. The aggregation product is formed 
from a strong, insoluble β-sheet structure, comprised of accumulated oligomers 
from the amyloid precursor protein (APP) cleavage products. Whilst the specific 
function of APP remains elusive, the processing steps involved in the formation of 
the β-amyloid product have been well defined (see review by O’Brien (O'Brien and 
Wong, 2011)).  
The APP protein is a single transmembrane protein that is trafficked onto the 
extracellular membrane of neurons from the Golgi apparatus. Here, the APP protein 
can be variably cleaved, first by either α- or β-secretase, and then by γ-secretase 
(Figure 1-1) (Cole and Vassar, 2008). APP cleavage by the β-secretase BACE1 (Beta-
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site APP-cleaving enzyme 1), allows for the formation of the amyloidogenic form of 
the β-amyloid (Aβ) protein comprised in plaques, Aβ1-42 (Figure 1-1B). A secreted 
product of the APP protein is also released as part of BACE1 cleavage, termed 
APPsβ (Vassar, 2004). The γ-secretase, comprised of the four essential subunits, 
presenilin 1 or 2 (PS-1, PS-2), nicastrin, APH-1 and PEN-2, normally produces 
predominantly non-amyloidogenic Aβ form of Aβ1-40, however cleavage of the 
slightly longer Aβ1-42 leads to the form predominantly found accumulated in AD 
plaques (Thinakaran and Koo, 2008). 
 
Figure 1-1 Amyloid processing pathways 
Different cleavage products can be formed through alternative APP processing. (A) 
Formation of APPsα and p3 via initial α-secretase cleavage of APP, whilst (B) APPsβ 
and Aβ are formed following β-secretase (BACE1) cleavage of APP. Adapted from 




Genetic mutations within the APP gene (Citron et al., 1992, Mullan et al., 1992, 
Nilsberth et al., 2001), as well as in proteins responsible for the variable cleavage of 
APP (e.g. in PS-1 and PS-2 (Scheuner et al., 1996, Hardy, 1997, Cruts and Van 
Broeckhoven, 1998) result in the familial inheritance of AD due to increased 
prevalence of the disease in families with these mutations. 
It has recently been identified that the soluble oligomers of Aβ can exert neurotoxic 
effects by activating a number of cell surface receptors, increasing the permeability 
of the cell membrane, or blocking correct cellular functions (see review by Kayed, 
and by Klein (Kayed and Lasagna-Reeves, 2013, Klein, 2013)). Each of these 
mechanisms is able to disrupt cellular signalling pathways and ions, induce 
hyperphosphorylation of tau protein in sites relevant for aggregation (De Felice et 
al., 2008), lead to mitochondrial dysfunction and activate apoptotic pathways 
(Kayed and Lasagna-Reeves, 2013). The formation of plaques has therefore, been 
suggested to be a protective measure to isolate these soluble Aβ oligomers 
together, to prevent toxicity and neuronal cell death (Treusch et al., 2009). 
 
1.2.2.2. Tau neurofibrillary tangles 
Neurofibrillary tangles (NFT) are the second hallmark protein aggregations found 
during AD pathology and are comprised of the tau protein (Serrano-Pozo et al., 
2011). The function of the tau protein has been specified as a microtubule 
associated protein involved in the assembly of tubulin monomers into microtubules 
in neuronal axons (Cleveland et al., 1977). Tau is transcribed from the MAPT 
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(microtubule-associated protein tau) gene and has a number of alternative splicing 
constructs (Buee et al., 2000). Furthermore, the tau protein has a large number of 
phosphorylation sites predominantly on serine and threonine residues, controlling 
the activity of its microtubule assembling capabilities. Greater phosphorylation of 
tau leads to decreased microtubule formation (Beharry et al., 2014). During AD 
pathology, tau becomes hyperphosphorylated, causing aggregation and the 
formation of paired helical filaments, which make up pre-tangles (Alonso et al., 
2001). Whether these insoluble paired helical filaments and tangles, or soluble 
oligomers of hyperphosphorylated tau, are the cause of neurotoxicity is also in 
debate, with many studies currently suggesting protective roles for the insoluble 
accumulations (Kopeikina et al., 2012). Toxicity due to tau misregulation has been 
indicated through disrupted organelle and cellular material transport, e.g. 
mitochondria, therefore causing incorrect localisation, decline in cell function, 
synaptic loss and ultimately cell death (Mandelkow et al., 2003, Reddy, 2011). 
Furthermore, tau has been identified as a downstream component to β-amyloid 
induced cell death (Rapoport et al., 2002, Chong et al., 2006). 
 
1.2.3. Metal hypothesis of neurodegeneration 
Another mechanism that has been highlighted as potentially playing a role during 
neurodegeneration in AD is through metal ion dysregulation. Metal ions implicated 
in neurodegeneration range from those that are present ordinarily at trace levels, 
holding toxic potential at increased concentrations such as lead or aluminium, to 
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those which are found as part of normal metabolic and cellular processes, such as 
zinc, copper and iron (Adlard and Bush, 2006).  
From studies investigating trace metal ions, lowering of cognitive performance in 
both children and adults has been correlated to lead accumulation in the blood and 
in bone samples (Lanphear et al., 2005, Weisskopf et al., 2007). Similarly, 
aluminium has been linked to AD (see review by Gupta (Gupta et al., 2005)) both 
through observations of greater cognitive decline or dementia risk with high 
aluminium intake (Rondeau et al., 2009) and also through the observation that 
injected aluminium salts leads to NFT aggregation (Klatzo et al., 1965) as well as the 
presence of aluminium in both NFT and Aβ plaques in AD (Tokutake et al., 1995). 
Whilst studies on trace metals do seem to show correlation against cognitive 
decline and greater dementia risks, their applicability to all AD cases is still limited 
and requires further evaluation. 
Biologically active metals however, such as iron, copper and zinc have been 
implicated in neurodegeneration and cognitive decline in both human patients and 
in animal models of disease (Zecca et al., 2004, Rivera-Mancia et al., 2010). 
Furthermore, it has been identified that all three of these metal ions are 
accumulated with amyloid plaque cores, therefore highlighting their involvement 
during AD (Lovell et al., 1998). The role of iron and copper is based on their 
enhancement of reactive oxygen species (ROS) production and resultant oxidative 
stress (see section 1.2.3.1), while zinc tends to be related to antioxidant processes. 
Iron content has been suggested to be increased in certain brain areas relevant for 
AD pathology using chemical methods (see section 1.4.1.1) as well as MRI based 
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approaches (see section 1.6.5). Elevated iron contents are linked directly to 
increased production of ROS (Smith et al., 1997, Sayre et al., 2000) (see section 
1.4.3.1), which has ultimately been implicated as a cause of cell and neuronal 
death. Furthermore, iron content has also been directly linked to amyloid 
processing (see section 1.4.3). Copper ion content has also been suggested to be 
altered in AD patients compared with controls (see review by Pal (Pal et al., 2015)), 
(Brewer, 2012), with copper ions undergoing the same chemical processes as iron 
to increase ROS levels to drive neuronal death (see section 1.2.3.1). Zinc 
involvement in AD is complicated given that there is no consensus on whether 
there is an increased or decreased concentration observed in comparison to 
controls (see review by Watt (Watt et al., 2010)). Zinc has been predominantly 
implicated in AD based on its involvement on amyloid processing, accumulation and 
degradation (Watt et al., 2010), with zinc being a cofactor for β-amyloid degrading 
enzymes (Leissring, 2008). Alternatively, changes in zinc translocation through 
transporters have been highlighted to play a role in cognitive decline and neuronal 
death (Lyubartseva and Lovell, 2012, Bush, 2013). 
 
1.2.3.1. Reactive Oxygen Species mechanisms 
Reactive Oxygen Species (ROS) are normally formed as part of oxidative 
phosphorylation, a critical process in cellular respiration and therefore for 
functioning of all cells (Bonda et al., 2011). They include a number of different 
species, all of which have a free unpaired electron, making them highly reactive 
compounds. The predominant ROS produced during oxidative phosphorylation is 
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the superoxide anion radical (O2
•-) within the mitochondria, the site of cellular 
respiration (Jomova et al., 2010). Cells ordinarily have very tight control over the 
levels of ROS, given the highly reactive nature of free radicals. SODs act to reduce 
levels of superoxide anion radical by catalysing conversion to the more stable 
product, hydrogen peroxide (H2O2) and then to water by glutathione peroxidases 
and catalases. However, in the presence of increased ferrous iron or cuprous 
copper (Cu+) within the cell, hydrogen peroxide can undergo the Fenton reaction 
(Figure 1-2), forming the hydroxyl free radical (OH•) (Jomova and Valko, 2011).  
 
Figure 1-2 Fenton and Haber-Weiss reaction 
(1) The Fenton reaction involves the conversion of hydrogen peroxide to produce the 
hydroxyl free radical under high levels of ferrous iron. (2) The superoxide anion can 
react with ferric iron producing the ferrous iron and oxygen in the Haber-Weiss 
reaction. 
 
This ROS is highly reactive causing lipid peroxidation, protein degradation and DNA 
damage. Lipid peroxidation occurs when the hydroxyl free radical is able to initiate 
and propagate the breakdown of lipids into further toxic products, such as 4-
hydroxynonenal (4-HNE) or 4-hydroxyhexenal (4-HHE) (Markesbery and Lovell, 
1998, Catala, 2009). Other evidence of lipid peroxidation assayed has been shown 
to be an increase in malondialdeyde and thiobarbituric acid-reactive substances 
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(TBARS). Protein damage can occur through ROS reactions with both the amino acid 
polypeptide chain and with the side chains (Pratico, 2008). ROS action on DNA can 
cause DNA-DNA or DNA-protein cross linkages, DNA strand breaks and oxidation of 
the base pairs (Lovell and Markesbery, 2007). 
Cell death from increased ROS and oxidative stress mechanisms has also been 
suggested to occur through excitotoxic mechanisms, due to loss of mitochondria 
membrane potential and ultimately apoptosis (Markesbery, 1997). Treatment of 
neuronal cells with hydrogen peroxide led to an increase in ROS production and 
eventually cell death by apoptosis, which could be limited using Coenzyme Q10 to 
maintain the mitochondria membrane potential (Somayajulu et al., 2005). 
Furthermore, mitochondria extracted from AD subjects that were subsequently 
transformed into control cells, demonstrated defects and reduced activity in 
Complex IV of the electron transport chain and increased basal intracellular calcium 
concentration (Sheehan et al., 1997).  
 
1.2.4. Evidence of ROS production in AD 
Evidence for oxidative stress in the pathology of AD has long been demonstrated in 
many studies. Increased lipid peroxidation products such as TBARS have been found 
in regions specific for AD, such as the hippocampus, cortex and amygdala (Subbarao 
et al., 1990, Lovell et al., 1995). Furthermore, enzymes involved in the reduction of 
ROS, including glutathione peroxidase and reductase and catalase showed elevated 
expressed in the hippocampus of AD patients (Lovell et al., 1995). Additionally, 
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evidence suggests that lipid peroxidation may occur prior to onset of AD, given the 
identification of lipid peroxidation products, malondialdehyde and TBARS in MCI 
and early AD patients’ superior and medial temporal gyri (Keller et al., 2005). 
Preclinical AD patients also showed increased 4-HNE and acrolein lipid peroxidation 
products in the hippocampus compared with controls (Bradley et al., 2010).  
Evidence of protein oxidation products has been demonstrated in the hippocampus 
of AD patients (Hensley et al., 1995, Butterfield et al., 2007) compared with control, 
whilst the cerebellum showed no change. More recently, changes in protein 
oxidation between MCI and control samples have been identified, highlighting this 
as a potential early occurrence in cognitive decline and AD (Butterfield et al., 2006). 
Furthermore, direct injection of Aβ1-42 into the rat brain induced the generation of 
protein oxidation products (Boyd-Kimball et al., 2005). 
DNA mutations can be detected in both nuclear and in mitochondrial DNA in AD 
cortical samples through the detection of oxidised base products (Mecocci et al., 
1994, Gabbita et al., 1998). Similarly, MCI subjects were also found to contain 
elevated oxidised base pairs in various cortical regions, again highlighting that 
oxidative stress may be occurring in the earliest points of cognitive decline and AD 
(Wang et al., 2006). DNA fragmentation was identified at greater levels in AD 
hippocampal tissue and this was colocalised to increased expression of pro-
apoptotic protein, Bax, highlighting potential causes towards neuronal cell death 




1.2.5. Clinical diagnosis and biomarkers of AD 
The sensitivity and specificity of a diagnostic test needs to be considered prior to its 
adoption into the clinic. The sensitivity of a test is its ability to correctly detect AD in 
a given population, i.e. will it detect all individuals with AD, and is measured by 
assessment of the number of positive cases detected compared with the number of 
patients in total with AD. The specificity of a test is its ability to detect only patients 
with AD as opposed to normal subjects, and is measured by assessment of the 
number of negative cases detected compared with the total number of patients 
without AD. Clinical tests can be compared using these measurements to evaluate 
which provides the best diagnostic capabilities. 
Current methods for diagnosis of AD remain predominantly based on memory and 
cognitive function assessment (McKhann et al., 1984). Numerous cognitive tests 
exist to understand the scope of dementia in patients. The predominant test 
routinely used is the Mini-Mental State Exam (MMSE) (Folstein et al., 1975), which 
was developed to be a short assessment of the cognitive functions of psychiatric 
patients. This test however, was eventually shown to hold limited differentiation 
between MCI patients and normal subjects (Mitchell, 2009) and has therefore 
allowed for the development of other cognitive tests. The Alzheimer’s Disease 
Assessment Scale (ADAS) (Rosen et al., 1984), was developed to be used in AD 
clinical trials. The Montreal Cognitive Assessment (MoCA) (Nasreddine et al., 2005) 
was later developed as a means to better distinguish MCI patients from normal 
subjects. Other tests in use include the Clinical Dementia Rating (CDR) (Morris, 
1993) and cognitive tests have even been developed for application over the 
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telephone, such as the modified Telephone Interview for Cognitive Status (TICS-M) 
(Brandt et al., 1988, Welsh et al., 1993), which was also able to identify patients 
with MCI (Cook et al., 2009). 
Whilst these tests are able to somewhat stratify between patients with MCI and AD, 
as well as to distinguish between these and normal subjects with relatively high 
accuracy, all the tests are non-quantitative and subject to bias. Furthermore, as the 
decline in cognitive function only manifests towards the end stages of disease 
(Figure 1-3), therapeutic intervention has been thought to only hold limited efficacy 
for patients, due to the significantly decreased population of neuronal cells 
remaining (Sperling et al., 2011). 
Definitive diagnosis of AD can only be performed post-mortem, by assessing the 
presence of amyloid plaques and NFT in different brain areas. Categorisation using 
systems such as the CERAD system, or using Braak staging allow for confirmed 
diagnosis of AD; at CERAD stage C and Braak stages V-VI (Braak and Braak, 1991, 
Alafuzoff et al., 2008). 
Given that memory assessments are non-quantitative, late stage and hold low 
specificity, alternative approaches have been evaluated for quantification of AD 
biomarkers, including the use of imaging modalities, such as MRI or PET (see section 
1.2.5.1), or by examining protein levels in either CSF or blood (see section 1.2.5.2). 
With elevated iron content though to play a role in AD (see section 1.4), the 
possibility for the early detection of brain iron content using MRI is currently being 
evaluated (see section 1.6.5). 
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A model for AD or dementia onset was proposed to highlight how novel biomarkers 
may be utilised to identify “at risk” individuals earlier (Figure 1-3), or to identify 
patients that have increased likelihood for conversion from MCI to AD (Jack et al., 
2010). Whilst earlier detection of alternative pathological hallmarks of AD may 
ultimately require a greater biological and temporal understanding of AD 
progression, these biomarkers may also provide a basis for the development of 
better therapeutic strategies against the earliest treatable stages of pathology (Jack 
et al., 2010). Indeed, if iron, or any other metal ion, is found to hold critical roles for 
AD pathology prior to Aβ1-42 generation or accumulation, this model may be 
amended to incorporate earlier biomarkers to incorporate these findings (Figure 
1-3). Roles for iron early on during pathology have already been suggested through 
increased iron staining in post-mortem human tissue from preclinical AD and MCI 
subjects, and correlation of iron staining levels to declining cognitive memory 
(Smith et al., 2010). 
 
Figure 1-3 Model for AD biomarkers expression cascade 
This model has been proposed as a method of detecting different pathological 
processes throughout AD, prior to the onset of symptomatic memory and cognitive 
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deficits (adapted from Jack et al., 2010). If greater evidence is found to support iron, 
or other metal ion, dyshomeostasis prior to Aβ accumulation, the model can be 
amended to incorporate this expression from an earlier time point. 
 
1.2.5.1. Imaging methods 
Many studies have used non-invasive imaging modalities, including positron 
emission tomography (PET) and MRI, to evaluate and monitor the 
neurodegenerative damage in AD. Frequently, these parameters are correlated 
against cognitive tests, and in some cases, against post mortem histological 
assessment. In general, volume loss has been highlighted as the major correlator to 
cognitive decline, with cortical and medial temporal systems showing the greatest 
rate and overall loss, attributed predominantly to synapse loss (Terry et al., 1991). 
Computational assessment of brain atrophy has allowed rates between AD and 
control patients to be detected by MRI (Fox and Freeborough, 1997). Measurement 
of hippocampal volume atrophy was able to predict conversion of MCI patients to 
AD (Jack et al., 1999). Furthermore, whole brain atrophy, as well as atrophy in the 
hippocampus, entorhinal cortex and ventricles was greater in patients that 
progressed from normal cognition into MCI or AD, than normal subjects during 
ageing. MCI patients converting to AD also showed greater atrophy in the brain 
regions highlighted above (Jack et al., 2004). Not only was MRI assessment of 
atrophy well correlated to cognitive testing scores, it was demonstrated to provide 
a more robust measurement (Fox et al., 1999, Jack et al., 2004). Evaluation of 
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atrophy rates in normal ageing individuals can even be detected, with whole-brain, 
temporal lobe and hippocampal volumes decreasing and ventricular volume 
increasing with increasing age, especially over 70 years (Scahill et al., 2003). 
PET imaging has been used in a small cohort to identify MCI conversion to AD, 
based on lower fluorodeoxyglucose (FDG) uptake into certain brain areas (Chetelat 
et al., 2003). Pittsburgh compound B (PiB) has been recently used in PET imaging to 
highlight amyloid plaques in the brain, alongside MRI based ventricle expansion 
rate determination (Jack et al., 2009). It was demonstrated that whilst amyloid 
plaque levels show very poor correlation to cognitive decline, as assessed using the 
CDR and MMSE, MRI based ventricular expansion assessment correlated strongly, 
highlighting that the level of neurodegeneration is likely to be the link to cognitive 
scores, whilst amyloid plaque load is not (Jack et al., 2009). 
Given the wide applicability for the use of both MRI and PET imaging systems for 
non-invasive assessment of AD, larger scale studies have been carried out over 
longer time courses, to allow for greater understanding of the clinical diagnostic 
potential of AD and dementia. Recently, hippocampal volume and hippocampal 
atrophy were shown to predict the conversion of normal aged subjects to AD over a 
10 year period (den Heijer et al., 2010). This study demonstrates that changes 
within the brain may be occurring well in advance of the appearance of clinical 
symptoms. Furthermore, within the same longitudinal study of patients, 
hippocampal shape was shown to provide additional predictive capability of 
subjects converting from normal cognition to dementia, than assessment of 
hippocampal volume alone over the 10 year period (Achterberg et al., 2013). 
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1.2.5.2. Other biomarkers 
Assessment of Aβ1-42 and tau levels from the CSF of AD, MCI and control patients 
demonstrates that these measures can provide a cut-off for AD detection, as well as 
being able to predict patients that will convert from MCI to AD (Shaw et al., 2009). 
Furthermore, similar to Aβ protein contents or plaque load assessed histologically, 
CSF Aβ did not correlate to hippocampal atrophy, whereas CSF measurement of 
tau, did correlate (de Souza et al., 2012). However, clinical CSF contents assessed in 
different centres still remain variable, and whilst Aβ1-42 and tau levels could be used 
to identify AD individuals from control groups, substantial overlap between 
different dementia types has been observed using this approach, due to 
overlapping biological phenotypes (Ewers et al., 2015).  
The use of blood-based biomarkers has also been evaluated in AD, with Aβ again 
demonstrating only minimal diagnostic or prognostic potential longitudinally 
(Rissman et al., 2012). Similarly, tau levels demonstrated substantial overlap 
between control and AD patients, despite significantly higher concentrations within 
the AD population (Zetterberg et al., 2013). The use of blood-based biomarkers may 
be severely hampered by the inherent heterogeneity of patient populations, as well 
as the numerous potential comorbidities that are associated with aged patients 
from either disease, or control groups (Henriksen et al., 2014). 
More recently however, higher-throughput methods have been employed utilizing 
proteomics approaches to identify blood-based biomarkers to differentiate 
between AD and control groups, with the identification of complement factor H 
(CFH) and α-2-macroglobulin (α-2M) differing between AD and control patients (Hye 
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et al., 2006). Indeed, panels of blood-based biomarkers are beginning to show 
reproducibility across multiple cohorts for detection of AD compared to controls 
(Kiddle et al., 2014). 
Metal ion detection has also been employed, with copper serum levels detectably 
increased in AD patients versus control samples in a small cohort study (Squitti et 
al., 2002), and additional evidence gleaned in monozygotic twins discordant for AD 
(Squitti et al., 2004). Additionally, altered miRNA expression patterns have been 
assessed from the brain and blood to establish a method for diagnosis of AD (Delay 
et al., 2012, Geekiyanage et al., 2012).  
Clearly, it is reasonable to postulate that no single biomarker will be sufficient to 
diagnose, stratify and evaluate the progression of AD between controls and all 
other diseases and it therefore seems likely that certain tests used individually, or in 
combination, will be required to satisfy the necessary requirements for novel 
biomarkers. 
 
1.2.6. Current AD therapies 
As neurodegeneration in AD severely impacts cholinergic systems, current AD 
treatments, such as Donepezil and Galantamine, have been directed towards 
enhancement of cholinergic neurotransmission. These function by inhibiting 
acetylcholinesterases, or modulating acetylcholine receptors to increase the levels 
of acetylcholine neurotransmitter at synapses (Mangialasche et al., 2010). Whilst 
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these treatments provide some benefits to patients, they tend to be anti-
symptomatic, with limited impact against neurodegeneration observed. 
More recently, therapeutics designed to target β-amyloid and tau aggregations 
have been developed, however none have provided clinical efficacy to reduce or 
prevent cognitive decline in AD (Mangialasche et al., 2010). Indeed, follow up of 
patients with Aβ1-42 immunisation demonstrated lower levels of β-amyloid plaques 
post-mortem, however no sign of improved cognition, or changes in mortality rate 
were detected (Holmes et al., 2008). Many other trials since, have also investigated 
the clearance of Aβ monomers, oligomers and fibrils from AD patients using 
immunotherapies, however all have showed similar limited efficacy at reducing the 
cognitive decline associated with pathology (Panza et al., 2014). Alternative 
methods for reducing the amyloid burden in AD, including secretase modulators 
and aggregation inhibitors, and more recently methods to interrupt tau 
phosphorylation and aggregation have also demonstrated limited efficacy in clinical 
trials (Mangialasche et al., 2010, Schneider et al., 2014). Therefore, given the 
considerable failures in clinical trials against AD, it seems clear that a greater 
understanding of the fundamental causes of neuronal death are required, with 
better preclinical models of disease to evaluate potential therapies, as well as to 






1.3. Iron, Uptake, Regulation and Distribution 
Iron is a critical element required throughout the body for a variety of key 
functions. A major role of iron in the body is for oxygen transport within the 
haemoglobin of erythrocytes, where the iron exists bound to a haem group (Perutz, 
1979). Iron ions can also make up the functional elements of essential proteins and 
enzymes within all cell types, either singly, or as part of iron-sulphur clusters. 
Examples of iron-containing proteins include: DNA polymerases (Netz et al., 2012), 
cytochrome P450 enzymes (Meunier et al., 2004) and iron regulatory proteins 
(IRPs) (Anderson et al., 2012, Lill et al., 2012). 
 
1.3.1. Iron in biological tissues 
There are a number of different forms of iron that exist within biological tissues. 
The two main classes described are haem iron and non-haem iron. Haem iron 
simply describes iron that is in complex with haem groups, such as those in 
haemoglobin, whilst non-haem iron describes all the other forms of iron, including 
low molecular weight complexes, metalloproteins, storage proteins and ionic 
complexes (Haacke et al., 2005): 
1) Low molecular weight complexes include iron associated with citrate, 
ascorbate and ATP present in cells (Bradbury, 1997, Moos et al., 2007) and is 
sometimes termed as ‘free’ iron, and forms the labile iron pool (LIP). This form 
of iron is considered to be at extremely low concentrations, compared with the 
overall presence of iron in cells (Schenck, 2003). 
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2) A key metalloprotein that binds iron is the transport protein, transferrin. 
Transferrin (TF) is a 79kDa protein consisting of two lobes (N- and C- lobe) and 
functions to transport iron in the body (Gomme and McCann, 2005). Serum TF 
protein is predominantly synthesised by the liver and without any iron bound, 
is known as apotransferrin (Beutler et al., 2000). A maximum of two iron atoms 
in the ferric form can bind to transferrin, one to each lobe (Nunez et al., 2012), 
Mutations in the transferrin gene give rise to the rare disease, 
atransferrinemia, causing reduced delivery of iron to the bone marrow and 
reduced haemoglobin synthesis (Beutler et al., 2000). 
3) Ferritin is the predominant storage protein for iron within all cell types and 
contains most of the iron present in cells. It consists of 24 protein subunits, 
comprised of heavy (H-) and light (L-) chains arranged into a spherical cage. The 
80Å core is capable of holding up to 4500 iron atoms in the ferric form as a 
crystalline structure, ferrihydrite (5Fe2O3.9H2O) (Harrison and Arosio, 1996). 
The heavy chain is involved in catalysis of ferrous iron to the ferric form, due to 
a ferroxidase activity, whilst the light chain is predominantly involved in the 
storage of iron. Ferritins are expressed across most tissue types, including the 
heart, spleen, pancreas and liver, and are composed of different combinations 
of the H- and L- ferritins, owing to post-translational regulation (Cairo et al., 
1991). The storage of iron in ferritin occurs by ferrous iron transport through 
ion entry channels of the protein cage, followed by ferroxidase catalysis to bind 
the growing ferrihydrite cores that are initiated at the nucleation sites inside 
the protein (Theil, 2011). Iron export from ferritin can also occur, however this 
process is less understood than the mechanism of iron entry (Theil, 2011). It 
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has been demonstrated that mutations in the ferritin light chain cause a series 
of neurodegenerative diseases clinically, known as neuroferritinopathies, which 
are characterised by iron overload, movement disorders and cognitive decline 
(Curtis et al., 2001). 
4) Hemosiderin is another storage form of iron, however has been suggested to 
be a degradation product of ferritin (Haacke et al., 2005). It remains unclear as 
to the true nature of hemosiderin, however it exists as an insoluble form and is 
more apparent during iron overload pathologies, such as haemochromatosis 
(Quintana, 2007). 
5) Finally, another form of iron that has been established to exist in biological 
tissues is magnetite, a crystal structure of Fe3O4 (Kirschvink et al., 1992). This 
form of iron was identified in both control and AD brains and has highly 
ferromagnetic properties. 
Critically, it should be noted that not all forms of iron exhibit similar effects on the 
MRI signal and this has added complexity to the application of MRI for 
understanding iron content changes in the brain during neurodegenerative diseases 
(see section 1.6.5). 
 
1.3.2. Normal brain iron uptake 
Specific functions within the brain can be attributed to iron-containing enzymes, 
such as those involved in neurotransmitter synthesis including tyrosine hydroxylase 
synthesis of dopamine (Daubner et al., 2011), and those involved in myelin 
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synthesis, including fatty acid hydroxylases (Connor and Menzies, 1996, Alderson et 
al., 2004, Todorich et al., 2009). As such, oligodendrocytes were found to hold 
greater levels of transferrin, ferritin and iron than any other cell types in both adult 
(28-49 years) and aged (60-90 years) brains (Connor et al., 1990). This is likely due 
to the high metabolic demands for iron required in myelin synthesis and 
maintenance, as well as the continued cell survival requirements, especially within 
the white matter regions of the human brain. 
As the brain is comprised of numerous cell types and regions, iron content is heavily 
varied across the brain, likely reflecting the different cellular and physiological 
functions. Furthermore, as iron can be toxic at high concentrations, (see section 
1.4.3.1) iron uptake and regulation into the brain must be tightly regulated.  
Whilst iron uptake into systemic tissues including heart and liver, can occur through 
the direct uptake of iron from blood plasma, uptake into the brain is further 
complicated due to the presence of the blood brain barrier (BBB), acting to prevent 
the passage of toxins and unnecessary proteins into the brain (Ward et al., 2014). 
Iron initially enters the blood through the duodenum endothelial cells following 
ingestion (see review by Anderson, and by Rouault (Rouault, 2001, Anderson et al., 
2012))Export of ferrous (Fe2+) iron from the duodenal endothelial cells occurs 
through ferroportin (FPN1), for loading onto transferrin, via the ferroxidase activity 
of hephaestin (Anderson et al., 2012). Hephaestin oxidises exported ferrous iron to 
the ferric (Fe3+) form, to load a capacity maximum of two ferric iron atoms per 
transferrin molecule (Nunez et al., 2012) for transporting iron to tissues with iron 
demand. Iron-bound TF circulating within the blood serum binds with high affinity 
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to the Transferrin Receptor (TfR) located on the BBB endothelial cell membrane 
(Figure 1-4). The TfR is then internalised via a clathrin-mediated mechanism. 
Acidification of the internalised endosome by a proton pump causes ferric iron 
release from the TF-TfR complex and following reduction to ferrous iron by a ferric 
reductase inside the endosome, is transported into the cytoplasm by the divalent 
metal transporter 1 (DMT1) transporter. Here, ferrous iron is either stored within 
ferritin or can be transported into the brain interstitial fluid by FPN1. 
 
Figure 1-4 Brain iron uptake, transport and storage mechanisms between 
different cell types 
Tf, Transferrin; TfR, Transferrin Receptor; Fpn, Ferroportin; H+ pump, proton pump; 
DMT1, divalent metal transporter 1; CP, ceruloplasmin; Fe2+, ferrous iron; Fe3+, ferric 
iron (adapted from Ward et al., 2014). 
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Iron exported into the interstitial fluid by FPN1 from the BBB endothelial cells can 
either be bound to TF, or is found in complex with citrate, ascorbate or ATP 
(Bradbury, 1997, Moos et al., 2007). From the interstitial fluid, iron can be 
transported through various mechanisms into neurons, astrocytes, 
oligodendrocytes and microglial cells. 
It has been demonstrated that TF is produced by oligodendrocytes (Connor et al., 
1990) and astrocytes, however only neurons express the TfR in the brain to 
therefore allow uptake of iron via this method. Neuronal uptake of iron can also 
occur by a non-Tf bound method, via ferrous iron transport through DMT1, given 
the expression of this protein in neurons (Moos et al., 2007). Iron uptake into 
neurons is also supported due to the storage of iron provided by ferritin expression 
(Moos et al., 2007). Ferrous iron is also able to be transported into microglia for 
storage in ferritin, due to detected expression of DMT1 and ferritin in these cell 
types similarly to neuronal cells (Urrutia et al., 2013). 
Ceruloplasmin (CP) expression is predominantly found in astrocytes, allowing 
conversion of ferrous iron to the ferric state, and subsequent binding of ferric iron 
to TF for iron export from cells (Loeffler et al., 2001, Vassiliev et al., 2005). Iron 
export from other cell types is less well understood however, some studies have 






1.3.3. Iron regulation of protein expression 
Iron content is able to provide direct feedback to cells for careful regulation of the 
uptake, storage and export of iron (Anderson et al., 2012). It has been 
demonstrated that cells under low iron content increase expression of the 
transferrin receptor and lower expression of ferritin, to promote iron uptake and 
availability within the cell (Figure 1-5) (Theil, 1990, Klausner et al., 1993, Zecca et 
al., 2004). This occurs through the presence of an iron responsive element (IRE) in 
the 3’-untranslated region (UTR) of the transferrin receptor mRNA transcript, which 
is bound by iron response proteins (IRPs) to stabilize the transcript (Casey et al., 
1989). An IRE in the 5’-UTR of the ferritin mRNA transcript inhibits expression of 
this protein due to IRP binding (Theil, 1990). Conversely, under high iron conditions, 
low IRE binding by IRPs leads to unstable transferrin receptor mRNA (Casey et al., 
1989), and a rise in the expression of ferritin, through IRP promotion of translation 




Figure 1-5 Translational regulation by iron 
IREs present in the 3’-UTR of transferrin receptor and 5’-UTR of ferritin regulates the 
translational expression of these mRNA transcripts in dependence with iron content 
in the cell, based on IRP binding to IREs (adapted from Zecca et al. 2004). 
 
1.4. Iron and AD 
1.4.1. Iron regulation in the aged and AD brain 
Given the hypothesis of iron involvement in AD, many studies have evaluated iron 
localisation, as well as the localisation and functioning of iron regulatory proteins 
(IRPs), such as ferritin and transferrin, between normal ageing (Connor et al., 1990) 





A number of brain regions, including the prefrontal, temporal, sensory and motor 
cortex, as well as the caudate nucleus, the putamen and the globus pallidus have 
been reported to show high accumulation of iron levels during the first 20-30 years 
of normal ageing, whilst the medulla oblongata showed no change in iron levels 
(Hallgren and Sourander, 1958). After 40 years of age, the increase in iron levels 
plateaus in all brain regions. Although greater levels of stainable iron have been 
identified histologically in cells within cortical areas from AD samples (Goodman, 
1953), global cortical iron levels remained comparable to normal (Hallgren and 
Sourander, 1960). This implies that a local redistribution of stainable iron may be 
occurring in AD in areas that demonstrate the greatest level of neuronal loss. 
The use of histochemical methods for iron evaluation has demonstrated elevated 
iron content within the cortex of AD samples, compared with age-matched 
controls, and was correlated to worsening CDR (Clinical Dementia Rating) scores 
(Smith et al., 2010). Furthermore, whilst a difference in stainable iron was detected 
in PD substantia nigra, no changes in stainable iron was detected in AD samples 
from the hippocampus, frontal cortex, substantia nigra, globus pallidus or putamen 
(Jellinger et al., 1990). The latter study contained slightly more patients than the 
prior, perhaps accounting for the discrepancy.  
Quantitative evaluation of iron has also been contradictory for iron content 
changes between control and AD patients (Deibel et al., 1996, Magaki et al., 2007, 
House et al., 2008, Schrag et al., 2011). Raised iron content was shown in the 
hippocampus (Deibel et al., 1996), and in the temporal cortex (House et al., 2008), 
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of AD patients compared with controls, however both studies were performed in 
small group of patients. Furthermore, whilst an increase in iron was reported within 
AD patients’ frontal cortex and globus pallidus, the results were normalised to 
protein content, and this protein content was also detectably lower in the frontal 
cortex (Loeffler et al., 1995). Equally, iron contents have been demonstrated to 
increase in some regions of AD samples, whilst decreasing in other regions, e.g. in 
the occipital cortex (Connor et al., 1992b). More recently, assessments for “loosely-
bound iron” demonstrated a decrease within hippocampal white matter from AD 
patients compared with control, whereas the overall iron contents were similar 
between the groups (Magaki et al., 2007). Similar levels of iron have also been 
demonstrated by other studies in cortical regions (Religa et al., 2006). Likewise, 
overall cerebrospinal fluid (CSF) iron levels were similar between control, MCI and 
AD, however “redox-active” iron was higher in MCI patients compared with controls 
(Lavados et al., 2008). 
Comprehensive assessments of iron content throughout the adult human brain 
have also recently been performed, again demonstrating the heterogeneous ranges 
of iron present in different brain areas (Krebs et al., 2014, Ramos et al., 2014). 
Comparison of controls against AD samples provided evidence of greater iron 
content in the hippocampus of AD patients, however only two AD patients were 
compared, limiting the certainty of these results (Ramos et al., 2014). Furthermore, 
no differences were observed between the genders, a parameter overlooked by 
most other studies (Ramos et al., 2014). Adding to the controversial and 
contradictory evidence for iron changes during AD, a meta-analysis of the 
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quantitative literature investigating iron contents within the AD human brain, 
recently identified the possibility of citation bias towards positive results for an 
increase in iron content in AD compared with controls (Schrag et al., 2011). A more 
recent meta-analysis of quantitative research provided evidence for lower serum 
iron levels in AD compared with control patients, whilst also highlighting raised iron 
contents in eight brain regions; including the globus pallidus, caudate nucleus, 
amygdala, putamen and the frontal, parietal and temporal cortex (Tao et al., 2014). 
The discrepancies observed between these two meta-analyses likely draw from the 
differences in inclusion criteria. The more recent study includes research performed 
subsequent to the earlier meta-analysis, but it also includes quantitative research 
data from the primary source of citation bias mentioned in the earlier meta study. 
Furthermore, whilst no citation bias was reported by the more recent study, this 
can be attributed to the exclusion of review articles, which was found to be the 
source of citation bias in the first article (Schrag et al., 2011, Tao et al., 2014). 
 
1.4.1.2. Iron storage 
During ageing, oligodendrocytes in the basal ganglia have been found with less iron, 
ferritin and transferrin staining, whilst no changes were observed from any other 
brain regions (Connor et al., 1990). Microglial ferritin staining was increased in a 
number of brain areas, whilst astrocytic ferritin expression was only increased in 
the cerebral cortex, basal ganglia, hippocampus and amygdala during ageing 
(Connor et al., 1990). The changes associated with decreased ferritin and iron in the 
basal ganglia oligodendrocytes, with a concomitant increase of ferritin in microglia 
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and astrocytes supports a potential notion of altered iron localisation in the brain 
during ageing, which has been hypothesised by other studies (Hallgren and 
Sourander, 1960). Furthermore, increased microglial ferritin with ageing supports 
the interaction of inflammatory processes during ageing and disease (Zecca et al., 
2004). 
H-ferritin has been predominantly found in neuronal cells and oligodendrocytes, 
whilst L-ferritin was mainly localised to microglia (Han et al., 2002). Whilst neurons 
expressed greater levels of H- than L- ferritin, oligodendrocytes contained similar 
levels of each of these ferritin isoforms (Connor et al., 1994). The differences in 
ferritin isoform expression in the brain have been thought to reflect the function of 
ferritin within each of these cell types, with H-ferritin indicative of stress response, 
whilst L-ferritin suggesting a greater role for iron storage (Connor et al., 1994). 
Indeed subsequent studies suggest that long term iron storage is maintained in 
microglia, expressing high proportions of L-ferritin as a readily available method for 
iron storage (Lopes et al., 2008). 
 
1.4.1.3. Iron transport 
TF protein in AD samples was increased in frontal cortex compared with elderly 
controls, and iron accumulation was detected in the frontal cortex and globus 
pallidus. Furthermore, correlation values of TF to iron were decreased in AD frontal 
cortex and globus pallidus compared to control, indicating a change in the 
mobilisation of iron in AD (Loeffler et al., 1995). Decreased correlation of TF to iron 
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was also observed in a number of regions in PD (Loeffler et al., 1995), again 
indicating a change in iron mobilisation. 
TF binding has also been identified around plaques in AD grey matter (Connor et al., 
1992a). TF was found expressed in astrocytes rather than in oligodendrocytes in AD 
white matter, however, this wasn’t the case in the hippocampus where TF was 
expressed predominantly in oligodendrocytes, as expected (Connor et al., 1992a). 
Finally, the TF gene is also implicated in a greater risk for AD, with the C2 allele, 
along with a mutation in the hemochromatosis (HFE) gene increasing risk (Robson 
et al., 2004). This is thought to be due to the C2 allele causing a change in the 
affinity of TF for iron, leading to accumulation. 
 
1.4.2. Iron accumulation and aggregation with Aβ and tau 
It has been demonstrated that both amyloid plaques and neurofibrillary tangles, are 
associated with iron (Good et al., 1992, Smith et al., 1997, Lovell et al., 1998). These 
studies have ranged from demonstrating association using histological methods, to 
chemical analyses. Using the chemical analytical method micro-PIXE (Particle 
Induced X-ray Emission) (see section 1.5.2), iron, copper and zinc were found 
accumulated within the cores and rim of amyloid plaques in AD amygdala 
compared with AD and control neuropil (Lovell et al., 1998). The accumulation of 
these metals was also confirmed to be localised to regions of β-sheet conformation 
in AD tissue (Miller et al., 2006). NFT containing neurons showed selective 
accumulation of iron and aluminium in AD hippocampus compared with control 
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using laser microprobe mass analysis (LAMMA) (Good et al., 1992). Furthermore, 
the accumulation of iron in plaques and tangles in the hippocampus has been 
shown histologically (Smith et al., 1997). 
It was identified that ferric iron, as well as Al3+ (aluminium ion) and Zn2+ (zinc ion) 
ions may hold a direct role in the aggregation of β-amyloid, as shown by a 
radiolabelled peptide aggregation assay using the βA4 peptide (Mantyh et al., 
1993). Furthermore, ferric iron, along with Al3+ were shown to increase amyloid 
aggregation into fibrillary oligomers, whereas Zn2+ and Cu2+ (copper ion) ions did 
not (Bolognin et al., 2011). 
Ferric iron was shown to bind and cause aggregation of tau into soluble paired 
helical filaments (PHF), dependent on the phosphorylation state of tau (Yamamoto 
et al., 2002). Furthermore, reduction of ferric iron to the ferrous form led to the 
solubilisation of insoluble PHF of tau, indicating that the presence of ferric iron may 
be involved in forming insoluble PHF (Yamamoto et al., 2002). 
 
1.4.3. Direct links between iron to APP and tau biology 
Most recently, direct regulatory links between iron and APP expression and 
processing have been identified that may promote the expression of Aβ during AD. 
An IRE was discovered on the APP mRNA transcript, highlighting a direct mechanism 
by which iron can affect expression of the APP transcript (Rogers et al., 2002). The 
location of the IRE is present in the 5’UTR, promoting translational expression 
under high cellular iron content, similar to ferritin expression (Rogers et al., 2002, 
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Rogers et al., 2008). Furthermore, links between the homeostasis of iron and 
specifically Aβ processing have been highlighted to occur through regulation of the 
proprotein convertase, furin. Furin is able to cleave and activate ADAM10, which is 
involved in the functioning of the α-secretase complex for APPα production (Anders 
et al., 2001, Hwang et al., 2006). Excess iron content can reduce furin expression 
(Silvestri et al., 2008), therefore reducing α-secretase activity and promotion of APP 
processing through BACE1 cleavage into Aβ (Silvestri and Camaschella, 2008). 
Whilst the function of APP has still not been confirmed, recent reports have 
highlighted it to be potentially involved with iron export from cells (Duce et al., 
2010). Ferroxidase activity was identified in APP, whereby catalysis of the ferrous to 
ferric form of iron could occur in a similar manner as that by ceruloplasmin for 
cellular export. APP was then identified to be involved in loading iron onto 
transferrin and exporting iron from cells via ferroportin (Duce et al., 2010). Iron 
overload in cells was rescued by administration of APP in cell models and primary 
neuronal cultures of APP-/- mice (Duce et al., 2010). Subsequently, a role for tau in 
iron export has also been suggested using primary cortical neurons, as tau-/- cells 
showed decreased surface trafficking of APP (Lei et al., 2012). 
 
1.4.3.1. Evidence for iron-related oxidative stress through ROS production 
Iron, along with other metal ions, is thought to lead to increased oxidative damage 
during brain ageing (von Bernhardi et al., 2010), and contribute to the “alternate 
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hypothesis” of neurodegeneration in AD (Lee et al., 2007) (see section 1.2.3 and 
1.2.3.1). 
The accumulation of iron in plaques and tangles described above was shown 
histologically to have redox capabilities, highlighting potential as a source for ROS 
production (Smith et al., 1997). In fact, both amyloid plaques and tangles only 
demonstrated redox potential following the addition of iron or copper salts, 
demonstrating that the metal ions bound in these protein aggregates are bound in 
a redox active manner in AD tissue. Also, tau protein was highlighted to make a 
contribution to the redox activity, assessed using a hydrogen peroxide-based assay 
(Sayre et al., 2000). 
Even more convincingly, Aβ1-42, the amyloidogenic form of amyloid, was shown to 
have an enhanced capability to cause redox reactions with iron and copper than 
Aβ1-40. Not only were redox active iron and copper demonstrated in a hydrogen 
peroxide detection assay in conjunction with Aβ1-42, but the reaction products were 
shown to generate the hydroxyl radical through increased TBARS measurement 
(Huang et al., 1999). Finally, it has also been demonstrated that Aβ1-42 may only 
show cell toxicity when iron is bound (Rottkamp et al., 2001). 
With iron’s suggested role in oxidative stress within the brain during ageing and 
disease, stress response proteins, such as heme oxygenase 1 (HO-1) have been 
evaluated (Smith et al., 1994, Hirose et al., 2003). HO-1 is a 32kDa protein and is 
able to catalyse the formation of biliverdin, iron and carbon monoxide from heme 
(Hirose et al., 2003). Its expression has been shown to increase with ageing in the 
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cerebral cortex and hippocampus, and was associated with higher levels of ferritin 
in the cortex, but not in the hippocampus (Hirose et al., 2003). 
In AD, HO-1 was associated with plaques and tangles in hippocampal tissue, and 
supports the possibility that iron mediates oxidative damage and ROS formation in 
areas relevant for disease pathology (Smith et al., 1994). Indeed the expression of 
HO-1 seems somewhat specific to disease pathology, with increased expression 
identified in both neurons and astrocytes found in the hippocampus and temporal 
cortex, but not in substantia nigra, of AD samples (Schipper et al., 1995). 
 
1.4.4. Role of iron in AD and neurodegenerative diseases from preclinical 
research 
The use of animal models in neurodegenerative disease research is paramount for 
greater understanding of the pathological processes underpinning disease, as well 
as for evaluation of novel therapies and in establishment of biomarkers to diagnose 
and monitor progression (Jucker, 2010). As neurodegenerative diseases only appear 
in humans in their fullest form, many genetically engineered models have been 
created, that comprise certain aspects of the disease. Frequently used models in AD 
research are mice that have been engineered to express mutant proteins that have 
been identified as strong risk factors for familial forms of AD in humans (Hardy and 
Selkoe, 2002). These are mostly based around the amyloid processing pathways, 
with many different gene mutations expressed in APP, PS-1 and PS-2 (Jucker, 2010). 
Mice have been created containing mutated forms of one, or even combinations of 
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genes, such as the APP/ PS-1 mouse, which contains an overexpressed mutated APP 
and mutated PS-1 protein (Borchelt et al., 1997). Similarly, fragments of APP have 
been expressed to yield β-amyloid accumulations and cognitive pathology in mice, 
by expressing the C100 fragment in mice (Neve et al., 1996). Furthermore, 
transgenic mice containing mutated tau protein, either alone, or in combination 
with APP, have demonstrated similar AD phenotypes (Ballatore et al., 2007). These 
animals tend to be characterised with accumulated β-amyloid protein or tau, loss of 
synapses, and declines in cognitive and memory tests (Oddo et al., 2003). 
Many of these animal models have been utilised for assessment of the role of iron 
during neurodegeneration, especially as iron accumulation is detected within the 
amyloid plaques from preclinical models, such as in the APP/PS-1 model (Falangola 
et al., 2005, Wengenack et al., 2011). Furthermore, transgenic mice overexpressing 
mutated ferritin light chains give rise to similar iron overload, ferritin aggregates (as 
inclusion bodies) and motor dysfunction as that observed with 
neuroferritinopathies, (outlined in section 1.3.2 (Curtis et al., 2001)), therefore 
highlighting the impact that incorrectly functioning ferritin holds within the brain 
(Vidal et al., 2008). 
However, using these animal models has also provided evidence for Aβ plaque 
formation as a protective role against iron toxicity (Maynard et al., 2002, Bishop 
and Robinson, 2003). Overexpression of APP lead to a reduction in iron content, as 
well as a reduction in the levels of other metal ions, in the Tg2576, C100.V717F and 
C100.wt transgenic mice lines (Maynard et al., 2002). Aβ also had a protective role 
when co-injected into rat cortex with iron (Bishop and Robinson, 2003). 
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1.4.5. Role of iron forms in AD 
AD patients also show differences in composition of ferritin and hemosiderin to 
control subjects and these changes were predominantly located to the 
oligodendrocytes of the hippocampus (Quintana et al., 2004, Quintana et al., 2006). 
Furthermore, X-ray Absorption Near Edge Spectroscopy (XANES) was used to 
establish the presence of unusual iron cores, such as magnetite, near senile plaques 
in AD compared to control samples (Collingwood et al., 2005). Similarly, magnetite 
levels were found to be elevated in female AD subjects compared with controls, 
however male AD subjects did not show elevated magnetite levels (Pankhurst et al., 
2008). From these studies, a direct role for iron overload and abnormal biochemical 
changes is apparent, leading to dysfunction of neuronal cells involved in cognitive 
memory (Quintana, 2007). Some of the chemical mechanisms underlying the 
generation of these unusual iron cores have been suggested to be due to β-amyloid 
plaque interaction with ferrihydrite iron, the form of iron found in ferritin, (see 
section 1.3.2) to reduce this iron form to magnetite (Everett et al., 2014a). Indeed, 
these processes may even outline novel mechanisms of cell death, whereby 
magnetite was found to affect microtubule formation and stability in vitro, and led 
to abnormal cell morphology and reductions in cell viability (Dadras et al., 2013). 
Furthermore, ferric iron can be catalyzed into ferrous iron by β-amyloid, which may 
allow a greater role for participation in the Fenton reaction enhancing ROS 





1.4.6. Chelation therapy potential 
Clinical, as well as preclinical studies have established a possible therapeutic benefit 
of iron chelation therapy against neurodegenerative disorders, whereby these 
compounds are able to bind and sequester heavy metals from taking part in any 
further, potentially damaging, reactions. Much of this research has been developed 
in PD models of disease, where ferritin overexpression, or the metal chelator 
Clioquinol, were able to reduce the effects of a 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) lesion in the substantia nigra (Kaur et al., 2003). 
Furthermore, pre-treatment with the BBB permeable, iron-specific chelator VK-28, 
was used to prevent loss of dopamine within the striatal regions in the 6-
hydroxydopamine (6-OHDA) lesioned rat (Shachar et al., 2004) leading to further 
development of BBB permeable iron chelators (Youdim et al., 2005). 
Deferoxamine is a bacterial siderophore, used for the treatment of iron overload by 
chelation, and has been used clinically in a small study of 48 subjects to slow the 
progress of AD by two-fold (McLachlan et al., 1991). Furthermore, Clioquinol, which 
has been shown to produce a significant decrease in iron levels in mice brains upon 
treatment (Yassin et al., 2000), has also provided stabilisation or even some 
symptomatic improvement for AD patients (Regland et al., 2001, Ibach et al., 2005). 
Drawbacks to these studies however, are that they use small patient numbers and 
were performed without control subjects. Novel iron chelators, VK-28 and M30 
have also shown neuroprotective roles in APP/PS-1 mice models of AD, and were 
similar to epigallocatechin-3-gallate (EGCG) to lower the expression of APP 
(Avramovich-Tirosh et al., 2007). Perhaps the most encouraging finding towards the 
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positive use of iron chelation strategies against neurodegenerative diseases stems 
from the positive outcomes observed during a recent 12 month double-blind 
placebo-controlled clinical trial, in which Deferiprone demonstrated efficacy using 
motor scores for PD patients (Devos et al., 2014). 
 
1.5. Iron Quantification in Biology 
Many approaches for iron detection in biological tissues have been employed, to 
evaluate both the concentration, as well as in understanding the form, of iron 
within tissue. Furthermore, by using these methods to qualitatively and 
quantitatively assess iron within biological tissues, any changes to iron biology can 
be assessed during disease, including during neurodegenerative diseases and 
dementia. 
 
1.5.1. Histological method assessments 
Histological approaches for iron evaluation utilise the redox potential of iron for 
staining. Perls iron stain uses soluble ferrocyanide addition to tissue, which reacts 
with ferric ions released by acid treatment, to form the blue crystal precipitate 
Prussian blue (van Duijn et al., 2013). Furthermore, the Turnbull blue method 
utilises a ferricyanide reaction with ferrous ions, for ferrous iron specific detection 
following acid treatment (Jellinger et al., 1990, Meguro et al., 2003). Enhancement 
of both Prussian blue and Turnbull blue stains can be performed through the 
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hydrogen peroxide dependent oxidation of 3,3-diaminobenzidine (DAB) producing a 
brown precipitate (Meguro et al., 2007, van Duijn et al., 2013). Using a similar 
method, the redox-potential of iron in plaques and tangles has been evaluated 
using hydrogen peroxide based assays coupled with DAB (Smith et al., 1997, Sayre 
et al., 2000). 
Whilst these methods are able to provide excellent understanding of the 
localisation of iron within tissue, quantification of iron content is complicated due 
to the inconsistency of staining methods and their dependence on many external 
factors (Meguro et al., 2007). Iron staining in brain tissue was found to be affected 
by factors such as fixation time length in 4% formalin, with fixation for longer than 
24 hours leading to a marked reduction in staining (Morris et al., 1992). 
Furthermore, different metals have been found to leach into fixative at different 
rates and the form in which they are bound can affect their rate of loss (Gellein et 
al., 2008). Fixation time has not, however, been shown to affect iron contents in 
brain tissue up to 18 months (Bush et al., 1995, Chua-anusorn et al., 1997, Gellein 
et al., 2008), although evidence does exist demonstrating decreased iron content 
following 4-6 years fixation (Schrag et al., 2010). Finally, it has also been noted that 
assessment of the chemical state of iron can be complicated by changes in 
oxidation environment in post mortem tissue, as well as by fixation and staining 
processes of biological tissue (Dobson and Grassi, 1996, Collingwood and Dobson, 
2006). It has also been shown that the Perls and Turnbull stains demonstrate some 




1.5.2. Chemical method assessments 
More recently, quantitative chemical approaches have been used to evaluate iron 
content within post-mortem tissue, using methods such as, inductively-coupled-
plasma mass spectrometry (ICP-MS), atomic absorption spectroscopy (AAS), micro-
particle induced X-ray emission (micro-PIXE) and synchrotron-radiation X-ray 
fluorescence (SR-XRF) (Lovell et al., 1998, House et al., 2007, Langkammer et al., 
2010, Antharam et al., 2012, Zheng et al., 2013, Stuber et al., 2014). 
ICP-MS involves the ionisation of atoms from a sample, prior to performing mass 
spectrometry analysis for various elements. This approach has been used to 
investigate the concentration of iron, as well as many other elements in the brain 
(Corrigan et al., 1993, Langkammer et al., 2010). AAS measures the concentration 
of elements in a sample by assessing the amount of light at a specific wavelength 
that is absorbed, and has similarly been used to assess the iron content in brain 
samples (House et al., 2007). Whilst these two methods are highly sensitive for iron, 
and other metal quantification, both require the excision of tissue for chemical 
assessment and therefore cannot be directly spatially correlated to other 
techniques, for example, to compare against MRI. Furthermore, whilst adaptations 
can be made for spatial assessment, e.g. using laser ablation ICP-MS (LA-ICP-MS) 
(Becker et al., 2010), all these techniques are also destructive, leading to the loss of 
material for any subsequent assessment, such as using histology. 
Micro-PIXE uses a high energy proton beam to collide with atoms in a sample, thus 
emitting X-rays that are specific for each chemical element that can be detected 
(Stuber et al., 2014). This technique has been used to quantify the iron content in 
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plaques and tangles (Lovell et al., 1998), as well as to quantitatively map iron, 
sulphur and phosphorus content in human cortical samples (Stuber et al., 2014), 
and allows for the non-destructive, and spatial assessment of iron. Similarly, SR-XRF 
can be used to spatially and quantitatively assess brain iron content and also 
provides the benefit of being a non-destructive technique. This approach uses high 
energy electron beams to produce X-ray photons that are able to eject inner shell 
electrons from atoms within a sample (Figure 1-6). The ejection of an inner shell 
electron allows outer shell electrons to drop into the inner shell, thus releasing 
photons that can be detected (Figure 1-6). The energy released from atoms is 
specific to the energy change and to the element, with the primary observation 
being Kα energy detection, whereby an electron from the L shell, drops into the K 
shell orbitals (Figure 1-6). Furthermore, the amount of energy released is directly 
proportional to the concentration of the element in the sample. This technique has 
recently been used to quantitatively correlate MRI measurements against iron 
content and to assess brain samples from AD tissue (Antharam et al., 2012, Zheng 




Figure 1-6 SR-XRF method for detection of specific elements 
High energy X-ray photons cause inner shell electrons to be ejected from an atom. 
Electrons from higher energy shells move into the inner K shell in place of lost 
electrons, which involves an energy release in the form of photons. Kα photons are 
produced when an electron moves from the L shell to the K shell. Kβ photons are 
produced when an electron moves from the M shell to the L shell. Lα photons are 
produced when an electron moves directly from the M shell to the K shell. Detection 
of these photons allows quantification of elements in a sample. 
 
1.6. MRI and Iron Quantification 
MRI is a non-invasive method for detection of magnetic nuclei, the most abundant 
of which are water protons in the body. Changes in the magnetic properties of 
water due to interaction with cellular components can be detected using various 
MRI acquisition methods that therefore highlight tissue microstructure. Due to the 
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paramagnetic effects of iron on water protons, a number of studies have 
established the potential for detection of iron using MR methods (Bartzokis et al., 
1993, Clark et al., 2003, Haacke et al., 2005, Wood, 2007, Langkammer et al., 2010). 
 
1.6.1. Relaxometry  
The most studied methods for imaging iron involves the shortening of the 
transverse relaxation times T2 and T2*, or increased rates R2 and R2* (Ordidge et 
al., 1994, Schenck et al., 2006). A basic overview of MRI relaxometry is provided 
here (see review by Deoni (Deoni, 2010)). 
Protons and neutrons spin randomly within atomic nuclei. In nuclei that have an 
even mass number, these spins cancel each other out, whilst within nuclei with an 
odd mass number, they do not. It is these nuclei that are MR active, as they 
therefore demonstrate net spin. Given that atomic nuclei have a positive charge 
due to the presence of protons, a magnetic moment is created around the spinning 
nuclei, induced by the spinning charged particle. Protons are the most frequently 
utilised nuclei in MRI due to the large net magnetic moment created by a single 
proton and their high abundance in both water and fat found within the body. 
When outside of a magnetic field, protons show no alignment. When placed inside 
a magnetic field however, protons will orientate either parallel or antiparallel with 
the applied magnetic field (B0). There is an excess in the population of protons 
orientated in the parallel orientation due to the lower energy requirement in this 
direction compared with the anti-parallel orientation. The excess of protons 
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orientated parallel to B0 creates a net magnetisation (MZ) in the direction of the 
external magnetic field. The overall size of the net magnetization vector increases 
with greater B0 magnetic field strength, since the population difference between 
parallel and anti-parallel magnetic moments is proportional to B0. 
Furthermore, proton spin axes precess when in an external magnetic field, due to 
interaction of the magnetic moments with the external field. The precessional 
frequency of protons can be determined through the Larmor frequency, shown 
below: 
𝜔 = 𝛾𝐵0 
Where, ω is the Larmor, or precessional frequency (rad s-1), B0 is the magnetic field 
strength and γ is the gyromagnetic ratio, a constant for each atom defined as the 
frequency of a particular nucleus at 1 Tesla (T). 
The gyromagnetic ratio is specific for each magnetic nuclei, and so each nuclei has 
its own Larmor frequency at a given field strength. The Larmor frequency of 
protons at 1T is 42.57 MHz, and therefore at 7T, will be 297.99 MHz. By applying a 
radiofrequency (RF) pulse (termed B1) at the Larmor frequency for protons at a 
given B0, protons resonate, with two events occurring simultaneously (Figure 1-7). 
The RF pulse ‘tips’ the net magnetization, MZ, through an angle,  (e.g. by 90⁰, 
Figure 1-7A), towards the transverse, MXY, plane. Furthermore, the proton spins 
become coherent, therefore showing the same phase (Figure 1-7B). With the 
magnetization vector now solely in the transverse plane and coherent, image 
acquisition can occur due to the transverse magnetization inducing an electrical 
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signal in the receiver coil. Two intrinsic characteristics of nuclei can be detected 
following this application of a 90⁰ RF pulse; the T1, spin-lattice (or longitudinal) 
relaxation time, and the T2, spin-spin (or transverse) relaxation time (Figure 1-8). 
 
Figure 1-7 Net magnetisation vector and effects of 90⁰ RF pulse application 
(A) The net magnetisation vector (Mz) is flipped θ⁰ (90⁰ in this example) into the 
transverse (MXY) plane following application of an RF pulse of sufficient energy, and 
at the corresponding Larmor frequency. (B) A RF pulse also causes protons to 
precess coherently, in the same phase. 
 
T1 is the time constant required for the magnetization to recover in the 
longitudinal, z direction, back up to Mz (Figure 1-8A), whilst T2 is the time constant 




Figure 1-8 T1 and T2 relaxation mechanisms 
This figure shows (A) the application of a 90⁰ RF pulse causing the direction of 
proton magnetisation to fall into the x,y plane and Mz = 0,  followed by T1 
longitudinal relaxation, and (B) T2 transverse relaxation, and decay of MXY. 
 
Evaluation of T1 and T2 relaxation times is commonly performed using a spin-echo 
(SE) based sequence (see section 1.6.2). Similarly, Mxy can be evaluated using a 
gradient-echo (GE) sequence to provide the T2* relaxation time (see section 1.6.3). 
 
1.6.2. Spin-echo (SE) acquisition of T1 and T2 
Spin-echo (SE) imaging is a commonly-used standard method for acquisition of T1 
and T2 weighted images, or for T1 and T2 quantification. Due to magnetic field 
inhomogeneities and spins acting on each other to speed up or slow down 
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precessional frequencies, dephasing of spins begins as soon as the 90⁰ RF pulse has 
completed (Figure 1-9A-C). Therefore, a rephasing step is performed by applying 
another RF pulse, flipping spins 180⁰ (Figure 1-9D). The different spin speeds 
continue at the same rate; faster spins continue to precess fast, slower spins 
continue to precess slowly, providing an echo when the spins rephase back to 
coherence (Figure 1-9E-F). At this point, image acquisition can occur at full 
transverse signal. 
 
Figure 1-9 SE acquisition mechanisms 
(A) A 90⁰ RF pulse causes the net magnetisation vector to move into the transverse 
plane. (B) Dephasing of spins occurs immediately on completion of RF pulse, with (C) 
precessional spins fanning out at different speeds with time. (D) A 180⁰ RF pulse 
causes the spins to flip around the transverse plane axes, (E) refocussing the 
precessional spins for (F) image acquisition. 
85 
 
The T1 and T2 of samples can be measured using spin-echo acquisitions by changing 
the two parameters necessary for generating image contrast; the repetition time 
(TR), and the echo time (TE). The TR is the time between 90⁰ flips, controlling the 
longitudinal relaxation signal recovery (Figure 1-10), such that at low TRs, minimal 
recovery of T1 relaxation has occurred, compared with long TRs which allow for full 
recovery of Mz. The TRs are much longer than the TE, which is the time between the 
90⁰ flips of precessional spins, and image acquisition (Figure 1-10). The 180⁰ flip 
occurs at TE/2, to ensure image acquisition occurs at maximal signal availability.  
 
Figure 1-10 Basic SE acquisition sequence 
RF pulses on the top line and signal acquisition on the bottom line. The two main 
parameters contributing to image contrast are shown; the repetition time (TR) and 
the echo time (TE), in correspondence with when RF pulses are provided (top line) 
and signal acquisition occurs (bottom line). Double line gaps indicate that the TR is 




Acquisition of several SE images with different TRs and a constant, short, TE allows 
the measurement of T1 relaxation (Figure 1-11A). A short TE is optimal for T1 
measurement, to ensure limited effects on the obtained signal due to T2 effects. 
Signal intensity increases with an exponential function according to Y = M0 x [1 – e
(-
X/T1)], where Y is the signal intensity of the image, M0 is the proton density and X is 
the TR (Figure 1-11A). By solving the equation with each TR, the T1 value can be 
obtained, corresponding to recovery of 63% of the z-component of the 
magnetisation, Mz. Similarly, acquisition of several SE images with different TEs and 
a constant, long, TR allows the measurement of T2 relaxation (Figure 1-11B). A long 
TR is optimal for T2 measurement, to ensure full recovery of longitudinal relaxation 
thus limiting T1 effects on the obtained signal. Signal intensity decreases with an 
exponential function according to Y = M0 x e
(-X/T2), where Y is the signal intensity of 
the image, M0 is the proton density and X is the TE (Figure 1-11B). By solving the 
equation with each TE, the T2 value can be obtained, corresponding to a 63% 
reduction of the total relaxation in the transverse plane. The reciprocal of T1 and T2 
relaxation times provides the R1 and R2 relaxation rates, and these have been 
demonstrated to show direct linear correlation to iron content both in vivo and ex 




Figure 1-11 Overview of SE measurement of T1 and T2 values in samples 
(A) Representative images at three increasing TRs (1 – 3) for T1 measurement and 
(B) representative images at three increasing TEs (4 – 6) for T2 measurement are 
shown. Mean signal intensity for each of the regions of interest (ROIs) (red circles) 
are plotted against TR or TE, for calculation of T1 or T2 values, respectively (graphs). 
 
1.6.3. Gradient-echo (GE) acquisition of T2* 
Gradient-echo (GE) acquisition provides another way of assessing the Mxy 
component of samples. The sequence is initiated in a similar way to SE sequences, 
with a RF pulse to flip the magnetization vector towards the transverse plane. 
Again, spins start to dephase as soon as the RF pulse is removed, however whilst a 
180⁰ RF pulse is applied in SE sequences to refocus spins, a GE sequence applies a 
negative gradient immediately after the original 90⁰ RF pulse to cause rapid 
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dephasing of transverse magnetisation. A positive gradient in the opposite direction 
can then be applied to reverse this dephasing and leads to echo formation for signal 
acquisition.  
The GE method is therefore only able to refocus dephasing that was caused by the 
negative gradient, and does not refocus spins that have been affected by magnetic 
field inhomogeneities. SE sequences however rephase spins based on their natural 
environments therefore limiting the effects from local inhomogeneities. Hence, T2* 
acquisition incorporates T2 effects, as well as effects from inhomogeneities and 
magnetic susceptibility. 
 
1.6.4. Fast acquisition of T2 and T2* 
Whilst the SE and GE acquisition methods described above provide standard 
approaches for evaluation of T1, T2 and T2*, these sequences have long acquisition 
times making their feasibility for clinical use difficult (Deoni, 2010). Furthermore, 
scan time is limited when performing preclinical animal studies, due to the use of 
anaesthesia to prevent unwanted movement during MR acquisition in vivo. Home 
Office regulations limit the amount of time that an animal can be left under 
anaesthesia, limiting the time available for scanning by MRI. Faster acquisition 
methods can therefore be used to acquire T1, T2 and T2* relaxometry. Multi echo 
(ME) T2 and multi gradient echo (MGE) T2* evaluation are described here, given 




Both fast ME and MGE acquisitions begin by flipping the net magnetisation into the 
transverse plane, using a 90⁰ RF pulse, as described above. Spins are then rephased 
time and time again (Figure 1-12), by either using 180⁰ RF rephasing pulses (for T2 
measurement) or by utilising gradients to perform 180⁰ rephasing steps (for T2* 
measurement). The number of rephased echoes is the echo train length (ETL). 
 
Figure 1-12 Fast ME T2 and MGE T2* acquisition sequence and method 
Sequence begins with a 90⁰ RF pulse to move net magnetisation vector into the 
transverse plane. A series of echoes (see the signal line) are then created by using 
repeated 180⁰ RF pulses to dephase and then rephase spins during this acquisition. 
Signal acquisition mid-way through each 180⁰ rephasing pulse therefore allows 
acquisition of multi-echo data, from one initial 90⁰ pulse. MGE data is acquired in 
the same way, however using gradients to rephase spins instead of RF pulses. ETL 
are the number of echoes created within the acquisition sequence. 
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1.6.5. Assessment of brain iron using MRI in ageing and AD 
Many studies investigating brain iron content against MRI rely upon previously 
published post-mortem data to correlate observed in vivo MRI results with iron 
contents (Schenker et al., 1993, Ogg and Steen, 1998, Jensen et al., 2009, House et 
al., 2010, Qin et al., 2011). Iron contents quantified across multiple brain regions 
and ages tend to be taken from the Hallgren and Sourander study, from 1958 
(Hallgren and Sourander, 1958). 
 
1.6.5.1. Relaxometry 
Relaxometry measurements in tissues depend on the tissue water content, as well 
as the interactions of water protons with macromolecules (Haacke et al., 2005). 
Furthermore, small amounts of paramagnetic material, such as iron, can strongly 
impact the relaxometry of protons given their large magnetic moments compared 
with protons (Haacke et al., 2005). As highlighted in section 1.3.1, non-haem iron is 
predominantly present within ferritin and hemosiderin in the brain (Dedman et al., 
1992, Vymazal et al., 1996b) and these are considered to be the main iron sources 
in biological tissues that provide MRI contrast (Schenck, 2003). The other sources of 
non-haem iron in the brain, transferrin and iron within the LIP (see section 1.3.1), 
are considered to be at concentrations that are too low to impact MRI contrast. 
The relaxation mechanism for iron in ferritin has been attributed to the Proton 
Exchange Dephasing Model (PEDM), in which relaxation occurs between water 
protons at the surface of the iron oxide ferritin core and exchange with the bulk 
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water protons (Gossuin et al., 2002). The impact of this model is that it provides 
first order relaxation mechanism whereby R2 linearly increase with magnetic field 
strength (Gossuin et al., 2002). 
R1 was directly correlated to iron content in multiple brain regions and was found 
to correlate to age with a similar exponential fitting as that observed for iron 
contents during ageing from the Hallgren and Sourander post-mortem study (Ogg 
and Steen, 1998). Furthermore, T2 values were correlated against Hallgren and 
Sourander post-mortem iron contents, to demonstrate similar changes in T2, as 
that found for iron contents with age, in both the globus pallidus and putamen 
(Schenker et al., 1993). In both studies, a large change in T1 or T2 was observed in 
the first 20-30 years, which then plateaus by 40 years, similar to iron contents 
(Schenker et al., 1993, Ogg and Steen, 1998). The decrease in T2 values has not only 
been demonstrated to be similar in nature to the changes in iron content within the 
brain during ageing, however differences in iron content were also related to motor 
and cognitive functioning in normal ageing, with decreased T2 values providing 
decreasing scores in these tests (Pujol et al., 1992). A mathematical model 
developed involving iron deposition in the brain, as assessed using T2*, 
demonstrated that this may precede decreases in hippocampal volume, that in turn 
correlated to worsening memory scores in normal ageing adults (Rodrigue et al., 
2012). Furthermore, more prominent iron deposition, assessed by T2* 
quantification, was also observed in aged patients with hypertension across a 
number of brain areas (Rodrigue et al., 2011). 
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Evidence for iron deposition in the hippocampus of AD patients was suggested 
using T2-weighted imaging compared to control subjects (Schenck et al., 2006). 
Similarly, the iron contents from Hallgren and Sourander were correlated to R2’ 
values in a small cohort and then used to demonstrate increased R2’ values in the 
hippocampus, caudate, putamen and parietal cortex of both MCI and AD patients 
(Qin et al., 2011). Furthermore, R2’ values were shown to be strongly correlated 
against declining MMSE scores in this cohort. 
More recently however, research efforts have involved attempts to validate MRI 
methods using quantitative assessments of iron, to understand and validate the 
specific impact iron has on various MRI parameters. Iron content, assessed by AAS, 
was correlated against R2, determined in a 4.7T MRI scanner, using post-mortem 
AD tissue to define the content of iron required to cause correlative changes as 
55µg/g wet tissue (House et al., 2007). A comprehensive investigation performed 
R2 and R2* relaxometry on deceased subjects, followed by the bulk analysis of 
small areas of brain regions using ICP-MS from a single brain slice (Langkammer et 
al., 2010). Strong correlations between iron content and both R2 and R2* were 
found across multiple brain regions and subjects, with R2* showing greater 
sensitivity (Langkammer et al., 2010). Whilst these studies clearly show correlation 
of iron content across different brain regions, they do not evaluate the spatial 
correlation of iron content to MRI measurements within brain regions, to 
understand whether different tissue-dependent factors may be affecting 
relaxometry values. To address this, one study has evaluated the differences in iron 
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content correlation to R1 and R2 values either within WM or GM tissue (House et 
al., 2008). 
More recently, quantification of iron content, as well as myelin content, spatially 
using micro-PIXE has been performed to attempt to model relaxivities based on the 
contributing factors from these two variables (Stuber et al., 2014). Strong 
correlations between iron content and relaxometry were again identified and linear 
regression was utilised to model iron and myelin contents from relaxometry maps 
in these control cortical samples. These spatial quantitative methods for iron 
detection are also now being used to evaluate samples from neurodegenerative 
diseases, such as Alzheimer’s or Parkinson’s disease. Indeed, hippocampal sections 
from Alzheimer’s disease patients were assessed by both R2 and R2* with SR-XRF 
elemental mapping performed subsequently (Antharam et al., 2012). Whilst no 
global differences in iron content or relaxometry were detected between control 
and AD samples here, strong correlations to R2 and R2* were observed and 
detectable pixel hyper intensities were identified in a greater proportion of AD 
samples than control, potentially highlighting amyloid plaques containing 
accumulated iron. 
 
1.6.5.2. Field dependence of R2 
Non-standard methods, such as field dependent R2 increase (FDRI) have also been 
used to detect iron. FDRI is the measurement of R2 values at different field 
strengths, and has been suggested as a specific detection method for ferritin iron. 
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This specificity for ferritin iron is attributed to the linear increase of R2 with field 
strength due to the PEDM (see section 1.6.5.1). Furthermore, given that ferritin is 
the predominant source of non-haem iron in biological tissues (see section 1.3.1) 
FDRI may provide an excellent method for iron detection in vivo. Indeed, FDRI 
proved sensitive for ferritin iron above other types of iron, including transferrin 
bound iron and ferric iron (Bartzokis et al., 1993). 
FDRI has been used to assess brain ferritin levels (Bartzokis et al., 1993) and post-
mortem iron concentrations in the frontal white matter, caudate nucleus, putamen, 
and globus pallidus of normal ageing in the human brain (Bartzokis et al., 1994a). 
FDRI has also been used to identify increased ferritin iron in the caudate, globus 
pallidus and putamen in AD (Bartzokis et al., 1994b, Bartzokis et al., 2000) and in 
the basal ganglia in HD (Bartzokis et al., 1999), compared to control subjects. 
Furthermore, the age and gender differences observed with neurodegenerative 
diseases has been attributed to differences in ferritin iron levels, as detected using 
this approach (Bartzokis et al., 2007a). The limitation for performing FDRI however, 
is the need for MRI scanning at different field strengths. 
 
1.6.5.3. Susceptibility 
Due to the highly paramagnetic nature of iron, measurement of susceptibility 
effects can also provide a means for iron detection and quantification (Haacke et 
al., 2004, Wallis et al., 2008). R2’ is the contribution of susceptibility effects due to 
local inhomogeneities, which is incorporated with the intrinsic transverse relaxation 
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from R2* measurement, and can therefore be simply calculated by subtracting R2 
from R2* (Miszkiel et al., 1997). Another, more recent approach for measuring 
susceptibility uses susceptibility weighted imaging (SWI) or quantitative 
susceptibility mapping (QSM), which utilises phase imaging for the detection of 
substances with different magnetic susceptibilities in adjacent tissues (Haacke et 
al., 2004, Haacke et al., 2005). 
Using SWI, differences were identified in brain iron deposition with age and even 
between brain hemispheres (Xu et al., 2008), however no differences due to gender 
were observed, unlike that shown by FDRI (Bartzokis et al., 2007a). In healthy 
subjects, R2* and phase from SWI showed high correlation values against iron 
concentration within the brain at a variety of field strengths (Yao et al., 2009). 
Furthermore, given the potential of SWI to detect iron in the brain, baseline phase 
behaviour in a number of brain regions has been acquired from 75 normal subjects, 
for future possible comparisons against neurological pathologies, including 
neurodegeneration (Haacke et al., 2007). Quantitative susceptibility mapping (QSM) 
has been developed as an approach to quantify the levels of iron in the brain (de 
Rochefort et al., 2010) with the red nucleus, substantia nigra and cerebellar nuclei 
showing increased iron levels compared to the rest of the brain tissue. Comparison 
of QSM to SR-XRF elemental iron contents in a whole post-mortem human brain 
slice, showed very strong correlation (Zheng et al., 2013). 
Using the APP/PS-1 mouse model of AD, SWI was compared against T2 and T2*-
weighted imaging for amyloid plaque detection and showed improved contrast to 
noise ratio in plaques with iron staining (Chamberlain et al., 2009). Whilst this study 
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provides strong evidence for the optimal detection of plaques by comparison 
against Perls stain, assessment of sensitivity can only be performed using 
quantitative measurements of iron content, such as using SR-XRF, which has been 
shown to correlate iron levels with SWI in AD transgenic mice (McCrea et al., 2008). 
 
1.6.5.4. Magnetic Field Correlation 
Magnetic Field Correlation (MFC) is another approach for iron detection by imaging 
of the magnetic field inhomogeneities within tissue (Helpern et al., 2004, Jensen et 
al., 2006). Whilst both R2* and R2’ measurements incorporate signal from 
inhomogenities, they are both also affected by transverse relaxation mechanisms 
caused by dipole-dipole interactions with water protons (Jensen et al., 2006). MFC 
was designed to provide a better method for inhomogeneity imaging than using 
R2* or R2’, and relies on the ability to measure the effect of inhomogeneities on the 
magnetic field, temporally (Jensen et al., 2006). 
MFC showed linear correlation to iron content in the basal ganglia of normal adults 
and was found to be significantly greater in regions from an aceruloplasminemia 
patient, in which greater brain iron levels are found (Jensen et al., 2009). Limited 
evidence for the application of MFC in AD has previously been performed, however 
MFC values were found to be higher in the globus pallidus, putamen and thalamus 
of MS patients than controls, and correlated to both MS lesions and to 




1.6.5.5. Imaging plaques 
It has been suggested that detection of plaques using MRI is due to iron 
accumulation raising the intrinsic paramagnetic properties of amyloid. Animal 
models of AD have again been invaluable for determining and validating transverse 
relaxation methods for plaque detection during pathology. In the first instance, 
imaging of plaques has highlighted differences in T2 and T2* weighted images in a 
longitudinal study of the APP/PS-1 mouse (Wengenack et al., 2011). These MR 
images were correlated against Perl’s stain for iron, Thioflavin S fluorescence for β-
sheet aggregated protein and Aβ-plaques using an antibody and showed that whilst 
T2 imaging was able to detect plaques in all brain regions, T2* images could only 
reliably detect iron loaded plaques in the thalamic areas but not those in the cortex 
and hippocampus (Wengenack et al., 2011). Similar findings were observed for iron 
loaded plaque detection in the APP(V717I) AD mouse model (Vanhoutte et al., 
2005). Calcium and iron accumulation have been suggested to create contrast in 
T2* quantification of plaques in APP/PS-1 mice (Dhenain et al., 2009). More 
recently however, disparity between human AD plaques and plaques from APP/PS-
1 mice was shown by evaluating R2* relaxivity and contrast. Whilst human plaques 
demonstrated R2* contrast associated with iron accumulation, R2* contrast in 
plaques from the APP/PS-1 mouse were not (Meadowcroft et al., 2009). Using 
deferoxamine to chelate iron from human AD plaques still provided contrast using 
R2* mapping, therefore suggesting that amyloid plaques are able to impact R2* 




1.6.5.6. Confounding effects for detection of iron in the brain 
It should be noted however that whilst MRI methods to assess iron content have 
been extensively reported in the literature, many other factors also affect 
relaxometry values in tissue, including water content, e.g. oedema (Kato et al., 
1986), or tissue microstructure (Deoni, 2010). White matter (WM) demonstrates 
very different composition to grey matter (GM) and has therefore been shown to 
strongly impact R1, R2, R2* and susceptibility quantification (Rooney et al., 2007, 
Schmierer et al., 2007, Fukunaga et al., 2010). Furthermore, given that 
oligodendrocytes contain high levels of iron for myelin production and maintenance 
(see section 1.3), attempts have been performed to understand the signal 
attributed to iron compared with myelin, mostly through the use of iron chelation 
to extract iron and leave myelin. Indeed, WM regions from post-mortem occipital 
cortex showed strong effects on R2* and susceptibility, which were substantially, 
but not completely, removed following iron chelation (Fukunaga et al., 2010). More 
recently, attempts to quantitatively model myelin content using sulphur and 
phosphorus, alongside iron content have been trialled using micro-PIXE, and 
showed that WM provides substantial influence on relaxation values (Stuber et al., 
2014). 
Additional complexity in the assessment of relaxometry values within regions of 
WM, are the discoveries that WM orientation can also substantially affect R2* 
values, which may equally need to be taken into account in quantifying iron 




1.7. Methodology Considerations 
1.7.1. Post-mortem evaluation 
1.7.1.1. Post-mortem interval (PMI) 
When using post-mortem human or mouse tissue, various factors must be taken 
into account. One such factor is the post mortem interval (PMI) which is the time 
taken from death until the brain is fixed or frozen at the brain bank. The post-
mortem delay (PMD) is the time taken from death until the brain is removed from 
the skull. During the PMI, many biochemical changes can occur, ranging from short 
term changes in protein and metabolite concentrations, to longer term tissue 
degradation (Perry et al., 1981, Petroff et al., 1988, Thompson et al., 2013). 
Metabolite changes in tissue composition have even been detected using 1H-MRS, 
from 3 days onwards in post mortem sheep and human brain (Ith et al., 2002) and 
used in attempts to estimate the PMI, purely based on metabolic profiles (Scheurer 
et al., 2005). However, very few studies have investigated the effect of PMI length 
on relaxometry assessment. An early study discovered that a minor decrease in T2, 
but not in T1 relaxivity values was observed between a two and 90 hour PMI in 
porcine brain tissue, however these samples were maintained at 8⁰C potentially 
attenuating any likely changes in relaxometry (Gyorffy-Wagner et al., 1986). More 
recently, conflicting evidence has been demonstrated using rat brain samples for 
the effects of PMI length on relaxometry values (Fagan et al., 2008, Shepherd et al., 
2009). In situ assessment of T1 and T2 values in the rat corpus callosum, striatum 
and cortex, decreased with PMI length during a 24 hour period of repeated 
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scanning (Fagan et al., 2008). T1 and T2 values continued to decrease even after 
stabilization of core body temperatures to the magnet temperature, after 10 hours 
post mortem (Fagan et al., 2008). Conversely, T1 and T2 values were increased 
using rat cortical samples immersed in formaldehyde fixation at increasing PMI 
lengths up to 24 hours (Shepherd et al., 2009). No effects of PMI directly on iron 
content exists from the limited literature (Loeffler et al., 1995). 
 
1.7.1.2. Fixation time 
Other factors that may affect MR results include the fixation time of samples. The 
fixation time of human post-mortem tissue indicates the period that samples have 
been submerged in formalin fixative solution. Fixation of tissues is a commonly 
performed technique for tissue preservation, to stop decomposition, whilst also 
maintaining protein interactions and localisation (Fox et al., 1985, Puchtler and 
Meloan, 1985). The fixation of samples using formalin involves the cross-linking of 
proteins together to preserve tissue in its initial form. As MRI involves the 
measurement of proton spins to generate contrast based on water proton 
environments, it has been well documented that changes in MR contrast and 
relaxometry can occur as a result of the fixation process compared with fresh tissue 
(Tovi and Ericsson, 1992, Blamire et al., 1999, Dawe et al., 2009). T1 and T2 values 
have been shown to decline with fixation time, although the decline is greater for 
T1 (Tovi and Ericsson, 1992, Blamire et al., 1999). Furthermore, T2 values were 
shown to change differently depending on the depth of tissue, highlighting longer 
times required for fixative to reach the deeper brain regions (Dawe et al., 2009). 
101 
 
These relaxometry changes are associated with decreased water proton availability 
and movement during fixation. 
 
1.7.2. Subjects’ age at death 
Few studies have been specifically performed evaluating any impacts of adult or 
aged subjects’ ages on relaxometry or iron contents. In general, these effects have 
only been determined from young, through to adult and old patients, where a steep 
increase in iron is detected for the first 20-30 years of age, until iron levels plateau 
(Hallgren and Sourander, 1958). Similar observations for T2 relaxation with age, as 
that in the Hallgren and Sourander study, have been observed (Pujol et al., 1992, 
Schenker et al., 1993). More recently however, an age dependent effect on normal 
iron contents has been observed in adult samples, which was also dependent on 




2. Thesis Aims, Objectives and Hypotheses 
The overall aim of this thesis is to evaluate the application of MRI methods to non-
invasively and accurately, detect and quantify iron during neurodegeneration. This 
work is the first to link iron assessment using MRI in an in vitro model with ex vivo 
post-mortem tissue and in vivo assessment of iron, within the same work.  This 
work also provides further validation of studies which have so far provided 
inconclusive and conflicting results with respect to detectable changes in iron 
content in the brain during neurodegenerative diseases. It is also the first to 
demonstrate and spatially assess elemental iron levels in the medial temporal 
gyrus, a region involved in Alzheimer’s disease alongside MRI data from the same 
region and includes a greater number of both control and Alzheimer’s disease 
human tissue samples than other studies, giving greater statistical power in the 
conclusions being drawn. 
Specific objectives are detailed in the relevant chapter for each study described in 
this thesis. 
 
Brain iron content appears to be elevated in neurodegenerative diseases (see 
section 1.4.1) and hence there is great interest in measuring iron non-invasively 
within the brain (see section 1.6.5). Evaluation of iron content by MRI in live, 
biological tissue however can be complex due to the heterogeneous localisation 
and forms of iron (see section 1.3.1), as well as the varied tissue environments. 
Thus, in the first instance, the ability of MRI to measure iron in a simple model using 
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agarose gel standards containing various concentrations of iron, will be assessed. 
Having explored the relationships between various MRI metrics with different iron 
concentrations and forms in simple in vitro models, the associations of iron with 
these MRI measures will be assessed in neurodegeneration in humans and in an 
iron induced mouse model of neuronal death.  
Whilst there is consistency in the use of MR methods as surrogate measures of iron 
during neurodegeneration, most involve clinical studies where correlation with iron 
is performed against previously published post-mortem iron data (see section 
1.6.5), or using histochemical Perl’s stain (see section 1.5.1). Whilst Perl’s stain 
provides important characterisation of iron localisation, this technique may be 
limited by non-specific staining and non-linear responses to varying iron 
concentrations, limiting analysis of the precise impact of iron content on MRI. Thus, 
the second objective of this project is to quantitatively assess iron content using SR-
XRF in AD compared with control tissue, and to correlate this with the detection of 
iron using MRI, for each group. This assessment was focussed on material from the 
medial temporal gyrus (MTG) given this region’s involvement in AD pathology (see 
section 1.2.1), as well as the presence of both WM and GM tissue in this region. The 
presence of both WM and GM in the MTG allows comparisons of influencing factors 
within human tissue that can also affect iron detection using MRI measurements, 
such as myelin content (see section 1.6.5.6). These observations can help 
understand how MRI measurements are affected by iron content in the brain, 
within different tissue types.  
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Finally, as it is impossible to validate iron-sensitive MR acquisition methods in the 
brain and to assess neurodegeneration directly due to iron in vivo in a clinical 
environment, an animal model will be utilised (see section 1.4.4). Animal models 
provide a useful tool to perform investigations within a controlled, in vivo, system 
and thus, the third objective of this project will be to validate iron-sensitive MR 
measurements in vivo and understand how iron may cause neuronal cell death. This 
study will be performed by directly injecting ferric citrate bilaterally into the mouse 
hippocampus, to explore the direct effect of iron induced neuronal death, without 
the detrimental effects associated with transgenic animal models of 
neurodegeneration that also give rise to iron overload. 
 
The hypotheses for this work are that: 
 Iron-sensitive MRI relaxometry methods will show strong, positive 
correlation to known amounts of iron in solution, or associated with ferritin, 
in simple agarose standards. 
 Iron-sensitive MRI relaxometry methods will positively correlate with SR-XRF 
elemental mapping of iron in control and AD post-mortem human MTG. 
 Myelination will affect iron-sensitive MRI relaxometry methods in control 
and AD post-mortem human MTG. 
 Iron sensitive MRI relaxometry methods will be able to quantify, and will 
correlate with, iron content detected by SR-XRF in an iron induced animal 
model of neuronal cell death. 
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 Iron content will show correlation to pathology severity, assessed using 
animal behaviour methods and histological staining for markers of neuronal 




3. Materials and Methods 
3.1. Materials 
3.1.1. Animals 
Male C57Bl/6 mice were used in all animal studies performed and were obtained 
from Harlan (Bicester, UK). Animal studies were performed in accordance with the 
Animals (Scientific Procedures) Act 1986 (UK) under project license (PPL) number 
70/7085 and personal license (PIL) number 70/24270. All mice were housed in pairs 
in standard cages under a 12 hour light and dark cycle with ad libitum access to 
RM1 food pellets (SDS, Essex, UK) and water. 
 
3.1.2. Reagents 
The following reagents were purchased for performing laboratory experiments. 
Agarose (low melting point; Life Technologies Ltd, UK), ferric chloride (Sigma, Poole, 
UK), ferrous chloride (Sigma, Poole, UK), hydroxylamine hydrochloride (Sigma, 
Poole, UK), 1,10-phenanthroline (Sigma, Poole, UK), sodium acetate (Sigma, Poole, 
UK), QG buffer (Qiagen, Venlo, Netherlands), ferritin from equine spleen in saline 
(Sigma, Poole, UK), sodium citrate (Sigma, Poole, UK), sucrose (Sigma, Poole, UK), 
phosphate buffered saline (PBS) tablets (Oxoid Ltd, Basingstoke, UK), sodium azide 
(NaZ) (Sigma, Poole, UK), sodium hydroxide (BDH, UK), 12M hydrochloric acid (HCl) 
(Fisher Scientific, UK), neg-50 cryoembedding medium (Thermo Scientific, UK). 
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The following reagents and antibodies were used for histological and 
immunohistochemical assessment. 
Xylene (general purpose grade; Fisher Scientific, UK), 30% solution hydrogen 
peroxide (Sigma, Poole, UK), tris (hydroxymethyl) methylamine powder (VWR 
International, Leicestershire, UK), triton-X100 (Sigma, Poole, UK), NaCl (VWR 
International, Leicestershire, UK), normal donkey serum (Jackson Laboratories, UK), 
rabbit polyclonal anti-Iba-1 antibody (019-19741; Wako Pure Chemical Industries, 
Richmond, VA), cresyl violet (VWR International, Leicestershire, UK), luxol fast blue 
(Sigma, Poole, UK), lithium carbonate (Sigma, Poole, UK), haematoxylin (VWR 
International, Leicestershire, UK), Immpact DAB peroxidase substrate kit (Vector 
Laboratories, UK), skimmed milk powder (SMP) (Marvel, UK), 100% industrial 
methylated spirit (IMS) (Fisher Scientific, UK), 100% acetic acid (VWR International, 
Leicestershire, UK), absolute ethanol (Fisher Scientific, UK), DPX mountant (Sigma, 
Poole, UK), swine anti-rabbit IgG (DAKO, High Wycombe, UK), anti-rabbit IgG 
VECTASTAIN Elite avidin-biotin peroxidase complex kit (ABC kit) (Vector 
Laboratories, UK), Impress Reagent ready-made kit horse anti-mouse peroxidise-
conjugated IgGs (Vector Laboratories, UK). 
 
The following reagents were purchased for performing animal work and surgeries. 
5% EMLA® cream (25mg/g Lidocaine, 25mg/g Prilocaine; AstraZeneca UK, Luton, 
UK), Lacri-lube preservative-free eye ointment (Allergan Ltd, Marlow, Bucks, UK), 
Vetergesic® (0.3mg/ml buprenorphine hydrochloride; Reckitt Benckiser Healthcare 
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(UK) Ltd, York, UK), heparin sodium 5,000 IU/ml (Wockhardt Ltd, UK), 100% w/w 
isoflurane (Abbott Animal Health, Kent, UK), Vetasept 0.75% w/w Povidone-Iodine 
solution (Animalcare Ltd, York, UK), Medical air and Medical oxygen (BOC Ltd, 
Guilford, Surrey), 4% paraformaldehyde (Pioneer Research Chemicals, UK), 
Aquapharm® 0.9% sterile saline solution (Animal Care, York, UK), Euthatal (sodium 
pentobarbital; Merian Animal Health, UK), Vetasept chlorhexidine clear spray 
(Animalcare Ltd, York, UK). 
 
The following reagents were purchased for performing MRI scanning: 




The following equipment was used during both in vivo and ex vivo MRI scanning: 
7T Agilent MRIS system (Agilent Technologies, Oxford, UK), 43 mm inner diameter 
(ID) quadrature volume coil (MRL, Oxford), 26 mm/ 33 mm/ 39 mm quadrature 





Blease Frontline Genius and Blease vaporiser (Spacelabs Healthcare, WA, USA), Fan 
Module (High Output) (SA Instruments, NY, USA), Heater Module (SA Instruments, 
NY, USA), ECG/Temperature module (SA Instruments, NY, USA), Control/ Gating 
Module (SA Instruments, NY, USA). 
The following items were only required for ex vivo MRI scanning: 
1 ml, 10 ml, 20 ml and 30 ml syringes (BD, NJ, USA), 1 ml heparinised syringes 
(Protech Medical Ltd, Glossop, UK), parafilm (Bemis Flexible Packaging, Neenah, 
WI), single edge razor blades (Fisher Scientific, UK). 
 
Surgical Procedures 
Equipment required for animal surgical procedures included: 
Stereotaxic frame (David Kopf Instrument, Tujunga, CA) with platform (Stoelting, 
Wood Dale, IL, USA), Contura electric razor (Wella, UK), 2.5μl Hamilton syringe 
(Hamilton Medical, Reno, NV), microsyringe pump and Micro4 pump controller 
(World Precision Instruments, Sarasota, FL, USA), homeothermic blanket control 
unit and blanket (Harvard Apparatus, Cambridge, MA, USA), V-Lux 1000 swan neck 
lighting unit (Volpi, USA), Microtorque II drill unit and Tech 2000 drill handpiece 
(Smooth N Sleek SDN BHD, Penang, Malaysia), micro drill steel burr (0.5mm) (Hager 
& Meisinger GmbH, Neuss, Germany), SES Little sister 3 autoclave unit (Eschmann 
Equipment, West Sussex, UK), sterile gloves (Latex Biogel, Mölnlycke Health Care 
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Limited, Bedfordshire, UK), cotton buds (Johnson and Johnson, Maidenhead, UK), 
scalpel (Swann-Morton Limited, Sheffield, UK),  0.20µm pore filter (Sartorius Stedim 
Biotech, UK), 4-0 vicryl sutures (Ethicon, USA), Fear Conditioning System (TSE 
Systems GmbH, Bad Homburg, Germany), metal gavage needle of 0.9mm gauge 
(Instech, PA, USA), perfusion equipment (AutoMate Scientific Inc., CA, USA). 
 
Laboratory based work required the following equipment: 
Leica SCN400F slide scanner (Leica, UK), pH meter 240 (Corning, MA, USA), 
benchtop centrifuge 5415D (Eppendorf, Stevenage, UK), Micro Centaur bench top 
centrifuge (MSE (UK) Ltd, London, UK), vortex (Jencons PLC, UK), Microm HM550 
cryostat (Thermo Scientific, MA, USA), SmartSpec Plus spectrophotometer (Bio-Rad 
Laboratories, CA, USA), plastic cuvettes (VWR International Leicestershire, UK), 
magnetic stirrer (Jencons, PLC, UK), staining tray (VWR International, Leicestershire, 
UK), superfrost plus glass microscopy slides (Fisher Scientific, UK), 4µm thick 
Ultralene® (SPEX SamplePrep, NJ, USA), C35 disposable microtome blades (Cellpath, 
UK), coverslips (VWR International, Leicestershire, UK), 15ml and 50ml centrifuge 
tubes (Corning, MA, USA), 50ml and 1000ml measuring cylinders (VWR 
International, Leicestershire, UK), Costar® 10ml stripette serological pipettes 
(Corning, MA, USA), glass bottles (VWR International, Leicestershire, UK), 0.5ml, 





3.1.3.1. Customised equipment 
Mouse brain holder 
In order to increase efficiency of scanning, a brain holder was developed to scan 
multiple brains within one acquisition time, rather than single scanning of one brain 
at a time (Figure 3-1) by modification of a 20 ml syringe tube. 
 
Figure 3-1 Customised brain holder 
(A) Individual components of the brain holder are shown, comprised of the syringe 
tube, brain divider and plunger. (B) Brain holder with the components together for 
scanning up to four brains at once. 
 
A plunger from either a 10 ml or 20 ml syringe was cut to a length of approximately 
3 cm to allow a mouse brain to sit within the length of the divider (Brain divider, 
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Figure 3-1A) and one lobe of the divider was sliced off to signify a “number 1” 
position, allowing identification of each brain within the holder to the user. Loading 
of the brains was performed from position 1, next to the sliced lobe of the divider 
and the divider pushed to the end of a 20 ml syringe tube with the end cut off 
(Figure 3-1A). Parafilm was used to seal the top of the syringe tube before Galden® 
was poured in. The 20 ml plunger was then used to seal the Galden® in at the end 
and pushed all the way down to the brain divider. The needle hole allows the 
plunger to be pushed down without a build-up of pressure in the tube. Any 
remaining bubbles could be removed by adding Galden® using a small syringe with 
needle into the needle hole. This hole in the tube was then sealed using tape, 
followed by using parafilm to ensure no leakage from the brain holder during 
scanning. 
 
Custom-made XRF slides 
Custom made slides were used for XRF elemental analyses, due to the high 
sensitivity of this analytical technique and the possibility of metal contamination of 
samples. Acrylic slides with identical dimensions to normal histological slides (76 x 
25 mm) were made, with a square hole in the centre of the slide with dimension 50 
x 18 mm (Vet Tech solutions, UK) (Figure 3-2). Acrylic slides were first washed in 
100% IMS before Ultralene® XRF film was glued across the slides so that samples 
could be mounted in the area with the gap. This provided an open area for XRF 
analysis of tissue samples, without any possibility of contamination from glass, or 




Figure 3-2 Image of custom-made slide for XRF elemental mapping 
An acrylic slide with a gap of 50 x 18 mm was custom made for XRF elemental 
mapping and Ultralene® XRF film glued over the top to mount samples within the 
open region of the slide, limiting possible contaminants during analysis. 
 
3.1.4. Software 
Computer software used included; JIM 5.0 (Xinapse Systems, Alwincle, UK), ImageJ 
(National Institute of Health, Maryland, USA), FSL (FMRIB Software Library, Oxford, 
UK), PyMCA (ESRF, France), Prism (GraphPad, SD, USA) and cocor (comparing 
correlation) (Diedenhofen and Musch, 2015). 
 
3.1.5. Preparation of Solutions 
Heparin solution for cardiac perfusions 
1. 1 ml Heparin (5000 IU/ml) was added per 100 ml saline producing a final 
concentration of 50 IU/ml. 
70% ethanol solution 
1. 30 ml distilled water (dH2O) added to 70 ml ethanol in a measuring cylinder. 
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PBS and PBS + sodium azide (0.05%) solutions 
1. Add one PBS tablet per 100 ml dH2O. 
2. Add a stirring magnet into the bottle and stir for 5 minutes until the tablet 
fully dissolves. 
3. If sodium azide (NaZ) was also required to be added to the PBS to help 
prevent bacterial growth during long-term storage of samples, 0.05 g 
sodium azide was added per 100 ml PBS. 
30% sucrose + sodium azide (0.05%) solution 
1. Weigh out 150 g sucrose powder. 
2. Add the powder to 400 ml PBS in a bottle. 
3. Add a stirring magnet into the bottle and stir the solution for 5-10 minutes 
until the sugar fully dissolves into the PBS. 
4. Weigh out and add 0.25 g Sodium Azide to the bottle. 
5. Pour the clear solution into a measuring cylinder and top up with PBS to 500 
ml. 
6. Pour back into bottle and store at 4⁰C until ready to use. 
2% agarose solution 
1. 1 g of agarose is weighed per 50 ml H2O 
2. Shake bottle well. 
3. Dissolve agarose powder by microwaving for approximately 1 minute, until 
the solution begins to boil and becomes clear. 
4. Allow the agarose solution to cool to near gelling point before use. 
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7.5% gelatin solution 
1. 3.25g of gelatin is weighed per 50ml dH2O. 
2. Shake bottle well. 
3. Dissolve gelatin powder by microwaving for approximately 1 minute, until 
the solution begins to boil and becomes clear. 
4. Allow the gelatin solution to cool to near gelling point before use. 
100 mM ferric or ferrous iron stock solution  
1. Weigh out each form of iron to formulate a 100 mM solution in 10ml dH2O 
(Table 3-1). 
2. 10ml of dH2O was then added and solutions inverted and vortexed to 
ensure the iron fully dissolved to formulate 100 mM stock solution 
Table 3-1 Table of ferric and ferrous chloride formulae, molecular mass and 
weights measured for producing top iron stock solutions at 100 mM 
 Formula MW Weight measured (g) 
Ferric chloride (Fe3+) FeCl3 162.3 0.1623 
Ferrous chloride (Fe2+) FeCl2.4H2O 198.8 0.1988 
MW = Molecular Weight 
1,10-phenanthroline solution 
1. Add 0.1802 g 1,10-phenanthroline to 200 ml dH2O to make 5 mM stock. 




Sodium acetate solution 
1. Add 10.206 g sodium acetate to 75 ml dH2O to make 1 M stock. 
Hydroxylamine hydrochloride solution 
1. Add 2.6059 g hydroxylamine hydrochloride to 50 ml dH2O to make 0.75 M 
stock. 
Tris buffer saline (TBS) (+/- triton X-100) solutions 
1. Made from 20 mM Tris base, 150 mM NaCl, pH: 7.4 
2. Add 2.422 g Tris base to approximately 950 ml dH2O in a bottle. 
3. Add 8.766 g NaCl to the Tris base solution. 
4. Add a stirring magnet into the bottle and stir the solution until powder fully 
dissolves. 
5. Adjust the pH of the solution to 7.4 by adding HCl. 
6. Add dH2O up to 1000 ml (TBS(-)). 
7. TBS(+) made by addition of 0.2% triton X-100. Triton X-100 is used to make 
membranes permeable during IHC. 
Blocking buffer solution 
1. Add 10 ml dH2O to powdered Normal Donkey serum, according to 
manufacturer’s instructions. 
2. 10% Normal Donkey serum added into 90% TBS(+). 
Primary and secondary antibody buffer solution 




1. DAB solution made up by adding 1 drop DAB reagent to 1ml DAB diluent, 
according to manufacturer’s instructions. 
0.1% luxol fast blue 
1. Add 0.1 g luxol fast blue to 100 ml IMS. 
2. Add 0.5 ml 10% aqueous acetic acid and mix solution well before use.  
0.05% lithium carbonate 
1. Add 0. 05 g lithium carbonate to 100 ml dH2O. 
Sodium citrate buffer for antigen retrieval 
1. Add 1.92 g/L sodium citrate into dH2O to make 10 mM solution. 
2. Adjust the pH to 6 using sodium hydroxide solution whilst stirring with a 
magnet. 
Nissl stain 
1. Weigh 0.05% cresyl fast violet powder into dH2O, with 0.1% acetic acid. 
2. Solution is heated up to 56⁰C in the microwave for full dissolution. Care was 
taken not to overheat the solution above this temperature. The solution was 
filtered prior to use to remove large clumps of cresyl violet in the solution. 
3. Prior to use, 0.5 ml of 10% acetic acid per 100 ml of cresyl violet solution is 




Ferric citrate solution formulation for animal injections 
The pH of ferric and ferrous sulphate solutions were measured dissolved in PBS, 
dH2O, or saline (Table 3-2). The pH meter was calibrated at pH 4.00, 7.00 and 10.00, 
prior to performing these measurements. 
Table 3-2 pH values of different ferric and ferrous iron solutions tested 
 Concentration (mM) PBS dH2O Saline 
Ferrous Sulphate 0 7.19 5.02 4.69 
 0.5 7.01 4.05 4.40 
 1 6.85 4.09 4.37 
Ferric Sulphate 0 7.21 5.20 4.76 
 2 6.20 2.47 2.75 
 
Both ferric and ferrous iron addition led to lowering pH values, which cannot be 
injected into the brain due to greater acidity. Furthermore, iron precipitated when 
adjusting the pH to 7. 
Therefore, ferric citrate was synthesised ourselves by addition of aqueous ferric 
chloride solution with equimolar sodium citrate (Armstrong et al., 2001). 4 mM and 
2 mM ferric citrate solutions were created for injections, whilst 4 mM sodium 
citrate solution was used for control dosing. 
1. Ferric chloride powder was weighed out to create a 2 x molar concentration 




2. Sodium citrate at equimolar concentration to the iron solution was made 
(i.e. at 8 mM). 
3. Equal volumes of ferric citrate and sodium citrate solutions were combined, 
to form a 4 mM ferric citrate solution. 
4. The pH was adjusted to pH 7.4 using aqueous sodium hydroxide. 
5. Solutions were filter-sterilized using a 0.20µm pore filter, prior to injections. 
 
3.2. Methods 
3.2.1. Iron agarose standards 
Iron standards were formulated in 2% agarose to allow MRI relaxometry to be 
performed in a model substance with relaxivity values close to that of brain tissue. 
 
3.2.1.1. Iron solutions 
In the first set of studies, 100 mM ferric chloride or ferrous chloride solutions were 
formulated in 10 ml ultrapure MilliQ water. These solutions were used as the 
highest stock dilutions. 40, 20, 10, 5 and 2 mM solutions were produced by serial 
dilution of the 100 mM stock iron solutions providing a consistent dilution factor 





Table 3-3 Table of dilutions for production of iron agarose standards  
Iron concentrations (mM) 100 40 20 10 5 2 0 
Dilution factor for serial dilution - 2.5 2 2 2 2.5 - 
Serial dilution volume (ml) 10 1 1 1 1 1 - 
MilliQ water volume (ml) - 1.5 1 1 1 1.5 10 
Dilution factor into 2% agarose 20 20 20 20 20 20 20 
Final concentration (mM) 5 2 1 0.5 0.25 0.1 0 
 
In a subsequent study, 100 mM ferric chloride or ferrous chloride solutions were 
produced in 10 ml ultrapure MilliQ water for a two-fold serial dilution, to provide 
further top solutions of 50, 25, 12.5, 6.25 and 3.13 mM. These provided final iron 
concentrations of 5, 2.5, 1.25, 0.63, 0.31 and 0.16 mM in the agarose standards. A 
control agarose standard with 0 mM iron was always prepared alongside iron 
concentrations to ensure reliability and reproducibility of iron agarose standard 
assessments. 
 
Monitoring of ferric and ferrous iron pH 
The pH of iron agarose standards were measured to evaluate any impact on 
relaxometry parameters. Measurement of the pH of ferric and ferrous iron directly 
in agarose was not performed due to the possibility of contaminating the pH sensor 
with agarose. Therefore, aqueous solutions of the ferric and ferrous iron were 
121 
 
formulated at the same concentrations as the final agarose standards and the pH of 
these solutions measured as a surrogate model to the agarose standards. 
 
Validation of the oxidation states of iron in agarose standards 
The oxidation states of iron in the agarose standards were validated using 1,10-
phenanthroline. 1,10-phenanthroline turns red in the presence of ferrous (Fe2+) iron 
ions and can be measured spectrophotometrically at an absorbance of 510nm. 
Hydroxylamine hydrochloride can be added into the assay mixture to reduce ferric 
(Fe3+) iron ions to the ferrous form, for subsequent detection with 1,10-
phenanthroline. 
To validate the oxidation states of iron in the agarose standards, 100 µl of each 
agarose standard was sliced off using a clean metal blade and the slice transferred 
into a centrifuge tube. 300 µl QG buffer was added to each tube and allowed to 
heat up to 60⁰C for 10 minutes. This QG buffer dissolves the agarose and prevents 
gelling under these conditions. Sodium acetate was added to 20 mM final 
concentration and the 1,10-phenanthroline to 0.75 mM final concentration. Water 
was added to a final assay volume of 5 ml. Hydroxylamine hydrochloride was not 
added to this assay mix to prevent the reduction of iron from the ferric to ferrous 
form and therefore allow validation of the oxidation states of iron in the standards. 
Final absorbance measurements were adjusted for the slight variations in weight of 




Validation of iron content present in agarose standards 
To validate the accuracy of iron content present in the agarose standards, a 
standard curve of ferrous iron was formulated at the following concentrations; 
10.00, 7.50, 5.00, 3.75, 2.50, 1.25, 0.63, 0.31, 0.16 and 0.00 mM. The 1,10-
phenanthroline assay was performed as above, with the addition of 0.015 M 
hydroxylamine hydrochloride to ensure the full reduction of iron to the ferrous 
form for reaction with 1,10-phenanthroline. 
The absorbance was measured spectrophotometrically at a wavelength of 510 nm. 
 
Examination of iron agarose standards for precipitation 
Approximately 200 µl of each concentration of freshly made ferric and ferrous iron 
agarose standards were transferred to glass microscopy slides and a coverslip 
added on top prior to gelling. Once the agarose had gelled, the slides were 
evaluated using microscopy at 40X magnification for the appearance of iron 
precipitation or accumulation. 
 
Ferric/ ferrous iron combinations 
Combinations of ferric iron to ferrous iron agarose standards were formed to 
evaluate how the two forms of iron affect MRI measurements. These were made 
first by making 100 mM combinations of ferric/ ferrous iron at 100/ 0, 80/ 20, 50/ 
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50, 20/ 80 and 0/ 100 %. These 100 mM stock solutions were then each serially 
diluted by two-fold, as described above. 
 
Ferritin iron agarose standard 
Ferritin iron agarose standard was formed by using ferritin from equine spleen (see 
materials). The iron content of ferritin was provided by the manufacturer and 
diluted to a stock solution of 100 mM iron content, for serial dilution by two-fold 
using dH2O, alongside fresh ferric iron chloride and ferrous iron chloride agarose 
standards, as study controls. 
 
3.2.1.2. 2% agarose iron standard samples 
200 µl of each ferric or ferrous iron solution was transferred into a new 15ml 
centrifuge tube, and freshly made 2% agarose added up to 4ml to provide a 1:20 
dilution of stock iron solutions. Solutions were then gently inverted two or three 
times to ensure full mixing of the iron solutions with the agarose. 
Prior to full gelling, 1 ml syringes were filled using each ferric or ferrous 2% agarose 
solution and then allowed to cool and gel fully in an upright orientation at room 
temperature. Once solid, the ends of each syringe were covered with parafilm to 
prevent water loss from the gels over time. These standards were each labelled and 




3.2.1.3. MRI relaxometry 
MRI acquisition 
The seven 1 ml syringes were held together tightly using autoclave tape for all the 
standards (Figure 3-3). These were placed into the 25 mm ID RF coil and secured. 
Relaxometry assessment was performed using a multi-slice spin-echo (SE) sequence 
for T1 and T2 measurement; T1 measured using TR: 70, 100, 150, 200, 400, 600, 
800, 1200, 2000, 4000 and 8000 ms and TE: 9 ms, T2 measured using TR: 4000 ms, 
TE: 9, 12, 15, 20, 25, 30, 45, 60, 90, 120, 180 and 250 ms. FOV = 26 x 26 mm, Matrix 
= 128 x 128, Averages = 1, Thickness = 2 mm, 5 adjacent slices acquired. A multi-
echo (ME) SE sequence was also used to assess T2, to provide a faster T2 
measurement than using a series of single echo time SE acquisitions. Acquisition 
parameters for this sequence were TR: 4000 ms, first TE = 9 ms, with 16 echos 
equally spaced by 9 ms. 
T2* was assessed using a single echo gradient-echo (GE) RF-spoiled sequence with 
TR: 4000 ms, TE: 3, 6, 9, 12, 15, 20, 30, 50, 75, 100 and 150 ms. FOV = 26 x 26 mm, 
Matrix = 128 x 128, Averages = 1, Thickness = 2 mm, 5 slices acquired, flip angle = 
20⁰. A multi-gradient-echo (MGE) sequence was also used to assess T2*, to provide 
a faster approach for T2* measurement than using a series of single echo time 
gradient-echo acquisitions. TR: 2000 ms, first TE = 2.5 ms, with equally spaced TEs = 
6 ms, 5 echoes, flip angle = 90⁰. Both GE and MGE sequences were acquired with 
thickness = 2 mm and 5 contiguous slices acquired, as well as thickness = 0.5 mm 
over 20  contiguous slices, due to imaging artefacts observed in 2mm thick slices 




Figure 3-3 Schematic diagram of iron agarose standards MRI acquisition 
(A) Schematic diagram of syringes showing how standards were placed into the RF 
coil for scanning and (B) photograph of iron agarose standard syringes taped 
together. 
 
MRI relaxometry analysis 
Calculation of relaxometry maps was performed by a pixel-by-pixel least-squares 
fitting method using JIM 5.0. Images were first converted to ANALYZE 7.5 format in 




(-TE/T2*), respectively, where y is the voxel intensity and M0 is the 
proton density at each corresponding TR or TE. R1, R2 and R2* maps were 
generated by calculating the reciprocal of T1, T2 and T2* maps. R2’ maps were 
calculated by subtracting SE R2 maps from GE R2* maps. 
 
3.2.1.4. Analysis 
Statistical testing was performed in Prism. Correlations were assessed using r2 
linear regression analysis and Pearson’s correlation, with significance level set at P ≤ 
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0.05. Number of asterisks denotes significance level; * P ≤ 0.05, ** P < 0.01, *** P < 
0.001 and **** P < 0.0001. Bland-Altman plots were produced by calculating the 
percentage difference between the two MR imaging methods (either SE R2 with ME 
R2, or GE R2* with MGE R2*) against the average of the measurements. Multiple t-
tests were used to compare the relaxometry values at each concentration of ferric 
to ferrous iron, with significance assessed using Holm-Sidak to α ≤ 0.05. Molar 
relaxivities (r1, r2, r2* and r2’) were assessed as the gradient of linear correlation 
regression lines, as relaxivity values per iron concentration (s-1mM-1). One-way 
ANOVA was used to assess differences between the relaxivity slopes of the 
different proportions of ferrous to ferric iron contents. 
 
3.2.2. Assessment of control and AD human MTG using MR relaxometry and 
SR-XRF elemental iron mapping 
Assessment of post-mortem human brain tissue was performed by using medial 
temporal gyrus (MTG) samples from control subjects and comparing against 
samples from the same region of Alzheimer’s disease (AD) patients. The post-
mortem samples were obtained from the MRC London Neurodegenerative Diseases 
Brain Bank and consent was obtained from all subjects for autopsy, 
neuropathological assessment and research. Tissues were taken for histological and 
neuropathological assessment for degenerative diseases, performed in accordance 
with institutional guidelines. AD pathology was classified using CERAD (Consortium 
to Establish a Registry for Alzheimer’s disease) pathological criteria assessing the 
presence of plaques (Alafuzoff et al., 2008), with staging based on Braak and Braak 
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classification (Braak and Braak, 1991). All AD samples used in this study showed 
Braak stages V-VI. Control cases are defined as having no history of neurological 
disease or cognitive decline clinically, and showing no, or only minor age-related, 
pathology following neuropathological assessment. 
 
3.2.2.1. MRI relaxometry 
Sample preparation 
Post-mortem formalin-fixed human brain samples (approximately 15mm x 15mm x 
5mm) from the MTG of Alzheimer’s Disease (AD) patients (n=15) and control 
subjects (n=15) were age, fixation time and post-mortem interval (PMI) matched 
(see section 1.7; see Appendix B for full list of human samples). 
Samples were carefully wrapped in tissue paper to limit susceptibility and 
inhomogeneity artefacts from the sample holder cassettes, and immersed in 
Galden® in a 50 ml tube. Samples were oriented perpendicular to the magnetic field 




Human brain samples underwent MRI using the 43mm ID quadrature volume coil. 
T1-relaxometry was performed using a spin-echo saturation recovery sequence 
with TR values of 300, 500, 800, 1200, 2000 and 4000 ms, and TE 12 ms. T2-
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relaxometry was also performed as above, but using TEs of 12, 15, 20, 25, 30, 45 
and 60 ms, with a TR of 4000 ms. T2*-relaxometry was performed using a single 
echo gradient-echo sequence with TE values of 5, 10, 15, 20, 25, 30 and 50 ms and a 
TR of 4000 ms. For T1-, T2- and T2*- relaxometry measurements, FOV = 28 x 28 
mm, matrix size = 256 x 192, 2 averages were used and 13 contiguous 0.5 mm thick 
slices obtained. T2-weighted MRI was also performed to obtain good white and 
grey matter contrast images for placement of regions of interest (ROIs), at TR/ TE = 
4000/ 30 ms. 
 
Relaxometry map generation 
All quantitative MRI measures were calculated as described in section 3.2.1.3. 
 
3.2.2.2. Synchrotron-radiation X-ray fluorescence elemental mapping  
Sample preparation 
Following MRI, the samples were processed on a 40 hour cycle going through 
alcohol, then chloroform, and then infiltration using a paraffin wax blend (70% soft 
paraffin wax, 20% beeswax and 10% dental wax). Molten paraffin wax was then 
used to embed the tissue in moulds and allowed to cool. Sample blocks were 
sectioned using a microtome to the central region of each brain sample and a 7 µm 
section was mounted onto the custom made XRF slides with Ultralene® film (Figure 
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3-2) for synchrotron-radiation XRF on the I18 beamline at the Diamond Light Source 
synchrotron (Didcot, Oxfordshire, UK). 
 
SR-XRF acquisition 
A ROI containing both grey and white matter of each sample was selected for XRF 
using the T2-weighted image. The beam energy was tuned to 11 keV and focussed 
to 100 x 100 µm and the sample scanned at constant time per pixel in a rastor 
fashion. Samples were mounted at 45⁰ with respect to the incoming X-ray beam in 
the plane of the orbiting electrons to minimise scatter contribution to the detected 
signal. Data collected is in the form of a spectrum showing the characteristic 
emission radiation from individual elements in the sample. Quantitative maps were 
generated using PyMCA (ESRF, France) to fit the characteristic Kα and Kβ peak areas 
for each element and quantify the iron content using the peak at energy level 6.40 
keV. Quantitative data was normalised to data obtained from a reference metal 
film (AXO, Dresden, GmbH) and adjusting the flux accordingly. 
Following XRF spectra acquisition across samples, the output data were converted 







3.2.2.3. XRF-MRI correlation 
Registration 
The T2-weighted image was aligned with SR-XRF elemental iron maps by eye to a 
position of similar orientation to the corresponding iron elemental maps, using 
cropping, resizing and transform tools in ImageJ. Relaxometry maps were then 




For each brain sample, regions of interest (ROIs) were manually selected around all 
the white (WM) or grey matter (GM) from the T2-weighted image using JIM 5.0. 
ROIs were drawn with a 1-2 pixel gap from the tissue boundaries, to avoid partial 
volume effects at these interfaces. The ROIs were then overlaid for each of the R1, 
R2, R2* and R2’ maps and a comparison of WM to GM was performed. Data from 
each WM and GM region was then separated between AD and control to compare 
group differences. Minor adjustments were made to ROIs applied in R2* maps, to 
avoid the enhanced susceptibility artefacts at the edges of samples, likely due to 





Twenty-four square ROIs of 3 x 3, or 5 x 5 pixels were placed across the white and 
grey matter regions of elemental iron maps and the mean intensities and standard 
deviations generated from each using ImageJ. Identical ROIs were placed in the 
same positions across T2-weighted images and then overlaid onto R1, R2, R2* and 
R2’ maps to extract mean values and standard deviations for correlation of each 
ROI between iron and relaxometry measurements. Twenty-four ROIs were used for 
this assessment to place an equal number of ROIs (eight) across each of the tissue 
regions identified; in the WM, MCL and dGM (see section 5.4.1), therefore avoiding 
bias when comparing correlations across samples. 
 
3.2.2.4. Immunohistochemical assessment  
Luxol fast blue (LFB) staining  
Adjacent sections to that used for XRF elemental mapping were sectioned at 14 µm 
thickness and mounted onto glass microscopy slides for standard histopathological 
assessment. Following dewaxing using 100% Xylene, samples were part rehydrated 
in 95% IMS, and stained overnight using luxol fast blue solution at 56⁰C. Sections 
were then washed in dH2O and differentiated using 0.05% lithium carbonate for 10 
seconds. Differentiation was continued using 70% IMS until dye stopped coming out 
and then sections washed in dH2O. Sections were counter stained using Nissl 
staining (0.05% cresyl fast violet solution; preheated to 60°C) for 3 minutes, before 
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differentiating in 95% IMS (with acetic acid) for 10-15 seconds. Slides were then 
dehydrated in 100% IMS and cleared in xylene for mounting with coverslips. 
 
Histopathological analysis 
Images of each sample were imaged using a Leica SCN400F slide scanner, acquiring 
at x40 magnification across each sample, at Institute of Neurology, University 
College London, UK. Images were obtained using auto-focus settings with a 65% 
compression for outputs, in the form of the .scn pyramidal tiff file format. Images 
were stored and could be retrieved using the Leica Digital Image Hub for correct 
orientation of samples and generation of magnified images. 
Analysis of luxol fast blue staining in the human tissue sample was performed by 
first cropping, rotating and registering the histological images by eye against the 
iron elemental maps using ImageJ. Images then had their resolution reduced to the 
equivalent resolution as the iron elemental maps for each corresponding sample. 
Image intensities were then inverted to provide a measure of myelin content. 
Whole region ROIs (for WM and GM tissue) were drawn and mean intensities 
obtained. Furthermore, twenty-four similarly placed 5x5 pixel ROIs as those used on 
both elemental iron and relaxometry maps were redrawn onto the LFB images for a 





3.2.2.5. Statistical data analysis 
Differences in the R1, R2, R2* and R2’ relaxometry measures and iron levels 
between whole white and grey matter regions were tested for statistical 
significance using Student’s unpaired t-test or one-way ANOVA. In all comparisons, 
number of asterisks denotes significance level of unpaired data; * P ≤ 0.05, ** P < 
0.01, *** P < 0.001 and **** P < 0.0001. Paired t-test or repeated-measures one-
way ANOVA were also used to evaluate the consistency of differences between 
regions within each individual sample. Number of hashtags denotes significance 
level of paired data; # P ≤ 0.05, ## P < 0.01, ### P < 0.001 and #### P < 0.0001. 
These statistical measures were also used to evaluate differences in relaxometry or 
iron content between AD and control samples. Tukey’s test for multiple 
comparisons was performed following one-way ANOVA testing. A value of P ≤ 0.05 
was considered statistically significant and all statistical tests were performed using 
Prism. Values are shown in mean ± standard deviation (SD). 
Using results from the twenty-four square ROIs of 5 x 5 pixels each, correlation 
plots were calculated for each sample between iron and relaxometry values and r2 
correlation coefficients and gradients were used for assessment of correlation. 
Group comparisons were made from the mean r2 values from each patient group. 
To evaluate overall correlation of iron against different relaxometry measures, all 
the twenty-four ROI mean values from either AD or control samples were 
correlated together against each relaxometry measurement. Graphs show 
correlation coefficients with significance level assessed using Pearson correlation. In 
all correlations, * P ≤ 0.05, ** P < 0.01, *** P < 0.001 and **** P < 0.0001. 
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Histopathological assessment using the twenty-four square 5 x 5 pixels was 
performed in a similar way as above, however using the luxol fast blue average 
values within the acquired image. 
Correlation comparisons were performed using cocor software available online 
(Diedenhofen and Musch, 2015) and using Pearson and Filon's z comparison for 
statistical significance to P ≤ 0.05. 
 
3.2.3. MR detection of exogenous iron in the mouse hippocampus 
3.2.3.1. Animals and treatment  
Ten week old C57Bl/6J male mice were obtained and housed under a 12-hour light/ 
dark cycle, with ad libitum access to food and water. All procedures were 




To perform surgery under asepsis, all metal items to be used were sterilised by 
autoclaving at 141⁰C with sonication prior to surgeries. The surgery table was wiped 
down using chlorhexidine clear and covered with a sterile drape. Equipment 
required for surgery was then placed onto the table, including; stereotaxic frame, 
heating unit and blanket, swan neck lighting unit, drill unit and drill and the syringe 
plunger pump. The heating blanket was placed below the platform of the 
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stereotaxic frame to help maintain animal body temperature whilst under 
anaesthesia. A sterile drape was also used to cover the animal for warmth and 
prevent contamination from other body areas. A sterile gown, hair net, mask and 
gloves were worn throughout the duration of surgeries. 
 
Bilateral hippocampal injection 
Mice were first weighed and randomly assigned to 3 groups (n = 6 per group); two 
groups received 2 mM and 4 mM ferric citrate injections, and one received 4 mM 
sodium citrate (control/ vehicle) solution. Anaesthesia was induced using 5%:95% 
isoflurane: oxygen and the head shaved to observe the skull location. The mouse 
head was then placed into the stereotaxic frame, with ear pins holding the head in 
place and anaesthesia was maintained with 1.5%: 98.5% isoflurane: oxygen for the 
duration of surgery. 
100 µl Vetergesic analgesic was injected i.p to prevent pain to the animal and 
Lacrilube gel covered over the eyes to prevent drying and damage to the eyes, 
during the long surgical procedure. Sterile PBS was used to wipe loose hair away 
from the top of the head and iodine solution used to clean and sterilise the area of 
scalp for surgery. A small incision was made dorso-ventrally across the mouse head 
to expose the skull. Sterile PBS was used to clean the skull of excess iodine. The 
needle was placed gently onto the skull above each hemisphere to ensure a flat 
head orientation medio-laterally. If a difference in height greater than 0.2 mm was 
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observed between each hemisphere, the head position was adjusted slightly by 
moving each of the ear pins up or down. 
The position of bregma was identified from the point in which the three skull plates 
join and was confirmed by placing the injection needle lightly on top, to observe a 
slight movement of all three skull plates (Figure 3-4A). Once confirmed, coordinates 
were recorded from the stereotaxic frame and injections were performed 2.1 mm 
caudal to bregma, ± 1.5 mm lateral to the midline (Figure 3-4B). 
 
Figure 3-4 Positioning of ferric citrate injections into the mouse hippocampus 
(A) Image of the skull highlighting the positions of bregma and the midline, used as 
markers for locating site of drilling, and (B) position in the hippocampus of the ferric 
137 
 
citrate injection (images obtained from the Paxinos Mouse Brain Atlas (Paxinos and 
Franklin, 2001)). 
 
The drill bit was cleaned by dipping into 70% ethanol, followed by dipping into 
sterile PBS. A hole was then made in the skull by gently drilling at the confirmed 
sites of injection. The needle was inserted to 1.8 mm below the dura (Figure 3-4B) 
for a 500 nl injection at a rate of 500 nl/minute using the injection pump. Solutions 
were injected bilaterally into the hippocampus. After injection, the needle was left 
in place for an additional minute to limit leakage of solution within the needle tract. 
The needle was also lifted out from the brain very slowly over the course of a 
minute to prevent fluid being drawn out from the syringe. The skin over the skull 
was then sutured together using sterile 4-0 vicryl sutures. 
Animals were allowed to recover in a warm box for 45 minutes after surgery, before 
being returned back into their cage with mashed pellets in water to aid recovery 
post-surgery. Published literature has shown serious side effects following iron 
injection (Armstrong et al., 2001) and therefore mice were monitored daily during 
their recovery period. We observed minor seizures in 5 of the 12 treated mice (two 
in the 2 mM and three in the 4 mM iron group) immediately following surgery. No 
recurrent long term movement or behavioural effects were observed after the first 
24 hours following surgery. Animal weights were monitored throughout the 




3.2.3.3. Fear conditioning behaviour assessment 
Fear conditioning was performed to evaluate contextual memory function following 
ferric citrate injection, due to the critical role the hippocampus plays in contextual 
memory. The protocol was adapted from Izquierdo et al. (Izquierdo et al., 2006) 
and from previous lab experiments. 
 
Fear conditioning training 
The fear-conditioning box was wiped down using 70% IMS prior to conditioning 
each animal. Mice were left in their cage until the conditioning was to be 
performed. Cages were kept outside of the fear-conditioning room to avoid long-
term distress to animals. Mice were placed into the fear conditioning box, the 
camera recording started and the Day 1 procedure initiated. The procedure 
provides three electric shocks; one after 90 seconds acclimatisation, a second 
electric shock another 90 second pause, and a third electric shock after 150 second 
pause. Electric shocks were administered at 0.60 mA Direct Current (DC). A final 60 
second pause was allowed before returning mice to their cage. 48 hours was then 
allowed before contextual memory testing. 
 
Contextual memory 
Hippocampal based contextual memory was measured 48 hours post conditioning. 
Prior to contextual memory recall, the fear conditioning box was wiped down using 
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70% IMS and each animal was placed into the box and recorded for 5 minutes 
without any external stimulus or shock to evaluate contextual memory recall. 
 
Behaviour assessment 
Assessment of fear conditioning behaviour was performed by evaluation of the 
freeze fear response. Typically, mice will freeze and prevent all movement when 
exposed to a stressful environment (Izquierdo et al., 2006). Scoring was performed 
by timing how long each animal spent frozen, as a percentage of total time for each 
phase of the behavioural study. 
 
3.2.3.4. Magnetic Resonance Imaging 
In vivo data acquisition 
Mice were allowed to survive 10 days post-surgery before in vivo MRI acquisition 
was performed. Mice were anaesthetised using 5%:95% isoflurane: oxygen and 
placed into a head holder with anaesthetic mask in the MRI scanner. Anaesthesia 
was maintained using 1.5%:98.5% isoflurane: oxygen and mice were placed in a 25 
mm ID radiofrequency (RF) coil. MRI was acquired using a ME SE sequence for T2 
relaxometry, parameters were: 16 echoes with echo time (TE) 9 – 144 ms, step size 
9 ms, repetition time (TR) 4600 ms and 2 averages. T2* relaxometry was performed 
using a MGE sequence with 5 echoes (3, 9, 15, 21, 27 ms), TR 2000 ms and 8 
averages. For all scans, the matrix size was 128 x 128, FOV was 18 x 18 mm, with 31 
140 
 
contiguous slices throughout the brain at 0.5 mm thick in axial orientation. The 
respiration rate and temperature were monitored during MR acquisition using a 
respiration pillow and temperature probe next to the animal, respectively. 
Temperature in the MRI scanner was maintained at 37⁰C using warm air from the 
heater module and fan. 
 
Cardiac perfusion 
Following the in vivo scans, mice were injected i.p. with 100 µl sodium 
pentobarbital. Once mice were terminally anaesthetised, by testing reflexes using 
the foot shock, an opening was made in the chest cavity to reveal the heart. A 
metal gavage needle of 0.9mm gauge was introduced into the left ventricle and 
heparinised-saline was used to wash out the blood before perfusion fixation with 
4% paraformaldehyde (PFA). 4% PFA was allowed to wash through the circulation of 
the mouse for an additional 15 minutes, ensuring tissue was fully fixed. Mouse 
brains were then extracted from the skull and left in 4% PFA for at least 48 hours 
before ex vivo scanning. 
 
Ex vivo data acquisition 
Four brains were placed into the customised brain holder for MRI (see section 
3.1.3.1), immersed in Galden®. Ex vivo scanning with a spin-echo (SE) sequence for 
T1 (TR = 550, 670, 800, 1000, 1200, 2000 and 4000 ms, TE = 11ms) and SE T2 (TR = 
4000 ms, TE = 11, 15, 20, 25, 30, 45 and 60 ms) relaxometry was performed. T2* 
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assessment was performed using a single echo gradient-echo (GE) sequence (TR = 
4000 ms, TE = 4, 8, 12, 20, 30 and 50 ms) with flip angle = 20⁰. Both SE and GE 
sequence acquisitions had FOV = 30 x 30 mm, matrix size 256 x 256 and averages = 
2, with 33 contiguous axial slices at 0.5 mm thickness. 
Fast ME T2 and MGE T2* measurements were also performed for comparison 
against standard sequences with ME T2; 16 echoes with echo time (TE) 11.6 – 185.6 
ms, repetition time (TR) 7000 ms and 4 averages, and MGE T2* using 5 echoes (2.5, 
8.5, 14.5, 20.5 and 26.5 ms), TR 2000 ms and 10 averages. For all scans, matrix size 
was 256 x 256 with FOV of 30 x 30 mm with 33 contiguous axial slices at 0.5 mm 
thickness. 
 
MRI image analysis 
Relaxometry maps were generated as described in section 3.2.1.3. 
 
Image registration 
The SE T2-weighted images (TR = 4000ms, TE = 20ms) from each of the six control 
mice brains were registered into the same image space as a correctly oriented 
sample, and averaged together to create a template T2-weighted image in FSL. 
A six parameter registration model (rigid body) was then used in FLIRT (FMRIB's 
Linear Image Registration Tool) to move each of the relaxometry maps into 
consistent image space according to the same transformation matrices as used to 
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register each brains’ T2-weighted image to the T2-weighted template image. This 
method allowed the consistent overlay of ROIs between R1, R2, R2* and R2’ 
relaxometry maps. 
 
3.2.3.5. Synchrotron radiation X-ray fluorescence (SR-XRF) mapping 
Sample preparation 
Following ex vivo MRI, brains were immersed in 30% sucrose for 48 hours before 
cryosectioning at 40µm onto XRF film. XRF film was pre-mounted onto the custom 
made acrylic slides following cleaning using 100% IMS. 
During cryosectioning, prior to a section being mounted onto XRF film, all surfaces 
and equipment were wiped down using 100% IMS to limit any possible 
contamination of metal elements within the sample or XRF slide. 
 
Cryosectioning methodology 
Once the front of the hippocampus had been reached by sectioning at 20 µm per 
slice, the following sequence of sectioning was performed. Five slides of 4 sections 
per slide were cut, with each slice separated by 100 µm within one slide (Figure 
3-5). Following all these sections (5 slides x 4 sections = 20 sections; 20 sections at 
20 µm each = 400 µm total) a 40 µm slice was obtained after cleaning down the 
cryostat, as explained above, as a “pre-XRF” section to ensure the cryostat was set 
to cut at the correct thickness. The second 40 µm section was then taken for XRF 
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(Figure 3-5; section 22) followed by a 20 µm “post-XRF” section obtained prior to 
starting a new “batch” of 5 slides (40 µm + 40 µm + 20 µm = 100 µm in total for 
acquisition of an XRF section). The slides with sections for histology were kept at -
20⁰C until use. The XRF slides were kept at room temperature until XRF scanning. 
 
Figure 3-5 Cryosectioning method for histological and XRF elemental analysis 
The cryosectioning method for the ferric iron injected mice brains is shown, where 
sections 1-20 were sectioned at 20µm, before changing the sections to be cut at 
40µm for XRF (section 22). Section 21 and 23 were obtained immediately prior to or 
post to the XRF section, due to changing the cryosectioning thickness from 20µm to 
40µm, and then back to 20µm. Numbers 1.1 – 1.5 at the bottom of each slide refer 
to the slide labelling process used. 
 
SR-XRF acquisition 
XRF mapping was performed on the Fluo X-ray fluorescence microprobe beamline 
at the ANKA synchrotron radiation facility (Karlsruhe Institute Technology (KIT), 
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Karlsruhe, Germany). The beam energy was tuned to 10keV and focussed to 100 x 
100 µm and the sample scanned at constant time per pixel. XRF slides were 
attached to magnetic slide holders using tape and a ROI around the hippocampus of 
each slice was selected for XRF by low-power optical microscopy with a stage 
calibrated to the beam-line motor coordinates (Figure 3-6).  
 
Figure 3-6 Method of selecting hippocampal area at KIT synchrotron 
XRF slide holding 3-4 mouse sections was mounted onto magnetic slide holders 
using tape. (B) A low-powered optical microscope used to define an area around the 
hippocampus of mouse tissue sections, using (C) motor coordinates calibrated 
against the beamline scanning coordinates. 
 
Data acquisition and analysis was the same as performed above (see section 
3.2.2.2), however data was normalised against the transmitted monitor radiation to 
generate quantitative data using PyMCA. Three animals per treatment group and 
the three hippocampal slices relating to areas acquired by MRI in each animal, were 
assessed by SR-XRF due to time restrictions at the ANKA beamline. 
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3.2.3.6. Statistical data analysis 
Iron content (in ppm) of hippocampal ROIs for both the whole hippocampus and 
lesion areas were obtained from iron elemental (n = 3 per group) and relaxometry 
(n = 6 per group) maps. Statistical testing between the control and treatment 
groups was determined using one-way ANOVA, followed by Tukey’s test for 
multiple comparisons. One animal from each of the ferric citrate treatment groups 
was excluded from the relaxometry analyses, due to no lesion observed in one 
hemisphere based on R2* maps. Similar to the iron agarose standards and human 
post-mortem tissue results, the number of asterisks denotes significance level in 
graphs; * P ≤ 0.05, ** P < 0.01, *** P < 0.001 and **** P < 0.0001. Total iron 
content in the treated animals was calculated by: lesion mean x lesion volume, for 
both elemental iron and relaxometry measurements, to assess the difference in 
total iron content detected using each measurement between the 2 mM and 4 mM 
treatment groups. Correlation of hippocampal relaxometry measures against iron 
was determined using both Pearson correlation coefficient and r2 linear regression 
analysis from every ROI. 
 
3.2.3.7. Histochemical assessment 
Immunohistochemistry 
Immunohistochemical staining was performed using antibodies detailed below. 
Sections were removed from the freezer and allowed to thaw to room 
temperature, before TBS(-) was added to each slide to rehydrate samples. Slides 
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were then dried using tissue, and a wax pen used to draw around samples on the 
slide. 1% hydrogen peroxide in TBS(-) was added and left for 30 minutes at room 
temperature to reduce background peroxidase activity prior to DAB staining. Slides 
were washed in TBS(-) for 5 minutes and then TBS(+) for 5 minutes. Blocking buffer 
was added (10% serum in TBS(+)) for 2 hours at room temperature. Primary 
antibodies were then added in 5% serum in TBS(+) and slides left at 4⁰C overnight 
(Table 3-4). 
Three washes for 15 minutes were performed in TBS(+) before the secondary 
antibody in 5% serum in TBS(+) was added and left on the sections for 2 hours at 
room temperature (Table 3-4). A further three washes were performed for 20 
minutes each, in TBS(+) twice and then TBS(-) once at the end. DAB solution was 
added on each slide and the reaction time recorded (Table 3-4). Once positive 
staining could be observed under the microscope, the DAB solution was tapped off 
into a waste container, the time recorded and the slides left in tap water to 
terminate the reaction. These were then left in tap water for at least 5 more 
minutes. Counterstaining could then be performed using either haematoxylin or 
nissl staining, as outlined below. 
Once immunohistochemical procedures were completed, samples could then be 
dehydrated and mounted by placing in 70% IMS for 5 minutes, then 95% IMS for 5 
minutes and then twice in 100% IMS for a further 5 minutes of each wash. Slides 
were then transferred into 100% xylene for 6 minutes twice before mounting, by 
placing a small volume of DPX onto the sections and placing coverslips gently on 
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top, avoiding the creation of air bubbles. The slides were finally allowed to dry in a 
fume cupboard overnight. 
 
Table 3-4 Outline of primary antibody dilutions, DAB staining times and 
counterstains applied onto mouse tissue from ferric citrate hippocampal injections 
Primary 
antibody 
Raised in Dilutions  Secondary 
antibody 
DAB stain time Counterstain 
Ferritin Rabbit 1:2500 Impress kit 4 mins Haematoxylin 
Iba1 Rabbit 1:1500 Impress kit 2 mins 15 secs Nissl 
 
Haematoxylin staining 
After at least 5 minutes in tap water following DAB staining, slides were 
counterstained in Harris’ Haematoxylin for 5 minutes. Slides were washed again in 
running tap water before the staining was differentiated using 0.5% acid alcohol for 
about 15 seconds. Slides were again then left in running tap water for 5 minutes, 
followed by dehydration and mounting as described above. 
 
Nissl staining 
After at least 5 minutes in tap water following DAB staining, slides could be 
counterstained using Nissl staining (0.05% cresyl fast violet solution; preheated to 
60°C) for 25 minutes at 60°C. Differentiation was then performed in 95% IMS for 
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10-15 seconds, with a few drops of 10% acetic acid added to accelerate the process. 
Sections were rinsed twice in dH2O before differentiating sections in an ascending 
series of alcohols and xylene as described below: 
a. 70% IMS for 5 minutes. 
b. 80% IMS for 2 minutes. 
c. 90% IMS for 2 minutes. 
d. 95% IMS for 2 minutes. 
e. 100% IMS for 2 minutes, twice. 
f. 50% IMS/ 50% xylene for 2 minutes. 
g. 100% xylene for 2 minutes. 
Sections were then checked for clear background microscopically prior to mounting 
with DPX. 
 
3.2.3.8. Microscopy evaluation 
Stained sections were imaged using a Leica SCN400F slide scanner, as described in 
section 3.2.2.4. Images were then obtained from the Leica Digital Image Hub for 





4. Results: Iron Agarose Standards 
4.1. Introduction 
In order to validate the MR relaxometry sequences to be used, it is necessary to 
understand the direct effect of different forms of iron on the MR signal without any 
other interfering effects. To do this, agarose standards have been used in a number 




The objectives for the work with iron agarose standards were: 
 To validate and assess iron-sensitive MRI relaxometry methods for 
measurement and quantification of iron content. 
 To understand the different effects that different iron ions, and bound 
compared with unbound iron can elicit on MR relaxometry values. 
 
4.3. Methods 
The methods for this work can be found in section 3.2.1. In brief, different 
concentrations of ferric and ferrous iron chloride were formed in 2% agarose and 
filled into 1 ml syringes. Furthermore, standards with iron loaded ferritin, as well as 
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combinations of ferric to ferrous chloride, were also generated at different 
concentrations in 2% agarose. These iron agarose standards were then scanned for 
R1, R2 and R2* relaxometry assessment using standard SE and GE sequences, as 
well as using fast ME and MGE sequences for R2 and R2* evaluation, respectively. 




4.4.1. T1- and T2- weighted qualitative observation of agarose standards 
T1- and T2- weighted images of the seven different concentrations of ferrous and 
ferric iron were first compared for differences in contrast and signal intensity 
(Figure 4-1). Taking each of the T1- or T2- weighted images separately, the seven 
standards with different concentrations of iron show different signal intensities to 
each other (Figure 4-1A and B for ferrous iron standards). 
Circular ROIs were placed over each iron agarose standard in MR images to obtain 
mean signal intensity values. Visually, curves for signal intensity versus TR and TE 
have higher initial slopes for higher iron concentration in the agarose standards 
(Figure 4-1C-D). Additionally, the signal intensity versus TR reaches a lower plateau 
level for higher iron concentration (Figure 4-1C). These observations pave the way 
for performing quantitative measurement of T1 and T2 values to correlate against 
iron content directly. 
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Relaxometry maps were generated by performing a pixel by pixel regression for T1 
and T2 using SE acquisition, and T2* using GE acquisition. Reciprocal T1, T2 and T2* 
maps were generated to produce R1, R2 and R2* maps for further assessments, 
given the strong evidence for direct correlation of these measurements with iron 
content (see section 1.6.5; Figure 4-2). 
Increased pixel intensities in the R1, R2 and R2* maps highlight regions with 
increased relaxivity values. Increasing concentrations of ferric or ferrous iron led to 
an increase in R1, R2 and R2* values within each map (Figure 4-2). A clear 
difference visually can be identified between the ferrous and ferric forms of iron, 
with the latter showing considerably higher R1, R2 and R2* relaxivity values by 






Figure 4-1 Ferrous iron agarose standards T1- and T2- relaxometry curves 
(A) Axial T1- weighted (T1w) image of the ferrous iron agarose standards at TR/TE = 
400/ 9 ms and (B) axial T2- weighted (T2W) image of the ferrous iron agarose 
standards at TR/TE = 4000/ 120 ms. Values overlaying T1 and T2 weighted images 
are ferrous iron concentrations in mM. Relaxivity curves for (C) T1 quantification 
and (D) T2 quantification of each concentration of the ferrous iron agarose 





Figure 4-2 R1, R2 and R2* relaxometry maps of ferrous and ferric iron in agarose 
standards 
R1, R2 and R2* axial relaxometry maps of (A-C) ferrous (Fe2+) and (D-F) ferric (Fe3+) 
iron chloride agarose standards. Values overlaying ferric and ferrous R1 relaxometry 
maps are iron concentrations in mM. Image contrasts are consistent between 
ferrous and ferric iron agarose standards for each relaxometry map. 
 
4.4.2. Quantification reproducibility 
To provide an accurate assessment of iron using MRI relaxometry, the consistency 
of iron measurements was first tested across multiple slices through the standards. 
Assessment of the R1 and R2 values across the five adjacent slices demonstrated 
reliable acquisition and measurement, with clearly separable and non-overlapping 
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profiles between each concentration of both ferrous and ferric iron (Figure 4-3A-B, 
D-E). 
R2* values however, were difficult to discern given the large image artefacts 
present, especially in the outermost agarose standards (Figure 4-4A-B, arrows). 
These image artefacts subsequently increased the variability of the mean relaxivity 
measurements for each standard (Figure 4-3C and F). None of the seven different 
concentrations of ferrous iron were discernible from each other, given the large 
variations in mean relaxivity values in each slice (Figure 4-3C, Figure 4-4A). 
Furthermore, none of the measurements were constant across slices, leading to 
overlapping profiles between concentrations. The 2 mM and 5 mM ferric iron 
standards are clearly separated, likely due to their substantially higher relaxivity 
values compared with the remaining standards (Figure 4-3F). The five remaining 
ferric iron standards however, were not discernible due to variability of mean 
relaxivities and overlapping profiles across the different slices (Figure 4-4B). R2* 





Figure 4-3 Mean R1, R2 and R2* quantification of iron agarose standards across 
multiple slices 
(A) R1, (B) R2 and (C) R2* profiles for ferrous iron demonstrates consistent and 
reliable acquisition of R1 and R2 values, whilst R2* profiles overlap. (D) R1, (E) R2 
and (F) R2* profiles for ferric iron demonstrates similar consistent and reliable 
acquisition of R1 and R2, whilst R2* values show substantial overlapping of profiles 
below 60 s-1. Graphs show mean values ± SD. 
 
In order to quantify the R2* relaxivities in the iron standards, the slice thickness 
was reduced from 2 mm to 0.5 mm to limit artefacts potentially arising from B0 
inhomogeneities. The same length of standards were acquired, therefore providing 
20 slices at 0.5 mm thickness (10 mm length total), instead of 5 slices at 2 mm 
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thickness (10 mm length total; Figure 4-4). Substantial improvements in the 
homogeneity of each standard were observed, with fewer artefacts observed than 
imaging 5 slices at 2 mm thickness (Figure 4-4; arrows). 
 
Figure 4-4 Image artefacts in R2* relaxometry maps dependent on thickness of 
slices 
Artefacts were observed in the R2* maps for both (A) ferrous iron, and (B) ferric iron 
agarose standards when imaging was performed with 2 mm thickness (5 slices) 
(arrows). Imaging with 0.5 mm thickness (20 slices) led to greater homogeneity of 
R2* values within the standards. 
 
Mean R2* relaxivities across slices were therefore more clearly delineated by 
reducing the slice thickness (Figure 4-5). In both the ferrous and ferric standards, 
R2* values across slices were more consistent with fewer overlapping profiles, 
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allowing quantification of R2* relaxometry. Greater SD of individual slice mean 
relaxivities can be observed in the 0.5 mm thickness acquisition however, likely as a 
result of lower signal-to-noise ratio (SNR) due to the reduction in slice thickness 
(Figure 4-5B and D). However, as the data is considerably more consistent, this 
variability is unlikely to interfere with data analysis. As image artefacts were still 
observed to a limited degree using this acquisition method, data containing 
artefacts were monitored and slices excluded from analysis in cases where the 
artefacts produce interfering effects on quantification. 
 
Figure 4-5 R2* measurement of iron agarose standards using different slice 
thickness 
(A) R2* values of ferrous iron across five slices at 2 mm thickness and (B) R2* values 
of ferrous iron across twenty slices at 0.5 mm demonstrating the substantially 
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improved profiles using 0.5 mm acquisition. (C) R2* values of ferric iron across five 
slices at 2 mm thickness and (D) R2* values of ferric iron across twenty slices at 0.5 
mm. SD error bars are larger in the 20 slices data likely due to lower SNR from 
acquisition of 0.5 mm thickness slices. Graphs show mean values ± SD. 
 
4.4.3. Standard and fast relaxometry measurements 
In vivo imaging requires faster scanning procedures to be employed in both clinical 
and preclinical settings. Therefore, faster measurements of R2 and R2* were 
performed using a multi-echo (ME) SE and a multi-gradient-echo (MGE) sequence 
respectively, for comparison against the standard spin-echo (SE) and gradient-echo 
(GE) acquisitions. 
Comparing the R2 relaxivity values measured with SE and ME sequences 
demonstrates that there seems to be an under-estimation of R2 using the ME 
sequence for all iron concentrations in both the ferric and ferrous forms (Figure 
4-6A-B). Furthermore, this under-estimation seems to be dependent on the R2 
value itself. This was tested further by plotting Bland-Altman correlation 
comparisons using both the ferric and ferrous relaxometry data (Figure 4-7A-B). 
Whilst the correlation of ME R2 was directly and linearly proportional to SE R2 
values (Figure 4-7A), consistent under-estimation of true R2 values were obtained 
using ME R2. The under-estimation of R2 was substantially greater at higher R2 
values than at shorter R2 values (Figure 4-7B). 
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Comparison of the R2* relaxivity values measured with GE and MGE sequences 
seem to show similar values in both the ferric and ferrous standards (Figure 4-6C-
D). Comparisons using Bland-Altman plots highlights MGE R2* to show a 
complicated relationship to GE R2* evaluation. The lowest R2* values are slightly 
under-estimated, whilst R2* values above 40s-1 are over-estimated (Figure 4-7C-D). 
 
Figure 4-6 Comparison of standard and fast relaxometry measurements in iron 
agarose standards 
SE and ME R2 measurement of (A) ferrous iron and (B) ferric iron agarose standards. 
GE and MGE R2* measurement of (C) ferrous iron and (D) ferric iron agarose 





Figure 4-7 Bland-Altman correlation comparisons of standard and fast 
relaxometry measurements 
 (A) r2 correlation of SE R2 compared with ME R2 measurement and (B) the 
percentage difference in SE to ME R2 values. (C) r2 correlation of GE R2* compared 
with MGE R2* values and (D) percentage difference in GE R2* to MGE R2* values. 
 
4.4.4. Validation of pH, oxidation state and content of iron agarose standards 
The pH of ferric and ferrous iron in aqueous solutions were measured as a 
surrogate model for the agarose standards (Figure 4-8, Table 4-1). Ferric solutions 
were significantly more acidic than ferrous solutions (mean ferrous solution pH = 
4.27 ± 0.14, mean ferric solution pH = 2.55 ± 0.08, P < 0.0001). The ferric solutions 
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also show a gradual decline in pH with increasing concentrations of iron, however 
this decline in pH was not significant (ferrous, P = 0.378, ferric, P = 0.077). 
 





5.00 4.22 2.46 
2.50 4.15 2.52 
1.25 4.26 2.51 
0.63 4.21 2.53 
0.31 4.24 2.60 
0.16 4.55 2.68 
0.00 3.75 3.85 
 
 
Figure 4-8 pH of ferric and ferrous iron aqueous solutions 
Ferric iron solutions are more acidic than ferrous iron solutions. 
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Measurement of the oxidation states of iron in the agarose standards was 
performed using the 1,10-phenanthroline assay, without hydroxylamine 
hydrochloride (Figure 4-9). The 1,10-phenanthroline assay mix using agarose 
standards with ferric iron only appeared very slightly red by eye even at the top 
concentration (5mM) of iron (Figure 4-9A). In contrast, the 1,10-phenanthroline 
assay mix using agarose standards with ferrous iron appeared very clearly red 
(Figure 4-9A). Absorbance measurements at each iron concentration of the ferrous 
and ferric standards clearly validates the visual differences observed (Figure 4-9B). 
 
Figure 4-9 Measurement of the oxidation states of iron in the agarose standards 
(A) Photograph of ferric (left) and ferrous (right) 1,10-phenanthroline assay without 
hydroxylamine hydrochloride. (B) Spectrophotometric absorbance measurements at 
510 nm of the ferric and ferrous iron agarose standards. 
 
In order to validate the actual final iron concentrations in the agarose standards, a 
standard curve was established using a series of ferrous iron chloride solutions, 
diluted from a single stock solution (Figure 4-10). The correlation value of the 
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standard curve was r2 = 1.00 and demonstrates that if given an unknown 
absorbance value, the concentration of iron can be calculated using the regression 
line equation (Figure 4-10). 
 
Figure 4-10 A standard curve of ferrous iron content compared with 
spectrophotometric measurement 
Spectrophotometric measurement of the 1,10-phrenanthroline assay at a 
wavelength of 510 nm provided a perfectly linear relationship to ferrous iron 
concentrations. 
 
Subsequently, the ferrous iron actual concentrations were calculated using the 
absorbance measurements taken above from the agarose standards (Figure 4-9) 
and comparing them to the standard curve. These actual concentrations were 
compared to the target concentrations (Figure 4-11). A correlation of r2 = 1.00 was 
observed between the target iron concentration and the actual iron concentrations 
in the agarose standards (Figure 4-11). Furthermore, the slope of 1.05 
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demonstrates that the concentrations in the final agarose standards are extremely 
close to the target concentrations. 
 
Figure 4-11 Calculated actual ferrous iron concentrations compared with target 
iron concentrations 
The actual iron concentrations in the ferrous iron agarose standards were calculated 
from the 1,10-phenanthroline assay absorbance measurements with the standard 
curve absorbance measurements. 
 
Microscopic evaluation of both the ferric and ferrous iron agarose standards 
demonstrated no evidence of precipitation or accumulation. 
 
4.4.5. Iron quantification using relaxometry 
Relaxometry maps were opened in ImageJ and circular ROIs placed over each iron 
agarose standard to obtain mean values across all the slices. Quantification of the 
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differences in relaxometry values between ferrous and ferric iron standards, and 
with increasing concentrations, were evaluated by averaging values across all slices 
from triplicate scans. 
R1 values of ferrous iron increased from 0.35 ± 0.02 s-1 at 0 mM to 2.36 ± 0.06 s-1 at 
5 mM with significant linear correlation of r2 = 1.00 (P < 0.0001). By comparison, R1 
values of ferric iron increased from 0.37 ± 0.01 s-1 at 0 mM to 37.12 ± 3.23 s-1 at 5 
mM, with significant linear correlation of r2 = 0.99 (P < 0.0001; Figure 4-12A). The 
slopes, defining the molar relaxivities (r1) of ferrous and ferric iron were also 
significantly different (ferrous r1 = 0.39 ± 0.01 s
-1mM-1 and ferric r1 = 7.48 ± 0.40 s
-
1mM-1, P < 0.0001). Ferric iron has significantly higher R1 values compared with 
ferrous iron from 0.1 mM up to 5 mM (Table 4-2). 
Standard SE R2 values of ferrous iron increased from 14.27 ± 0.28 s-1 at 0 mM to 
33.09 ± 1.58 s-1 at 5 mM with significant linear correlation of r2 = 0.99 (P < 0.0001; 
Figure 4-12B). Ferric iron SE R2 values increased from 14.14 ± 0.29 s-1 at 0 mM to 
170.93 ± 1.45 s-1 at 5 mM, with significant linear correlation of r2 = 0.99 (P < 
0.0001). The r2 of ferrous and ferric correlations were also significantly different 
(ferrous r2 = 3.61 ± 0.19 s
-1mM-1 and ferric r2 = 31.55 ± 1.08 s
-1mM-1, P < 0.0001). 
Ferric iron has significantly higher SE R2 values compared with ferrous iron from 
0.25 mM up to 5 mM (Table 4-2). Similar observations were made for ME R2 
measurements, showing significantly different r2 (ferrous r2 = 3.01 ± 0.16 s
-1mM-1 
and ferric r2 = 25.75 ± 0.64 s
-1mM-1, P < 0.0001) and differences between ferric and 
ferrous iron detected upwards from 0.25 mM (Figure 4-12E and Table 4-2). 
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GE R2* values of ferrous iron increased from 14.28 ± 1.41 s-1 at 0 mM to 32.65 ± 
0.50 s-1 at 5 mM with significant linear correlation of r2 = 0.98 (P < 0.0001; Figure 
4-12C). Ferric iron GE R2* values increased from 13.95 ± 1.55 s-1 at 0 mM to 177.84 
± 2.85 s-1 at 5 mM, with significant linear correlation of r2 = 0.99 (P < 0.0001). The 
r2* gradient of ferrous and ferric correlation were also significantly different 
(ferrous r2* = 3.47 ± 0.23 s
-1mM-1 and ferric r2* = 32.86 ± 1.56 s
-1mM-1, P < 0.0001). 
R2* of ferric iron was significantly higher compared with ferrous iron from 0.25 mM 
up to 5 mM (Table 4-2). Again, similar observations were made for MGE R2* 
measurements, showing significantly different r2* gradient (ferrous r2* = 3.70 ± 
0.23 s-1mM-1 and ferric r2* = 34.36 ± 1.67 s
-1mM-1, P < 0.0001) and differences 
between ferric and ferrous iron detected upwards from 0.1 mM (Figure 4-12F and 
Table 4-2). 
R2’ values were calculated by subtracting mean SE R2 values from mean GE R2* 
values. No significant correlation or significant differences were observed either 
with increasing iron contents or between ferric and ferrous iron standards. The 
resultant R2’ values were all approximately zero, giving evidence that the 




Figure 4-12 Ferrous and ferric iron agarose standards assessed by relaxometry 
measurements 
Graphs showing (A) R1, (B) SE R2, (C) GE R2*, (D) R2’, (E) ME R2 and (F) MGE R2* 
relaxometry values against different concentrations of ferric and ferrous iron 
chloride in 2% agarose standards. r2 are the correlation values; r1, r2 and r2* are the 










P-values between Ferrous and Ferric 
R1 SE R2 ME R2 GE R2* MGE R2* 
0 0.270 0.617 0.543 0.801 0.884 
0.10 0.013a 0.040 0.246 0.965 0.020a 
0.25 0.001a 0.006a 0.009a < 0.001a 0.006a 
0.50 < 0.001a 0.002a < 0.001a < 0.001a < 0.001a 
1.00 < 0.001a < 0.001a < 0.001a < 0.001a < 0.001a 
2.00 < 0.001a < 0.001a < 0.001a < 0.001a < 0.001a 
5.00 < 0.001a < 0.001a < 0.001a < 0.001a < 0.001a 
a denotes significance between ferric and ferrous iron reached using multiple t-tests, 
following Holm-Sidak method for multiple comparisons to α ≤ 0.05. Significant 
results highlighted blue. 
 
Assessment of uncertainty in R2, R2* and R2’ measurements was performed by 
calculating the mean absolute deviation of the triplicate measurements from each 
ferric and ferrous agarose standard (Table 4-3). Low mean absolute deviations were 
apparent at each concentration of ferric or ferrous iron from R2 and R2* 
measurements, however R2’ uncertainty was large compared with the mean value 
(Figure 4-13A-C). Very high percentage coefficients of variation of R2’ values further 




Figure 4-13 R2, R2* and R2’ uncertainty across the triplicate measurements 
The mean absolute deviation of each ferric and ferrous iron standard measurements 
was evaluated using (A) R2, (B) R2* and (C) R2’ relaxometry. 
 
Table 4-3 Mean absolute deviations of ferric and ferrous iron standards using R2, 
R2* and R2’ 
Iron (mM) 
Ferric  Ferrous 
R2 R2* R2'  R2 R2* R2' 
0.00 0.21 1.19 1.36  0.19 1.08 1.08 
0.10 0.16 1.11 1.27  0.58 1.17 1.64 
0.25 0.36 0.28 0.28  0.67 0.23 0.77 
0.50 0.32 0.16 0.48  0.90 0.40 0.95 
1.00 0.35 0.87 1.05  0.73 0.64 0.64 
2.00 0.40 1.04 1.43  0.94 0.42 1.14 




Table 4-4 Percentage coefficients of variation of ferric and ferrous iron standards 
using R2, R2* and R2’ 
Iron (mM) 
Ferric (%)  Ferrous (%) 
R2 R2* R2'  R2 R2* R2' 
0.00 2.1 11.1 952.4  2.0 9.9 13073.1 
0.10 1.3 8.7 379.3  5.1 9.5 228.1 
0.25 2.4 1.8 46.0  5.6 2.0 534.5 
0.50 1.8 1.0 74.5  6.6 3.1 264.5 
1.00 1.3 3.3 77.1  4.8 4.2 443.4 
2.00 0.9 2.1 75.5  5.2 2.3 759.6 
5.00 0.9 1.6 54.5  4.8 1.5 264.6 
 
 
4.4.6. Combinations of ferric and ferrous iron agarose standards 
To evaluate the differences observed between ferric and ferrous iron on 
relaxometry measurement further, combinations of these iron ions were 
formulated to evaluate the potential of ferric to ferrous ratio detection based on 
the differences in molar relaxivities between these ions. Combinations of ferric to 
ferrous iron were formulated at 100/0, 80/20, 50/50, 80/20 and 0/100 %, and 
serially diluted by a factor of 2 from the highest concentration. 
Linear regression of iron concentration to relaxometry values for each ferric-to-
ferrous combination, demonstrated significant linear correlation with R1, R2 and 
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R2* (P < 0.0001; Figure 4-14). The molar relaxivity slopes were found to be 
significantly different between the different proportions of ferrous to ferric iron 
contents tested across every relaxometry measurement taken (Table 4-5).  
 
Figure 4-14 Molar relaxivity changes with different proportions of ferrous to ferric 
iron contents 
(A) R1, (B) SE R2 and (C) GE R2* assessment demonstrate increasing molar relaxivity 













Molar relaxivities (s-1mM-1) 
SE r1 SE r2 ME r2 GE r2* MGE r2* 
100/ 0 6.70 ± 0.43 32.15 ± 1.83 25.19 ± 0.84 34.32 ± 2.29 32.23 ± 1.99 
80/ 20 4.32 ± 0.28 21.57 ± 1.10 19.79 ± 1.15 21.13 ± 1.11 21.44 ± 1.17 
50/ 50 2.28 ± 0.12 11.75 ± 0.41 10.87 ± 0.46 11.40 ± 0.52 11.76 ± 0.38 
20/ 80 0.98 ± 0.06 5.97 ± 0.19 5.37 ± 0.14 5.66 ± 0.21 5.79 ± 0.23 
0/ 100 0.33 ± 0.01 2.72 ± 0.16 2.41 ± 0.18 2.63 ± 0.19 2.58 ± 0.11 
P-value P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 
Significance assessed using one-way ANOVA with significance reached at P ≤ 0.05. 
 
4.4.7. Bound and unbound iron 
To investigate the differences in relaxometry between iron ions, compared to 
bound iron, ferritin from equine spleen was used to formulate agarose standards as 
a form of bound iron. Ferritin contains iron in the form of ferrihydrite crystals (see 
section 1.3.2) which are in the ferric form. Ferric and ferrous iron agarose standards 
demonstrated similar correlations and molar relaxivity slopes to the previous set of 
standards (Table 4-6). Ferritin also demonstrates strong linear correlation with iron 
content (Figure 4-15 and Table 4-6). Ferritin r1 was lower than that of both ferric 
and ferrous iron (Figure 4-15A), however ferritin r2 and r2* were only lower than 
the ferric form of iron, showing no significant difference compared with the ferrous 
173 
 
form (Figure 4-15B-C, Table 4-6). R2’ values were, again, all approximately zero at 
each iron concentration, including using the ferritin iron standards (Figure 4-15D). 
 
Figure 4-15 R1, R2, R2* and R2’ relaxometry assessment of ferrous and ferric iron, 







Table 4-6 Correlations and molar relaxivities of ferritin compared with ferric and 
ferrous iron agarose standards 
   R1 R2 R2* 
Ferric r2 0.98 0.99 0.99 
 Mol. rel. 6.07 ± 0.34 a 28.74 ± 1.19 a 29.60 ± 1.40 a 
Ferrous r2 0.99 0.98 0.97 
 Mol. rel. 0.29 ± 0.01 a 2.43 ± 0.14 2.17 ± 0.16 
Ferritin r2 0.95 0.98 0.99 
 Mol. rel. 0.03 ± 0.00 2.86 ± 0.16 2.12 ± 0.11 
P-value  P < 0.0001 P < 0.0001 P < 0.0001 
Significance assessed using one-way ANOVA with significance reached at P ≤ 0.05. a 
denotes significance compared with ferritin, at P < 0.0001. Mol. rel. = molar 
relaxivity. Significant results highlighted blue. 
 
4.5. Discussion 
The main outcome from this chapter shows that iron concentration provides a 
strong, positive and linear impact on R1, R2 and R2* relaxometry measurements. 
Furthermore, the form of iron has been shown to directly affect the molar relaxivity 
values using r1, r2 and r2* in agarose standards, with the ferric form of iron greatly 
increasing molar relaxivities, compared with the ferrous form of iron. Ferritin iron 




4.5.1. Quantitative MRI of standards 
The application of MRI for detection of iron in biological tissue is complicated by the 
presence of different cell types, biochemical composition and water contents. 
Furthermore, assessment of iron content in vivo can be further complicated due to 
movements within tissue (e.g. blood) and due to difficulties in confirming iron 
contents for correlating against MRI. Therefore, to understand the fundamental 
impact of iron on MRI measurements, simple model standards are used (Bartzokis 
et al., 1993, Zheng et al., 2013). Agarose standards are a popular choice of 
standard, as the matrix has similar relaxation properties to that in biological tissues 
(Mitchell et al., 1986). 
Furthermore, the use of quantitative measurements of relaxation characteristics is 
far superior to T1- or T2- weighted imaging, as quantitative approaches provide 
measurements of intrinsic relaxation parameters, unaffected by differences in 
external factors, such as hardware (Kjos et al., 1985, Cheng et al., 2012). These 
approaches have therefore been used in this work, to evaluate the impact iron has 
on relaxometry measurements in iron agarose standards. 
 
4.5.2. Quantitative relaxometry for iron detection 
Using quantitative MR relaxometry methods, these results using agarose standards 
are in line with the literature highlighting direct, linear correlation of R1, R2 and R2* 
to iron contents (Bartzokis et al., 1993, Vymazal et al., 1996b, Haacke et al., 2005, 
Langkammer et al., 2010). R2 relaxation rate has been well documented to be 
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affected by iron content in standards and, in human tissue (Pujol et al., 1992, 
Bartzokis et al., 1993, Wood, 2007), and this has been attributed due to the 
paramagnetic nature of iron impacting proton spin dephasing, thus enhancing T2 
relaxation. R2* has been shown to provide greater sensitivity to iron contents than 
R2 (Langkammer et al., 2010) likely due to R2* dependence on both the intrinsic 
transverse relaxation, as well as T2’ susceptibility effects provided by local 
inhomogeneities (Haacke et al., 2005). Furthermore, R1 values have also been 
shown to correlate with iron contents (Vymazal et al., 1996b, Ogg and Steen, 1998), 
highlighting that the paramagnetism of iron affects longitudinal relaxation, as well 
as transverse relaxation, although possibly to a lesser degree (Schenck, 2003). 
 
4.5.3. Different forms of iron impact relaxometry measurements differently 
Ferric iron ions demonstrated higher R1, R2 and R2* values than ferrous iron. The 
differences in R1 and R2 relaxation between ferric and ferrous iron have been 
suggested to be due to the greater correlation time of magnetic dipole-dipole 
interactions with water protons for ferric iron, compared to ferrous iron (Tokuhiro 
et al., 1996). It was also suggested that the paramagnetism of iron was not the main 
cause of these differences (Tokuhiro et al., 1996), and evidence exists showing 
susceptibility effects were similar between these two ions (Dietrich et al., 2013). 
Unpaired electrons enhance relaxation and the 5 unpaired electrons in ferric iron 
give rise to the paramagnetic nature of this form of iron. The 4 unpaired electrons 
in the ferrous form of iron also makes this paramagnetic, however when bound by 
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certain ligands into an octahedral configuration, ferrous iron can become 
diamagnetic, showing minimal effects on proton relaxation.  
The forms of iron within these agarose standards were confirmed using the 1,10-
phenanthroline assay, with the ferric form predominantly present in the ferric 
agarose standards and the ferrous form present in the ferrous agarose standards. 
There was also no evidence of precipitation or accumulation of iron particles within 
the agarose standards upon evaluation using microscopy, highlighting that iron ion 
presence remained within solution. 
With the pH of ferric solutions at approximately 2.55, the form of iron present 
within these agarose standards is likely to be predominantly as the ferric ion, Fe3+ 
(Hem and Cropper, 1962). It is likely, however, that alternative states of iron may 
have also been present at low concentrations within these solutions, such as 
[Fe2(OH)2]
4+, [FeOH]2+ and [Fe(OH)2]
+ (Snoeyink and Jenkins, 1980). The presence of 
any alternate forms of iron, even at low concentrations, may provide an 
explanation for the apparent deviation from linear correlation that seems to be 
observed using this ion. Furthermore, with the pH of the ferrous solutions at 
approximately 4.57, the form of iron present in these agarose standards is likely to 
be predominantly as the ferrous ion Fe2+ (Hem and Cropper, 1962). Linear 
regression has been used to evaluate the correlation of iron with relaxometry 
measurements due to the well-established literature present discussing this 
approach (Bartzokis et al., 1993, Vymazal et al., 1996b, Haacke et al., 2005, 
Langkammer et al., 2010). 
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R2 and R2* molar relaxivities were similar for both ferric iron (r2 = 31.55 s
-1mM-1; 
r2* = 32.86 s
-1mM-1) and ferrous iron (r2 = 3.61 s
-1mM-1; r2* = 3.47 s
-1mM-1) 
suggesting that there is no influence of field inhomogeneities detected in these 
standards, and that all the transverse relaxation can be associated to intrinsic T2 
relaxation. Indeed, this was confirmed after calculating R2’, to show that no 
correlation could be detected with iron content using these agarose standards. 
Further support for the lack of R2’ correlation with iron content in these agarose 
standards was proven due to the extremely high error in R2’ values, given the 
accumulation of error by subtracting R2 from R2* maps on a pixel by pixel basis. 
These observations were also apparent when using R2’ to measure ferritin iron 
agarose standards. With these standards providing a very simple model for iron 
quantification, clearly the agarose matrix provides a homogeneous solution of iron 
ions, containing very few inhomogeneities (Tokuhiro et al., 1996). Furthermore, this 
is in agreement with the similar susceptibilities detected for the two forms of iron, 
as highlighted above (Dietrich et al., 2013). 
It has also been demonstrated here that different proportions of ferric to ferrous 
iron can be detected based on their molar relaxivities, using agarose standards. This 
may provide a novel approach to determine the ferric to ferrous iron concentration 
in samples, by serial dilution of solutions and measurement of the molar 
relaxivities. A similar approach has already been used for measurement of radiation 
levels, through the conversion of ferrous to ferric iron upon application of radiation 
to a ferrous standard, and measurement of the NMR changes (Appleby et al., 1987). 
These approaches may provide a non-invasive and readily available method to 
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determine proportional concentrations of ferric to ferrous iron, compared to the 
complex and restrictive chemical analyses also available. Whether this approach 
provides the same sensitivity using biological samples however, still requires 
evaluation (Dietrich et al., 2013). 
Finally, iron bound within ferritin storage protein was assessed for relaxivity values 
and molar relaxivity compared with iron ions. Whilst ferritin showed similar, strong 
positive correlation values as both ferrous and ferric iron, the r1, r2 and r2* molar 
relaxivities were more similar to the ferrous form of iron, despite iron within ferritin 
being held as ferrihydrite crystals, in the ferric form (Harrison and Arosio, 1996). 
Ferritin has been shown to provide effects on R1 and R2 relaxivities based on its 
loading factor (Vymazal et al., 1996a), as well as protein concentration (Gossuin et 
al., 2004). The low impact of ferritin on relaxivity, especially in in vitro model 
systems is in agreement with other findings (Gossuin et al., 2004, Bennett et al., 
2008). To obtain ferritin relaxivities in vitro closer to those detected in tissue, 
ferritin had to be aggregated either using trypsin or by binding ferritin to actin prior 
to polymerisation, leading to enhanced T2 relaxation (Gossuin et al., 2007, Bennett 
et al., 2008). However these methods still only enhanced T2 relaxation by 20-30%, 
remaining substantially less than that observed for ferric iron. This highlights that 
ferritin iron does not impact relaxometry values to the same extent as ferric iron. 
The effects of ferritin on relaxivity values have been attributed due to a number of 
different theories, one of which, the proton exchange dephasing model, relies on 
exchange of bulk water protons, with exchangeable protons bound to the iron core 
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in ferritin, providing greater transverse relaxation effects (Gossuin et al., 2002, 
Gossuin et al., 2004). 
It therefore seems plausible that if there is a misregulation of iron during diseases, 
including in AD, whereby normal-loaded, dispersed ferritin can be converted into 
various pathological forms, then this may strongly impact the MRI relaxation 
characteristics without a change in iron content. This is further supported by 
comparisons performed here between ferric and ferrous iron, with ferritin on R1, 
R2 and R2* relaxometry. Indeed, the discovery of greater levels of magnetite in the 
brains of AD patients (Collingwood et al., 2005, Pankhurst et al., 2008) may also be 
noteworthy, given that magnetite shows enhanced impact on relaxometry (Gossuin 
et al., 2004). 
 
4.5.4. Acquisition artefacts and sequence comparison 
R2* measurements demonstrated image artefacts when acquired with slices of 2 
mm thickness, which was attributed to B0 inhomogeneities. Re-acquisition of 
agarose standards at 0.5 mm thickness led to the reduction of these artefacts. This 
was therefore due to lower impact of B0 inhomogeneities within thinner slices, 
providing improved image acquisition. Despite the reduction in slice thickness 
affecting SNR and therefore the variability of pixels intensities within each ROI, the 
different iron concentrations could still be detected using this method of R2* 
assessment. To improve future acquisitions however, increasing the number of 
averages to improve SNR could be carried out. 
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Comparing R2 and R2* standard acquisition methods against fast acquisition 
methods demonstrates that the values from each technique are well correlated 
with each other, however they provide slightly different absolute values. This 
highlights that whilst these faster acquisition methods can be utilised as part of 
future experiments, especially when used consistently within a study, care should 
be taken if attempting to measure “true” relaxivity values, or if comparing against 
relaxometry values from different acquisition sequences. Similar to the detectably 
lower R2 values measured here with ME acquisition, it has been observed that T2 
decay was slower using multiple echoes in the faster spin-echo acquisition 
methods, leading to higher signal intensity for later echoes than by using standard 
acquisition of T2 (Hennig, 1988, Poon and Henkelman, 1992). This therefore 
confirms the need to understand how the standard and fast acquisition methods 
compare to each other, when understanding the work within this project utilising 
both standard and fast MRI sequences. 
 
4.5.5. Conclusion 
R1, R2 and R2* relaxometry measurements have been validated for their use in 
assessment of iron content non-invasively using MRI, as outlined within the 
objectives (see section 4.2), and all showed strong, linear correlations to iron 
content. The impact of different forms of iron on these measurements has also 
been established, with the ferric form of iron showing greater influence on R1, R2 
and R2* than the ferrous form. Using R2’ measurements, it was not possible to 
assess the iron ion content within agarose standards, due to the relatively minimal 
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contribution of magnetic field inhomogeneities in these standards. Finally, ferritin 
iron demonstrated substantially lower longitudinal and transverse relaxation 
characteristics than ferric iron, despite the equally strong, linear correlation to iron 
content. As one of the objectives within this chapter was to gain an understanding 
of the different effects that different iron ions, and bound compared with unbound 
iron can elicit on MR relaxometry values (see section 4.2), it may therefore be 
important to consider that not all MR relaxometry changes observed within tissue 
may be solely due to iron concentration, given the varied measurements observed 





5. Results: Iron Measurement in Control and AD 
Human Medial Temporal Gyrus 
5.1. Introduction 
This chapter first assesses MR relaxometry values in aged healthy control samples 
from the medial temporal gyrus (MTG), and corroborates these with quantitative 
SR-XRF elemental iron mapping to understand how iron content directly affects 
relaxometry. The correlation of relaxometry values is also measured specifically 
against iron content. Subsequently, MR relaxometry of AD brain samples from the 
MTG are evaluated and again, corroborated and correlated with quantitative SR-
XRF elemental iron mapping. Comparisons are made between control and AD tissue 
samples to explore changes in relaxivity values or iron content, or to evaluate any 
changes in the correlation between these measurements in neurodegenerative 
disease. Myelin content was also evaluated in these brain samples to understand 
the impact that tissue microstructure holds on relaxometry values. 
 
5.2. Objectives 
The objectives for the work with control and AD human post-mortem tissue were: 
 To perform quantitative R1, R2, R2* and R2’ relaxometry on control, and 




 To quantify SR-XRF elemental iron content in control, and subsequently 
compared with AD, post-mortem human brain tissue from the MTG. 
 To correlate the spatial distribution of iron content with R1, R2, R2* and R2’ 
relaxometry methods, both within individual samples, and across multiple 
samples, in control, and subsequently compared with AD, post-mortem 
human brain tissue. 
 To evaluate the sensitivity of MRI relaxometry methods to assess iron 
content within specific tissue types, such as WM or GM, from control, and 
subsequently compared with AD, post-mortem human brain tissue. 
 To determine the effect of tissue microstructure on MRI-iron correlations, in 
particular the degree of myelination, in control, and subsequently compared 
with AD, MTG brain tissue. 
 
5.3. Methods 
The majority of methods for this work can be found in section 3.2.2. In brief, human 
control samples underwent R1, R2, R2* and R2’ relaxometry at 7T and were then 
sectioned for XRF elemental iron mapping and histology. Quantitative MRI 
relaxometry measurements and SR-XRF elemental iron contents were compared 
between tissue areas and correlated both within individual samples, as well as 
across multiple samples. The same assessments were also performed using AD 
human tissue samples from the MTG, and compared against the control samples. 
Luxol fast blue (LFB) staining was performed on adjacent sections to those taken for 
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XRF elemental iron mapping from both control and AD samples, for assessment of 
the impact myelin holds on relaxometry values in both control, and compared with 
AD tissue. 
 
5.4. Results of Control Human MTG Assessment 
5.4.1. Qualitative assessment of relaxometry and iron elemental maps in 
control samples 
T2-weighted (T2W) images were each registered manually to their corresponding 
elemental iron maps by first re-orientating and then cropping images to match the 
iron maps (Figure 5-1A-C; see section 3.2.2.3). The T2W and XRF maps were then 
visually inspected to compare tissue architectural similarities. The same registration 
process was used to register R1, R2 and R2* maps with corresponding elemental 
iron maps (Figure 5-1D-F). 
In both relaxometry and elemental iron maps, increased pixel intensities 
correspond to increased relaxivity values and iron contents, respectively (Figure 
5-1C-F). The WM from brain tissue was clearly observed as dark areas in the T2W 
images of MTG (Figure 5-1B) corresponding to higher iron content in the elemental 
iron map (Figure 5-1C). The brighter GM regions in T2W images (Figure 5-1B) were 
localised at the outer areas of each tissue sample, with correspondingly lower iron 
contents (Figure 5-1C). R1, R2 and R2* maps matched the GM and WM localisation 
as shown in T2W images and in iron content maps, with higher relaxation rates in 
WM and lower relaxation rates in GM (Figure 5-1C-F). Only relaxivity values within 
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the cropped area of relaxometry maps were compared against elemental iron 
contents. 
 
Figure 5-1 Alignment and qualitative comparison of relaxometry and iron 
elemental maps 
(A) Full T2W image of a representative control human tissue sample from the 
medial temporal gyrus (MTG). (B) Registered region of T2W image that is 
comparable to the region acquired in (C) SR-XRF elemental iron mapping. (D) R1, (E) 
R2 and (F) R2* maps were then registered in the same way as T2W images to the 
acquired elemental iron map. 
 
Given that WM and GM regions are two of the dominant features observed in MR 
brain imaging in vivo, ROIs were drawn around these two tissue regions from all 
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samples acquired, on both elemental iron and relaxometry maps. Closer inspection 
of both T2W structural images and elemental iron maps allowed the delineation of 
distinct cortical layers within the GM, seemingly related to their iron content 
(Figure 5-2). Therefore, in addition to ROIs for WM and GM, two further ROIs were 
drawn corresponding to this mid-cortical layer (MCL), situated at cortical layers IV-V 
at the boundary between GM and WM, and to the distal GM layers (dGM), at the 
outermost edges of the cortex (Figure 5-2). 
 
Figure 5-2 Whole ROI placement on R2 and elemental iron map of control sample 
Typical WM, MCL and dGM ROI placement on (A) an R2 map and (B) an elemental 
iron map. The whole GM ROIs incorporate both the dGM and MCL ROIs. 
 
5.4.2. Effect of PMI, fixation time and subjects’ age on relaxometry and 
elemental iron content in control samples 
As mentioned in section 1.7, a number of factors may influence relaxivity values 
and iron content in post-mortem human tissue. Therefore, the effects of post-
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mortem interval (PMI), fixation time and subjects’ age at death were evaluated 
initially, prior to quantitative analysis of tissue samples. 
 
5.4.2.1. PMI 
R1, R2, R2* and R2’ relaxometry values, and elemental iron content were 
unaffected by PMI in our control human tissue samples (Figure 5-3, Table 5-1). PMI 
had no significant effects on any of the relaxivity values assessed using Pearson’s 
correlation, in either GM (R1, P = 0.575; R2, P = 0.618; R2*, P = 0.683 and R2’, P = 
0.929) or WM (R1, P = 0.345; R2, P = 0.627; R2*, P = 0.831 and R2’, P = 0.883; Figure 
5-3A-D). Iron contents were also not significantly affected by PMI length in either 
GM regions (P = 0.480) or WM regions (P = 0.426; Figure 5-3E). The different GM 
cortical layers were also separately assessed, showing no significant effects of PMI 
on relaxometry or iron contents in these tissue areas (dGM: R1, P = 0.584; R2, P = 
0.713; R2*, P = 0.361; R2’, P = 0.316 and iron, P = 0.519, and MCL: R1, P = 0.612; R2, 




Figure 5-3 Effect of PMI on relaxometry values and elemental iron contents in 
control samples 
The effect of PMI length of control tissue samples, against (A) R1, (B) R2, (C) R2* 
and (D) R2’ relaxivity values, and against (E) elemental iron content. Correlation was 
assessed using Pearson’s correlation with significance level set at P ≤ 0.05 (n =15). 
 
5.4.2.2. Fixation time 
Increasing time in fixative significantly increased R1 relaxivity values in both GM 
and WM (GM: r2 = 0.59, P = 0.0009 and WM: r2 = 0.59, P = 0.0008; Figure 5-4A) and 
also of R2 relaxivity values in only GM (GM: r2 = 0.27, P = 0.047 and WM, P = 0.085; 
Figure 5-4B, Table 5-1). No significant effects of fixation time were detected on R2* 
or R2’ relaxivity values, or with iron content in GM (R2*, P = 0.440; R2’, P = 0.360 
and iron, P = 0.770) or WM of control human MTG samples (R2*, P = 0.588; R2’, P = 
0.440 and iron, P = 0.371; Figure 5-4C-E). 
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Again, the effects of length of fixation on relaxometry and iron measures were 
compared separately in dGM and MCL. Both dGM and MCL R1 values were 
significantly increased with increasing fixation times (dGM: r2 = 0.57, P = 0.0012 and 
MCL: r2 = 0.59, P = 0.0008). R2 values were also significantly increased in the dGM 
with increasing time in fixative (r2 = 0.40, P = 0.011) but not in the MCL (P = 0.143). 
R2* relaxivity values (dGM, P = 0.165; MCL, P = 0.611), R2’ values (dGM, P = 0.658; 
MCL, P = 0.356) and iron contents (dGM, P = 0.364; MCL, P = 0.935) were 
unaffected by fixation time (Table 5-1). 
 
Figure 5-4 Effect of fixation time on relaxometry values and elemental iron 
contents in control samples 
The effect of fixation time of control tissue samples, against (A) R1, (B) R2, (C) R2* 
and (D) R2’ relaxivity values, and against (E) elemental iron content. Correlation was 
assessed using Pearson’s correlation with significance level set at P ≤ 0.05. * P ≤ 
0.05, ** P < 0.01, *** P < 0.001 and **** P < 0.0001 (n = 15). 
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Samples with fixation time greater than 18 months were therefore excluded from 
subsequent assessments, given that iron content remains stable up to this point 
(Gellein et al., 2008), and fixation time has less effect on results. 
 
5.4.2.3. Age 
The influence of the age of subjects at death on relaxometry values and iron 
content were also studied (Figure 5-5, Table 5-1). Age of subjects at death had no 
significant effects on GM or WM relaxivities (GM: R1, P = 0.169; R2, P = 0.903; R2*, 
P = 0.269 and R2’, P = 0.051 and WM: R1, P = 0.104; R2, P = 0.641; R2*, P = 0.967 
and R2’, P = 0.575; Figure 5-5A-D). Iron contents were also unaffected by age in GM 
(P = 0.342) and WM (P = 0.985; Figure 5-5E). Individual correlations of dGM and 
MCL with subject age at death also showed no effect of age on relaxivities (dGM: 
R1, P = 0.178; R2, P = 0.913; R2*, P = 0.309 and R2’, P = 0.162 and MCL: R1, P = 
0.177; R2, P = 0.993; R2*, P = 0.408 and R2’, P = 0.070) or on iron contents (dGM, P 




Figure 5-5 Effect of subjects’ age at death on relaxometry values and elemental 
iron contents in control samples 
The effect of control subjects’ age at death, against (A) R1, (B) R2, (C) R2* and (D) 
R2’ relaxivity values, and against (E) elemental iron content. Correlation was 









Table 5-1 Summary table of the assessed factors’ r2 correlation values, on control 
sample relaxivity values and iron contents 
 R1 R2 R2* R2’ Iron 
PMI WM 0.07 0.02 0.00 0.00 0.05 
GM 0.02 0.02 0.01 0.00 0.04 
MCL 0.02 0.05 0.01 0.01 0.05 
dGM 0.02 0.01 0.06 0.08 0.04 
Fixation Time WM 0.59*** 0.21 0.02 0.05 0.06 
GM 0.59*** 0.27* 0.05 0.06 0.01 
MCL 0.59*** 0.16 0.02 0.07 0.00 
dGM 0.57** 0.40* 0.14 0.02 0.07 
Subjects’ Age WM 0.19 0.02 0.00 0.02 0.00 
GM 0.14 0.00 0.09 0.26 0.07 
MCL 0.14 0.00 0.05 0.23 0.14 
dGM 0.14 0.00 0.08 0.15 0.08 
Correlation was assessed using Pearson’s correlation with significance level set at P 








5.4.3. Quantitative assessment of control tissue 
5.4.3.1. R1, R2, R2* and R2’ relaxivity value assessment 
Mean relaxometry values are summarised in Table 5-2. R1, R2, R2* and R2’ WM 
values were all significantly higher when compared with overall GM values only (R1, 
P = 0.05; R2, P < 0.0001; R2*, P < 0.0001 and R2’, P < 0.0001; Figure 5-6, Table 5-2). 
Separate comparison of the dGM and MCL sub regions with WM also demonstrated 
significant differences between these three tissue types using one-way ANOVA (R1, 
P = 0.045; R2, P < 0.0001; R2*, P < 0.0001 and R2’, P < 0.0001; Figure 5-6, Table 
5-2). More specifically, R2 and R2* values were consistently higher in WM 
compared with MCL (R2, P < 0.0001; R2*, P < 0.0001) and the MCL showed 
consistently higher values than dGM (R2, P < 0.0001; R2*, P = 0.0095; Figure 5-6B-
C). R2’ values in WM regions were significantly higher than both MCL and dGM (P < 
0.0001), however the MCL did not show significantly different R2’ values than the 
dGM region (P = 0.911; Figure 5-6D). Similarly, R1 values were only higher in WM 
compared to dGM (P = 0.040), whilst differences between WM and MCL (P = 0.197) 
and MCL and dGM (P = 0.711) were not significant (Figure 5-6A, Table 5-2). 
To evaluate the consistency of higher relaxivities in WM compared to GM within 
each sample, paired statistics were also employed. Paired t-testing showed R1, R2, 
R2* and R2’ relaxivities were found to increase significantly between GM and WM 
regions (P < 0.0001; Figure 5-6A-D). Furthermore, repeated-measures one-way 
ANOVA testing of dGM, MCL and WM regions demonstrated values consistently 
increasing in the order of dGM < MCL < WM for R1, R2 and R2* relaxometry (R1, P < 
0.0001; R2, P < 0.0001 and R2*, P < 0.0001; Figure 5-6A-C). R2’ values did not 
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consistently increase in this order across the three tissue regions, as values 
between dGM and MCL were similar (P = 0.761; Figure 5-6D). 
 
Figure 5-6 Relaxometry values in WM and GM tissue of control samples 
Graphs showing the mean GM and WM region relaxivity values for (A) R1, (B) R2, (C) 
R2* and (D) R2’ from control MTG samples. Significance was assessed using 
Student’s unpaired (*), or paired (#) t-test between GM and WM. Mean MCL and 
dGM sub regions of GM ROIs were separately assessed with WM values, using one-
way ANOVA (*), or repeated-measures one-way ANOVA (#), with Tukey’s test for 
multiple comparisons. Graphs show mean values ± SD (n = 12). 
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Table 5-2 Relaxivities and iron content from control MTG samples 
Tissue Region R1 (s-1) R2 (s-1) R2* (s-1) R2’ (s-1) Iron (ppm) 
GM 1.10 ± 0.25 33.42 ± 2.31 42.38 ± 3.98 8.82 ± 2.59 133.2 ± 20.4 
WM 1.31 ± 0.26 44.64 ± 3.75 64.39 ± 6.16 19.74 ± 3.60 223.9 ± 55.2 
P-value 0.050 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
WM 1.31 ± 0.26 44.64 ± 3.75 64.39 ± 6.16 19.74 ± 3.60 223.9 ± 55.2 
MCL 1.13 ± 0.25 35.86 ± 2.78 44.92 ± 4.88 9.05 ± 2.84 150.1 ± 27.4 
dGM 1.05 ± 0.24 29.89 ± 2.29 38.44 ± 3.82 8.53 ± 2.89 115.7 ± 16.3 
P-value 0.045 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
(GM) grey matter, (WM) white matter, (MCL) mid-cortical layer and (dGM) distal grey matter regions. Values are mean ± SD. Statistical testing 
between GM and WM was performed using Student’s unpaired t-test. Statistical testing between dGM, MCL and WM was performed using 
one-way ANOVA, with Tukey’s test for multiple comparisons. Significance level set at P ≤ 0.05 (n = 12). 
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5.4.3.2. XRF elemental iron assessment 
Iron contents were also identified as being significantly higher in WM compared 
with GM regions from the MTG of control samples (P < 0.0001; Figure 5-7, Table 
5-2). Subdivision of the GM region into the MCL and dGM demonstrated that mean 
iron content was significantly different between the three tissue regions (P < 
0.0001; Figure 5-7, Table 5-2). Following Tukey’s test for multiple comparisons 
however, only WM regions were significantly higher compared with both MCL and 
dGM (P < 0.0001), whilst iron content was similar between MCL and dGM (P = 
0.072; Figure 5-7). Using paired statistics, iron content was consistently higher in 
the WM compared to GM for each sample (P < 0.0001; Figure 5-7). Repeated-
measures one-way ANOVA testing of dGM, MCL and WM demonstrates values 
consistently increasing in the order of dGM < MCL < WM in iron content (P < 
0.0001) between these three tissue types (Figure 5-7). 
 
Figure 5-7 Elemental iron content in WM and GM tissue of control samples 
Graphs showing the mean GM and WM region iron contents from control MTG 
samples. Significance was assessed using Student’s unpaired (*), or paired (#) t-test. 
Mean MCL and dGM sub regions of the GM ROIs were separately assessed with WM 
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iron contents, using one-way ANOVA (*), or repeated-measures one-way ANOVA 
(#), with Tukey’s test for multiple comparisons. Graphs show mean values ± SD (n = 
12). 
 
5.4.3.3. Gender comparison 
Similar relaxometry values and iron contents were observed between male and 
female subjects within GM and WM regions of control MTG samples using two-way 
ANOVA, with Holm-Sidak test for multiple comparisons (R1, P = 0.158; R2, P = 
0.240; R2*, P = 0.093; R2’, P = 0.119 and iron, P = 0.793; Figure 5-8, Table 5-3). 
Furthermore, neither the dGM nor MCL layers demonstrated significant differences 
between male and female subjects (R1, P = 0.105; R2, P = 0.231; R2*, P = 0.084; R2’, 





Figure 5-8 Gender comparison of relaxometry and elemental iron contents in 
control samples 
(A) R1, (B) R2, (C) R2*, (D) R2’ relaxometry values, and (E) elemental iron contents, 
from male (n = 7) and female (n = 5) subjects in GM and WM tissue, and in the MCL 
and dGM sub regions. Graphs show mean values ± SD. Significance assessed using 
two-way ANOVA, with Holm-Sidak test for multiple comparisons with a level set to P 









Table 5-3 Relaxivities and iron content of control MTG from male and female 
subjects 
GM R1 (s-1) R2 (s-1) R2* (s-1) R2’ (s-1) Iron (ppm) 
Male 1.15 ± 0.31 33.97 ± 2.04 43.64 ± 3.06 9.52 ± 2.77 132.7 ± 25.2 
Female 1.02 ± 0.09 32.65 ± 2.67 40.63 ± 4.79 7.86 ± 2.21 133.9 ± 13.8 
WM      
Male 1.38 ± 0.33 45.41 ± 4.17 66.21 ± 5.38 20.78 ± 2.85 228.4 ± 68.0 
Female 1.21 ± 0.08 43.57 ± 3.19 61.85 ± 6.86 18.29 ± 4.34 217.6 ± 37.0 
MCL      
Male 1.19 ± 0.31 36.59 ± 2.55 46.86 ± 4.10 10.25 ± 2.72 151.1 ± 33.9 
Female 1.05 ± 0.10 34.83 ± 3.05 42.20 ± 4.94 7.37 ± 2.26 148.6 ± 18.3 
dGM      
Male 1.10 ± 0.31 29.97 ± 2.31 38.38 ± 2.69 8.36 ± 2.96 113.8 ± 19.9 
Female 0.99 ± 0.08 29.78 ± 2.53 38.52 ± 5.40 8.76 ± 3.13 118.5 ± 11.2 
Values are mean ± SD. Statistical testing performed using two-way ANOVA, with 
Holm-Sidak test for multiple comparisons with a level set to P ≤ 0.05 (male (n = 7) 
and female (n = 5)). 
 
5.4.4. Correlation of relaxometry to iron in control samples 
5.4.4.1. Correlation of whole tissue type ROIs 
Mean dGM, MCL and WM R2, R2* and R2’ demonstrated significant positive 
correlations to iron (R2: r2 = 0.71, P < 0.0001; R2*: r2 = 0.76, P < 0.0001; R2’: r2 = 
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0.66, P < 0.0001; Figure 5-9B-D). R1 values were not significantly correlated (r2 = 
0.046, P = 0.211) across multiple control tissue samples (Figure 5-9A). 
 
Figure 5-9 Whole tissue ROI correlations from control samples 
Mean (A) R1, (B) R2, (C) R2* and (D) R2’ values correlated against iron content for 
the control samples of all dGM, MCL and WM regions (n = 36). Correlation assessed 
using Pearson correlation with significance level set at P ≤ 0.05. 
 
In order to gain a greater understanding of the spatial correlation of relaxometry 
measurements to iron content in control samples (see section 1.6.5.1), equally sized 
square ROIs (see section 5.4.4.2) per tissue region (i.e. dGM, MCL and WM) were 
placed across each of the samples (Figure 5-10). Eight ROIs per tissue area were 
used to allow the variability of correlations within a single sample to be better 
understood (see section 5.4.4.3), whilst also preventing any bias in correlations 
within each sample (see section 3.2.2.3). Furthermore, eight ROIs per tissue area 




Figure 5-10 Representative relaxometry and elemental iron maps showing 
placement of 24 small ROIs in control sample 
Representative (A) R1, (B) R2, (C) R2*, (D) R2’ and (E) elemental iron maps, 
demonstrating the placement of the eight equally sized ROIs within each tissue 
region (twenty four ROIs in total across each sample). 
 
5.4.4.2. Comparison of ROI sizes 
Different sizes (3x3 and 5x5 pixel) of ROIs were used to evaluate whether 
relaxometry to iron correlations are affected by the size of the ROI used within a 
sample (Figure 5-11). Other work has used ROI sizes of 3x3 pixels (Antharam et al., 
2012). The regression correlation gradients and y-intercepts between relaxometry 
values and iron in individual samples were similar between 3x3 and 5x5 pixel ROIs, 
in all the control samples evaluated (representative correlations from one sample 
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are shown in Figure 5-11A-C). However the r2 correlation values of each individual 
sample were significantly greater using 5x5 pixels compared to the 3x3 pixel ROIs 
for each of the samples (R1, P = 0.0032; R2, P = 0.0026; R2*, P = 0.0029; Figure 
5-11D-F). This is likely due to the greater sampling of pixels using larger 5x5 pixel 
ROIs than the 3x3 pixel ROIs. Therefore, ROIs of 5x5 pixels were chosen for 
analyses, being more sensitive to correlations without affecting correlation 
gradients or y-intercepts. 
 
Figure 5-11 Comparison of 3x3 or 5x5 ROI sizes for spatial assessment across 
control tissue 
Correlation of (A) R1, (B) R2 and (C) R2* values to elemental iron, in one sample, 
using twenty-four 3x3 (red) or 5x5 (blue) pixel ROIs. The r2 correlation values were 
significantly improved using 5x5 (blue) pixel ROIs compared with 3x3 (red) pixels 
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using (D) R1, (E) R2 and (F) R2* values to elemental iron content. (D-F) Each point 
represents the r2 correlation of relaxometry values to iron within one sample and 
assessed for significance using paired t-test, with level set at P ≤ 0.05 (n = 12). 
 
5.4.4.3. Individual sample correlations 
Averaging all the individual r2 correlations using the 5x5 pixel ROIs within each 
control sample (representative single sample ROI placement as shown in Figure 
5-10, with individual correlation plots in Figure 5-12) demonstrated strongly 
significant correlations between each relaxometry measurement with iron content 
(R1, r2 = 0.77 ± 0.12; R2, r2 = 0.81 ± 0.12; R2*, r2 = 0.83 ± 0.10; R2’, r2 = 0.65 ± 0.18; 
Table 5-4). Mean R2’ correlations were found to be significantly lower than R2 and 
R2* correlations using one-way ANOVA with Tukey’s multiple comparisons test (R2’ 
compared with: R2, P = 0.024 and R2*, P = 0.012; Table 5-4). R1, R2 and R2* 
relaxometry were not significantly different in their individual correlations to iron 
across all the samples (R1 to R2, P = 0.848; R1 to R2*, P = 0.706; R1 to R2’, P = 0.153 






Figure 5-12 Representative relaxometry correlations against elemental iron for 
one control tissue sample 
Representative (A) R1, (B) R2, (C) R2* and (D) R2’ correlation graphs against iron 
content for one control post-mortem sample (see Figure 5-10). Correlation assessed 












Table 5-4 The r2 correlation values for relaxometry against iron content for each 
individual control sample 
Sample R1 R2 R2* R2’ 
1 0.70 0.81 0.76 0.62 
2 0.87 0.89 0.90 0.72 
3 0.88 0.74 0.80 0.39 
4 0.74 0.56 0.57 0.43 
5 0.89 0.92 0.91 0.80 
6 0.88 0.84 0.85 0.75 
7 0.57 0.93 0.84 0.51 
8 0.90 0.87 0.94 0.83 
9 0.58 0.94 0.94 0.82 
10 0.83 0.71 0.88 0.81 
11 0.70 0.89 0.76 0.39 
12 0.71 0.68 0.80 0.78 
Mean ± SD 0.77 ± 0.12 0.81 ± 0.12 a 0.83 ± 0.10 a 0.65 ± 0.18 
Significance assessed using one-way ANOVA with Tukey’s multiple comparisons test 
to significance set at P ≤ 0.05 (n = 12). a denotes significance compared with R2’. R2’ 
correlations were lower than R2 and R2* correlations to iron, highlighted in blue. 
 
5.4.4.4. Grouped correlations of control samples 
In order to evaluate the iron content correlations against relaxometry values for 
both intra- and inter- samples variation, rather than using the mean of each 
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samples’ correlation (from Table 5-4), the individual 24 ROIs of all the samples 
together, were correlated with iron (Figure 5-13). Similar results to section 5.4.4.1 
were obtained, with R2 and R2* demonstrating strongest correlation with iron 
content (R2, r2 = 0.62, R2* r2 = 0.68 and R2’, r2 = 0.54; all P < 0.0001) and R1 
demonstrating very low correlation (r2 = 0.05; Figure 5-13, Table 5-5). The 
correlation between R2* and iron was significantly higher than the correlation of R2 
with iron (P = 0.005). Both R2 and R2* had higher correlation with iron content than 
R2’ (R2’ against R2, P = 0.046 and R2’ against R2*, P < 0.0001; Table 5-5, Table 5-7). 
R1 values displayed much lower correlation across multiple samples (Figure 5-13A, 
Table 5-5) than was observed by evaluation of the individual sample correlations 
(Table 5-4). This indicates that other factors may impact the correlation of R1 with 
iron between samples. Indeed, an outlier seems to be apparent from the R1 
correlation to iron content (Figure 5-13A), with the cluster of points between 1.5 
and 2.0 s-1 all belonging to the same sample. This sample was investigated in 
greater detail, however could not be excluded as there was no evidence of β-
amyloid, tau, or any other unusual pathology. Furthermore, the fixation time, PMI 
and age of death were within the range of other samples and there was no 
evidence of abnormal R2, R2* or R2’ relaxometry measurements or unexpected 
iron contents. Molar relaxivities for each relaxometry measurement to iron are also 




Figure 5-13 Correlation of relaxometry values against elemental iron content 
across all control samples 
Graphs of (A) R1, (B) R2, (C) R2* and (D) R2’ correlation with iron content, as 
assessed using the twenty-four 5x5 pixel ROIs for control samples. Each point 
corresponds to one ROI pairing between the relaxometry map and the elemental 
iron map. Correlation assessed using Pearson correlation with significance level set 
at P ≤ 0.05 (n = 288). 
 
Individual sample regression lines (single representative correlation shown in Figure 
5-12) were also displayed together to observe the inter-sample variability in 
correlations between relaxometry and iron (Figure 5-14). Wide variations in 
regression gradients, y-intercepts and ranges for R1, R2, R2* and R2’ relaxometry 
and iron measurements are observed for the 12 individual samples (samples with 
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fixation times longer than 18 months have already been excluded) (Figure 5-14A-D). 
Furthermore, despite R2 and R2* correlating to iron content extremely consistently 
within samples (Table 5-4) and between samples (Figure 5-13B-C), both these 
measurements also demonstrated substantial variability in regression gradients 
between individual samples (Figure 5-14B-C). These variations in correlation 
highlight that other factors must clearly be affecting the correlation of relaxometry 
values with iron content, in a different manner per subject. 
 
Figure 5-14 Variability in individual control sample correlations for relaxometry 
measurements against elemental iron contents 
Regression lines for (A) R1, (B) R2, (C) R2* and (D) R2’ relaxometry values against 




5.4.4.5. Region-specific correlations in control tissue 
To study correlations of relaxometry measurements with iron content in different 
tissue types, i.e. within WM or GM, the 5x5 ROIs from each region (Figure 5-10) 
were correlated separately with iron contents (Figure 5-15, Table 5-5). R2, R2* and 
R2’ relaxometry measurements all continued to correlate significantly with iron 
levels, whether in the WM (R2, r2 = 0.19; R2*, r2 = 0.34 and R2’, r2 = 0.20, all P < 
0.0001) or in the GM tissue types separately (R2, r2 = 0.38; R2*, r2 = 0.37 and R2’, r2 
= 0.11, all P < 0.0001; Figure 5-15B-D and F-H, Table 5-5). However, these region-
specific correlations were substantially lower than using ROIs from both WM and 
GM regions together (Table 5-5). R1 values displayed much lower correlation to iron 
in WM between multiple samples with a slight decreasing regression gradient (r2 = 
0.09, P < 0.0001; Figure 5-15A) and GM R1 values did not correlate to iron content 
(Figure 5-15E). Therefore, R1 values in separate tissue regions were not compared 
any further. 
Molar relaxivities and correlation values were compared between the WM and GM 
tissue types for each relaxometry measurement to understand whether tissue 
microstructure effects the correlation of relaxometry with iron content. GM R2 
correlation with iron content was greater than that for WM (P = 0.041), and with a 
higher molar relaxivity (P < 0.0001; Table 5-6). GM R2* correlation with iron was 
similar to that for WM (P = 0.775), but also had a higher molar relaxivity (P = 
0.0003; Table 5-6). GM R2’ values were correlated with iron similarly as that for 
WM R2’ values (P = 0.282) and had similar molar relaxivities (P = 0.692; Table 5-6). 
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Evaluating for different relaxivity measurements in WM only, R2* values were 
significantly more correlated to iron content than R2 (P = 0.018) or R2’ values (P = 
0.016), and R2 and R2’ values were correlated to iron similarly (P = 0.909; Table 5-5 
and Table 5-7). In the GM regions only, R2* and R2 values were similarly correlated 
to iron (P = 0.786), and both were better correlated with iron content than R2’ 
values (R2 and R2*, P < 0.0001; Table 5-5 and Table 5-7). 
 
Figure 5-15 Correlation of relaxometry values against elemental iron content for 
all control samples in WM or GM tissue 
Graphs showing (A-D) WM and (E-H) GM correlations to iron contents, using R1, R2, 
R2* and R2’ relaxometry assessment in control samples. Correlation assessed using 
Pearson correlation with significance level set at P ≤ 0.05. Solid circles are GM ROIs 




Table 5-5 Summary of correlations for all regions, WM only, or GM only regions 
between relaxometry values and iron contents 
Measure All regions WM only GM only 
R1 r2 0.05 0.09 0.00 
r1 (s
-1 ppm-1) 0.001 -0.001 0.00 
R2 r2 0.62 0.19 0.38 
r2 (s
-1 ppm-1) 0.096 0.034 0.088 
R2* r2 0.68 0.34 0.37 
r2* (s
-1 ppm-1) 0.182 0.072 0.130 
R2’ r2 0.54 0.20 0.11 
r2’ (s
-1 ppm-1) 0.086 0.038 0.043 
Significance between correlations was assessed using Pearson and Filon’s z, with 
level set to P ≤ 0.05, and significant values summarised in Table 5-7. R1 values were 
not compared due to low correlation values and regression gradients. 
 
Table 5-6 Summary of significant differences comparing correlation values and 
molar relaxivities, between WM and GM control tissue 
Measurement r2 Molar relaxivity 
R1 - - 
R2 GM > WM GM > WM 
R2* GM = WM GM > WM 
R2’ GM = WM GM = WM 
> denotes values are significantly different, = denotes values are similar. 
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Table 5-7 Summary table of relaxometry to iron correlation comparisons in 
different tissue regions 
Region Selection Order of significance 
All ROIs (WM and GM)  R2* > R2 > R2’ > R1 
WM only R2* > R2 = R2’ > R1 
GM only R2* = R2 > R2’ > R1 
Significance between correlations was assessed using Pearson and Filon’s z, with 
level set to P ≤ 0.05. > denotes values are significantly different, = denotes values 
are similar. 
 
5.4.5. Myelin assessment in control samples 
Luxol fast blue (LFB) stain was used to assess myelin content in control MTG tissue 
samples to quantitatively compare and correlate against relaxometry 
measurements and iron contents. 
 
5.4.5.1. Qualitative comparison of myelin 
LFB was used to stain for myelin in tissue slices adjacent to elemental iron maps. 
Images obtained demonstrate clear distinction between GM and WM regions, with 
intensely stained WM and less intense staining in GM (Figure 5-16C). WM and GM 
were found in similar locations as observed by structural T2W MRI and XRF 
elemental iron mapping (Figure 5-16A-B). Furthermore, similar delineation of 
different cortical layers in the GM region can be observed in the LFB images (Figure 
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5-16C), separating the GM into MCL and dGM regions (as described in section 5.4.1, 
Figure 5-2). 
 
Figure 5-16 Representative T2W, elemental iron and LFB image of a control 
sample 
Representative images of a (A) T2W, (B) an elemental iron map and (C) the 
corresponding adjacent tissue slice to iron maps stained for luxol fast blue (LFB). 
WM and GM regions are highlighted. 
 
5.4.5.2. Effect of PMI, fixation time and subjects’ age on myelin in control 
samples 
Prior to quantitative analysis, the effects of PMI, fixation time and age of subjects’ 
death on myelin were evaluated (as performed for relaxometry and iron contents, 
see section 5.4.2). Length of PMI had no significant effects on myelin content in 
either GM (P = 0.052) or WM (P = 0.919; Figure 5-17A). The separated dGM and 
MCL myelin contents were also not correlated with PMI length (dGM: P = 0.078 and 
MCL: P = 0.106). Fixation time lengths also demonstrated no significant correlations 
with myelin in either GM (P = 0.484) or WM (P = 0.076; Figure 5-17B), or following 
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separation of GM into dGM (P = 0.598) and MCL (P = 0.543). Finally, the age of 
subjects at death demonstrated no significant correlations with myelin in GM (P = 
0.325) or WM (P = 0.763; Figure 5-17C), or through separation of GM into dGM (P = 
0.361) or MCL (P = 0.345). 
 
Figure 5-17 Effect of PMI, fixation time and subjects’ age at death on myelin 
contents in control samples 
Graphs showing (A) PMI, (B) fixation time, and (C) subjects’ age at death of control 
samples, against myelin measurement. Correlation was assessed using Pearson’s 
correlation with significance level set at P ≤ 0.05 (n = 15). 
 
5.4.5.3. Quantitative assessment of myelin in control tissue 
WM had significantly higher myelin content compared with GM (P < 0.0001; Figure 
5-18) and when compared separately with MCL and dGM (MCL, P < 0.0001 and 
dGM, P < 0.0001; Figure 5-18). Whilst the MCL could be readily visualised in the LFB 
stained tissue samples, myelin was not significantly higher in the MCL compared to 
the dGM (P = 0.078) across all samples (Figure 5-18). However, using paired 
statistics, MCL was shown to have higher myelin content than dGM consistently 
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within each sample, in the order dGM < MCL < WM (repeated measures one-way 
ANOVA: dGM to MCL, P < 0.0001; MCL to WM, P < 0.0001 and dGM to WM, P < 
0.0001; Figure 5-18). 
 
Figure 5-18 Myelin content in WM and GM tissue of control samples 
Graphs showing the mean GM and WM region LFB staining of myelin from control 
MTG samples. Significance was assessed using Student’s unpaired (*), or paired (#) 
t-test. Mean MCL and dGM sub regions of the GM ROIs were separately assessed 
with WM iron contents, using one-way ANOVA (*), or repeated-measures one-way 
ANOVA (#), with Tukey’s test for multiple comparisons. Graphs show mean values ± 
SD (n = 12). 
 
5.4.5.4. Gender comparison of myelin in control samples 
Significantly lower myelin content was detected in female subjects compared with 
male subjects using two-way ANOVA across GM and WM tissue regions (P = 0.0033) 
and when comparing the dGM, MCL and WM tissue regions (P = 0.0003; GM: male, 
106.44 ± 7.20; female, 93.58 ± 9.48; WM: male, 165.18 ± 10.17; female, 152.35 ± 
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10.46; dGM: male, 101.08 ± 6.92; female, 88.93 ± 9.45 and MCL: male, 111.15 ± 
7.80; female, 98.45 ± 9.33; Figure 5-19). However, no individual tissue region was 
statistically different following Holm-Sidak’s test for multiple comparisons (all 
regions, P = 0.060; Figure 5-19). 
 
Figure 5-19 Gender comparison of myelin content in control tissue 
Myelin contents in the GM and WM tissue regions, as well as GM sub regions, 
separated between male (n = 7) and female (n = 5) samples. Significance assessed 
using two-way ANOVA, with Holm-Sidak’s test for multiple comparisons with the 
level set at P ≤ 0.05. Graphs show mean values ± SD. 
 
5.4.6. Correlation of myelin against relaxometry and iron in control tissue 
5.4.6.1. Correlation of whole tissue type ROIs 
Myelin content demonstrated strong correlation to iron content (r2 = 0.63) using 
the dGM, MCL and WM mean values (Figure 5-20A). Correlation to R1, R2, R2* and 
R2’ relaxometry measurements were also significant, with greatest correlation to 




Figure 5-20 Whole tissue ROI correlations against myelin from control samples 
Correlation of myelin with (A) mean elemental iron content and (B) R1, (C) R2, (D) 
R2* and (E) R2’ relaxometry values for the control samples using the dGM, MCL and 
WM regions (n = 36). Correlation assessed using Pearson correlation with 
significance level set at P ≤ 0.05. 
 
5.4.6.2. Individual sample correlations 
The same 5x5 pixel ROIs used to evaluate the individual sample correlations 
between elemental iron and relaxometry measurements (Figure 5-10) were placed 
over the LFB images to spatially correlate the variation in myelin content, compared 
with iron or relaxometry values. Significant correlations were demonstrated 
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between myelin and R1, R2, R2* and R2’ across individual samples (R1, r2 = 0.80 ± 
0.11; R2, r2 = 0.84 ± 0.10; R2*, r2 = 0.88 ± 0.07 and R2’, r2 = 0.71 ± 0.16; Table 5-8). 
Myelin correlation to iron content was also very high (r2 = 0.84 ± 0.10). R2’ values 
correlated significantly less to myelin, than iron content, R2 and R2* did (iron to 
R2’, P = 0.03; R2 to R2’, P = 0.037 and R2* to R2’, P = 0.002; Table 5-8). Iron content, 
R1, R2 and R2* correlations to myelin were similar (Table 5-8). 
 
Table 5-8 The r2 correlation values of myelin against relaxometry and iron content 
for each individual control sample 
Sample Iron R1 R2 R2* R2’ 
1 0.87 0.84 0.87 0.79 0.57 
2 0.79 0.93 0.80 0.94 0.91 
3 0.87 0.67 0.85 0.85 0.61 
4 0.78 0.75 0.80 0.85 0.40 
5 0.82 0.80 0.95 0.95 0.85 
6 0.82 0.72 0.83 0.86 0.59 
7 0.91 0.89 0.86 0.90 0.75 
8 0.88 0.89 0.94 0.95 0.85 
9 0.82 0.75 0.86 0.94 0.76 
10 0.71 0.83 0.58 0.72 0.61 
11 0.93 0.59 0.81 0.86 0.79 
12 0.90 0.95 0.93 0.95 0.87 
Mean ± SD 0.84 ± 0.06 a 0.80 ± 0.11 0.84 ± 0.10 a 0.88 ± 0.07 a 0.71 ± 0.16 
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Significance assessed using one-way ANOVA, with Tukey’s multiple comparisons test 
with significance level at P ≤ 0.05 (n = 12). a denotes significance compared with R2’. 
R2’ correlations were lower than iron content, R2 and R2* values correlations to 
myelin, highlighted in blue. 
 
5.4.6.3. Grouped sample correlations in control tissue 
Correlation of myelin to both iron and relaxometry for inter- and intra- sample 
variability measurement using the twenty-four 5x5 pixel ROIs (as in section 5.4.4.4) 
demonstrated that myelin content correlated strongly with iron content (r2 = 0.57, 
P < 0.0001) as well as R1, R2, R2* and R2’ relaxometry measurements (R1, r2 = 0.17; 
R2, r2 = 0.63; R2*, r2 = 0.71 and R2’, r2 = 0.58, all P < 0.0001), with the strongest 
correlation to R2* (Figure 5-21, Table 5-9). 
R2* correlation to myelin was greater than iron (P < 0.0001), R2 (P = 0.0003) and 
R2’ (P < 0.0001) correlations to myelin, whilst similar correlations with myelin were 
observed between iron and R2 (P = 0.061), iron and R2’ (P = 0.739) and R2 and R2’ 
(P = 0.179; Table 5-9 and Table 5-10). R1 correlation to myelin was much lower 
across multiple samples (r2 = 0.17; Figure 5-21A) than by evaluation of the 
individual sample correlations (Table 5-8). Again, this indicates that other factors 
may impact the correlation of R1 with myelin between samples. R1 correlation with 
myelin was also substantially less than iron content, R2, R2*and R2’ correlations 
with myelin (Figure 5-21; Table 5-10). Regression gradients of each measurement to 




Figure 5-21 Correlation of relaxometry values and elemental iron contents against 
myelin across control samples 
Graphs of (A) elemental iron, (B) R1, (C) R2, (D) R2* and (E) R2’ against myelin 
content, as assessed using the twenty-four 5x5 pixel ROIs for control samples. Each 
point corresponds to one ROI pairing between the myelin image and elemental iron 
map/ relaxometry maps. Correlation assessed using Pearson correlation with 
significance level set at P ≤ 0.05 (n = 288). 
 
5.4.6.4. Region-specific correlations to myelin in control tissue 
Both WM and GM separated ROIs demonstrated substantially lower correlations 
compared with assessment of all ROIs together, indicating that correlation of iron 
content and relaxometry values against myelin is predominantly driven by GM and 
WM regions than specifically evaluating within each region in control samples 
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(values and regression gradients are summarised in Table 5-9). Therefore, individual 
region correlation comparisons were not explored further. 
Table 5-9 Summary of r2 correlation values for all regions, WM only, or GM only 
regions between relaxivities or iron contents, compared with myelin 
 Iron R1 R2 R2* R2’ 
All regions r2 0.57 0.17 0.63 0.71 0.58 
All regions gradients 1.39 0.00 0.18 0.34 0.16 
WM r2 0.20 0.00 0.02 0.10 0.09 
WM gradients 1.84 0.00 0.05 0.16 0.11 
GM r2 0.05 0.06 0.09 0.04 0.00 
GM gradients 0.54 0.00 0.11 0.11 0.01 
Significance between correlations was assessed using Pearson and Filon’s z, with 
level set at P ≤ 0.05. Significant values summarised in Table 5-10. R1 values were 
not compared due to low correlation values. WM and GM specific values were not 
compared due to substantially lower correlations to myelin. 
 
Table 5-10 Summary table of comparisons between relaxometry or iron content 
correlation with myelin 
Region Selection Order of significance 
All ROIs (WM and GM)  R2* > iron = R2 = R2’ > R1 
Significance between correlations was assessed using Pearson and Filon’s z, with 




5.4.7. Summary of control human MTG assessments 
 Elemental iron maps demonstrated comparable tissue architecture to R1, 
R2, R2* and R2’ relaxometry maps, identifying GM and WM tissue. Different 
cortical layers (MCL and dGM) were also detected (see section 5.4.1). Myelin 
content highlighted similar cortical architecture as that observed in both 
elemental iron and MR images.  
 Fixation time of samples significantly increased R1 values across all tissue 
regions, and increased GM R2 values. PMI and subjects’ age at death did not 
affect relaxometry values or iron contents (see section 5.4.2; Table 5-1). 
Myelin content was not affected by PMI, fixation time or subjects’ age at 
death (see section 5.4.5.2). 
 R1, R2, R2* and R2’ relaxometry values, and iron contents, were all higher in 
WM than GM from control MTG. R1, R2 and R2* relaxometry values and 
iron contents increased in the order of dGM < MCL < WM within each 
sample. R2’ values did not (see section 5.4.3). Myelin content was greater in 
WM than GM, and also consistently increased in the order of dGM < MCL < 
WM for each sample (see section 5.4.5.3). 
 Males and females demonstrated similar levels of iron, as well as 
relaxometry values (see section 5.4.3.3), however myelin contents were 
lower overall in females compared with males (see section 5.4.5.4). 
 Spatial correlation of samples was performed using twenty-four 5x5 pixel 
square ROIs across relaxometry and elemental iron maps. 
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 Mean correlations of individual samples between R1, R2 and R2* with iron 
content were similar, whilst R2’ was less correlated to iron content than R2 
and R2* (see section 5.4.4.3; Table 5-4). Mean correlations of individual 
samples between R1, R2, R2* and iron with myelin were similar, with R2, 
R2* and iron content correlating with myelin better than R2’ (see section 
5.4.6.2). 
 Grouped correlations assessing inter- and intra- sample variation together 
demonstrated low R1 correlation to iron content, whilst R2, R2* and R2’ 
correlation with iron content was strong. Relaxometry correlation to iron 
content was in the order of R2* > R2 > R2’ (see section 5.4.4.4; Table 5-7). 
 Substantial variation of individual sample ranges and regression gradients 
were observed between relaxometry and iron contents. 
 Region-specific correlations were much lower than whole sample 
correlations. R2 and R2* were more sensitive for iron content in GM than in 
WM tissue (see section 5.4.4.5; Table 5-6). R2* showed greatest correlation 
to iron content within WM. 
 Grouped correlations demonstrated that R2* was the most sensitive 
measurement for myelin (see section 5.4.6.3). Region-specific relaxometry 
and iron content correlations with myelin were very low by comparison to 






5.5. Results of AD Human MTG Assessment 
5.5.1. Qualitative assessment of relaxometry and iron elemental maps in AD 
samples 
As described in section 5.4.1, both relaxometry and elemental iron maps show 
increasing pixel intensities corresponding to increasing relaxivity values and iron 
contents, respectively (Figure 5-1). WM can be clearly observed as dark areas in 
T2W images, with GM adjacent to these WM areas appearing as brighter pixels in 
the AD MTG tissue, as observed in control human brain samples (Figure 5-1). 
Similarly, iron contents match the tissue architecture of AD WM and GM from T2W 
images, with more intense pixels in WM areas compared to GM. Comparison of the 
T2W images and elemental iron maps together, again allowed delineation of a MCL, 
corresponding to cortical layers IV-V, at the boundary between GM and WM, as 
observed in control tissue (see section 5.4.1). ROIs were drawn around the WM and 
GM from each elemental iron and relaxometry maps, as well as around the MCL 




Figure 5-22 Qualitative comparison of control and AD iron elemental and 
relaxometry maps 
(A) Iron elemental map, (B) R1, (C) R2 and (D) R2* maps of a control human tissue 
sample compared with (E) iron elemental map, (F) R1, (G) R2 and (H) R2* maps of a 
representative AD human tissue sample from the MTG. 
 
Figure 5-23 Whole ROI placement on R2 and elemental iron map of AD sample 
Typical WM, MCL and dGM ROI placement on (A) an R2 map and (B) an elemental 
iron map. The whole GM ROIs incorporate both the dGM and MCL ROIs. 
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5.5.2. Effect of PMI, fixation time and subjects’ age on relaxometry and 
elemental iron content in AD samples 
A number of factors may affect relaxivity values and iron contents in post-mortem 
human tissue (see section 1.7), including PMI, fixation time and subjects’ age at 
death.  Whilst control samples have already been assessed (see section 5.4.2), the 
influence of these factors on measurements in AD tissue were also evaluated prior 
to subsequent data analyses, and to observe whether these factors may influence 
disease tissue differently than to control tissue. 
 
5.5.2.1. PMI 
PMI length did not significantly affect relaxivity values using Pearson correlation in 
GM (R1, P = 0.263; R2, P = 0.261; R2*, P = 0.247 and R2’, P = 0.610), or WM (R1, P = 
0.443; R2, P = 0.693; R2*, P = 0.641 and R2’, P = 0.656; Figure 5-24A-D, Table 5-11). 
Iron contents were also unaffected by PMI in GM (P = 0.990) or WM (P = 0.863; 
Figure 5-24E). Separation of GM into two sub-regions demonstrated no significant 
correlations between relaxometry and PMI length in the dGM (R1, P = 0.291; R2, P = 
0.294; R2*, P = 0.153 and R2’, P = 0.585) or MCL (R1, P = 0.257; R2, P = 0.309; R2*, P 
= 0.334 and R2’, P = 0.669; Table 5-11). Similarly, iron contents did not correlate 




Figure 5-24 Effect of PMI on relaxometry values and elemental iron contents in AD 
samples 
The effect of PMI length of AD samples, against (A) R1, (B) R2, (C) R2* and (D) R2’ 
relaxivity values, and against (E) elemental iron content. Correlation was assessed 
using Pearson’s correlation with significance level set at P ≤ 0.05 (n = 15). 
 
5.5.2.2. Fixation time 
Increased R1 values were significantly correlated to increasing fixation times in AD 
tissue in both GM (r2 = 0.52, P = 0.003) and WM (r2 = 0.62, P = 0.001; Figure 5-25A, 
Table 5-11), as observed in control tissue (Figure 5-4). R2 and R2* were unaffected 
by fixation time in both GM (R2, P = 0.964 and R2*, P = 0.252) and WM (R2, P = 
0.875 and R2*, P = 0.408; Figure 5-25B-C, Table 5-11). Decreased R2’ values were 
significantly correlated with increased fixation times in both GM and WM (GM: r2 = 
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0.49, P = 0.004 and WM: r2 = 0.27, P = 0.04; Figure 5-25D). Iron was not affected by 
fixation times (GM, P = 0.105 and WM, P = 0.199; Figure 5-25E, Table 5-11). 
Assessing the MCL and dGM areas separately demonstrated similar results as 
described above, with R1 values positively correlating to fixation time (dGM: r2 = 
0.51, P = 0.003 and MCL: r2 = 0.52, P = 0.002) and R2 and R2* values showing no 
correlation (dGM: R2, P = 0.584 and R2*, P = 0.770; and MCL: R2, P = 0.843 and R2*, 
P = 0.283; Table 5-11). R2’ values in the dGM did not correlate with fixation time (P 
= 0.148), whilst the R2’ values in MCL did (r2 = 0.38, P = 0.014; Table 5-11). Iron 
contents were unaffected by fixation time within dGM (P = 0.132) or MCL (P = 
0.100; Table 5-11). 
 
Figure 5-25 Effect of fixation time on relaxometry values and elemental iron 
contents in AD samples 
The effect of fixation time of AD samples, against (A) R1, (B) R2, (C) R2* and (D) R2’ 
relaxivity values, and against (E) elemental iron content. Correlation was assessed 
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using Pearson’s correlation with significance level set at P ≤ 0.05. * P ≤ 0.05, ** P < 
0.01, *** P < 0.001 and **** P < 0.0001 (n = 15). 
 
Prolonged tissue fixation of AD samples demonstrated similar correlations to 
relaxivity values as observed with control tissue samples (see section 5.4.2.2). 
Therefore again, samples with fixation time greater than 18 months were excluded 
from all further analyses and correlations under the same exclusion criteria (see 
section 5.4.2.2).  
 
5.5.2.3. Age 
Age of patients at death had no significant effects on any of the relaxometry values 
assessed in either GM (R1, P = 0.084; R2, P = 0.911; R2*, P = 0.839 and R2’, P = 
0.443) or WM (R1, P = 0.111; R2, P = 0.690; R2*, P = 0.637 and R2’, P = 0.642) of AD 
MTG tissue (Figure 5-26A-D, Table 5-11). Iron contents were also unaffected by age 
in GM (P = 0.766) and WM (P = 0.977; Figure 5-26E). No significant correlations 
were observed compared with age in the dGM (R1, P = 0.096; R2, P = 0.791; R2*, P 
= 0.874; R2’, P = 0.436 and iron, P = 0.602) or MCL sub-regions (R1, P = 0.085; R2, P 
= 0.944; R2*, P = 0.880; R2’, P = 0.617 and iron, P = 0.726) of AD MTG samples 




Figure 5-26 Effect of subjects’ age at death on relaxometry values and elemental 
iron contents in AD samples 
The effect of AD subjects’ age at death, against (A) R1, (B) R2, (C) R2* and (D) R2’ 
relaxivity values, and against (E) elemental iron content. Correlation was assessed 
using Pearson’s correlation with significance level set at P ≤ 0.05 (n = 15). 
 
Table 5-11 Summary table of the assessed factors’ r2 correlation values, on AD 
sample relaxivity values and iron contents 
  R1 R2 R2* R2’ Iron 
PMI WM 0.05 0.01 0.02 0.02 0.00 
 GM 0.10 0.10 0.10 0.02 0.00 
 MCL 0.10 0.08 0.07 0.01 0.00 
 dGM 0.09 0.08 0.15 0.02 0.00 
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Fixation Time WM 0.62*** 0.00 0.05 0.27* 0.12 
 GM 0.52** 0.00 0.10 0.48** 0.19 
 MCL 0.52** 0.00 0.09 0.38* 0.19 
 dGM 0.51** 0.02 0.01 0.15 0.17 
Subjects’ Age WM 0.20 0.01 0.02 0.02 0.00 
 GM 0.21 0.00 0.00 0.05 0.01 
 MCL 0.21 0.00 0.00 0.02 0.01 
 dGM 0.18 0.01 0.00 0.05 0.02 
Correlation was assessed using Pearson’s correlation with significance level set at P 
≤ 0.05. * P ≤ 0.05, ** P < 0.01, *** P < 0.001 and **** P < 0.0001. Significant results 
highlighted blue. 
 
5.5.3. Quantitative assessment of AD tissue 
5.5.3.1. R1, R2, R2* and R2’ relaxivity value assessment 
R1, R2, R2* and R2’ relaxivity values were all significantly higher in WM, compared 
with GM in AD MTG samples using unpaired t-test (R1, P = 0.011; R2, P < 0.0001; 
R2*, P < 0.0001 and R2’, P < 0.0001; Figure 5-27, summarised in Table 5-12). 
Separation of GM into the MCL and dGM sub-regions also demonstrated 
significantly different R1, R2, R2* and R2’ values across all three tissue regions, 
using one-way ANOVA (R1, P = 0.001; R2, P < 0.0001; R2*, P < 0.0001 and R2’, P < 
0.0001; Figure 5-27, Table 5-12). Following correction for multiple comparisons, R1 
values were only significantly greater in WM than dGM (P = 0.001), with differences 
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between WM and MCL (P = 0.06) and MCL and dGM (P = 0.26) not significant 
(Figure 5-27A, Table 5-12). R2 values were significantly different between the three 
tissue regions following correction for multiple comparisons (P < 0.0001; Figure 
5-27B, Table 5-12). R2* and R2’ relaxometry however were only able to 
differentiate the WM values compared with MCL (both, P < 0.0001) and dGM (both, 
P < 0.0001), whereas dGM to MCL regions were similar to each other overall (R2*, P 
= 0.052 and R2’, P = 0.614; Figure 5-27C-D, Table 5-12). 
Paired statistical testing allowed identification of consistently increased relaxivity 
values in WM compared with GM for each sample (R1, P = 0.0006; R2, P < 0.0001; 
R2*, P < 0.0001 and R2’, P < 0.0001; Figure 5-27). Similarly, R1, R2 and R2* values 
were consistently significantly increasing in the order of dGM < MCL < WM for each 
tissue sample when the different cortical layers were considered separately (R1, P = 
0.0002; R2, P < 0.0001 and R2*, P < 0.0001; Figure 5-27A-C). R2’ values however 
were only significantly higher in WM compared with MCL or dGM (both P < 0.0001), 




Figure 5-27 Relaxometry values in WM and GM tissue of AD samples  
Graphs showing the mean GM and WM region relaxivity values for (A) R1, (B) R2, (C) 
R2* and (D) R2’ from AD MTG samples. Significance was assessed using Student’s 
unpaired (*), or paired (#) t-test between GM and WM. Mean MCL and dGM sub 
regions of GM ROIs were separately assessed with WM values, using one-way 
ANOVA (*), or repeated-measures one-way ANOVA (#), with Tukey’s test for 
multiple comparisons. Graphs show mean values ± SD (n = 12).  
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Table 5-12 Relaxivities and iron content from AD MTG samples 
Tissue Region R1 (s-1) R2 (s-1) R2* (s-1) R2’ (s-1) Iron (ppm) 
GM 1.05 ± 0.10 33.25 ± 3.38 42.94 ± 4.26 9.60 ± 1.95 142.1 ± 25.0 
WM 1.21 ± 0.17 42.53 ± 5.70 61.75 ± 9.45 19.25 ± 4.48 213.6 ± 57.3 
P-value 0.011 < 0.0001 < 0.0001 < 0.0001  0.0007 
WM 1.21 ± 0.17 42.53 ± 5.70 61.75 ± 9.45 19.25 ± 4.48 213.6 ± 57.3 
MCL 1.08 ± 0.10 35.33 ± 3.87 45.35 ± 5.31 10.07 ± 2.41 155.3 ± 29.4 
dGM 1.00 ± 0.10 30.02 ± 2.97 38.78 ± 3.64 8.84 ± 2.05 123.7 ± 18.2 
P-value 0.001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
(GM) grey matter, (WM) white matter, (MCL) mid-cortical layer and (dGM) distal grey matter regions. Values are mean ± SD. Statistical testing 
between GM and WM performed using Student’s unpaired t-test. Statistical testing between dGM, MCL and WM performed using one-way 
ANOVA with Tukey’s test for multiple comparisons. Significance level set at P ≤ 0.05 (n = 12). 
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5.5.3.2. XRF elemental iron assessment 
Iron contents were significantly increased in AD MTG WM compared to GM using 
unpaired t-test (P = 0.0007; Figure 5-28, Table 5-12). Subdivision of the GM region 
into dGM and MCL demonstrated significantly different iron contents between 
these three tissue regions (P < 0.0001), with WM iron content significantly 
increased compared with dGM (P < 0.0001) and MCL (P = 0.002), but similar 
between MCL and dGM (P = 0.127; Figure 5-28, Table 5-12). 
Paired statistical testing of the same data revealed that WM consistently showed 
increased iron content than GM within samples (P < 0.0001) and that across the 
three tissue regions, iron content increases consistently in the order of dGM < MCL 
< WM, in each sample (P < 0.0001; Figure 5-28). 
 
Figure 5-28 Elemental iron content in WM and GM tissue of AD samples 
Graphs showing the mean GM and WM region iron contents from AD MTG samples. 
Significance was assessed using Student’s unpaired (*), or paired (#) t-test. Mean 
MCL and dGM sub regions of the GM ROIs were separately assessed with WM iron 
contents, using one-way ANOVA (*), or repeated-measures one-way ANOVA (#), 
with Tukey’s test for multiple comparisons. Graphs show mean values ± SD (n = 12). 
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5.5.3.3. Gender comparison 
Comparing relaxivities in GM and WM were similar for male and female AD tissue 
(R1, P = 0.662; R2, P = 0.144; R2*, P = 0.081 and R2’, P = 0.075), however a trend 
towards higher R2* and R2’ values seem to be apparent for female AD samples 
compared with males, in WM regions (Figure 5-29A-D, Table 5-13). Separate 
assessment of the dGM and MCL with WM showed female AD samples with an 
overall trend towards significance of greater R2* values than males (P = 0.074), and 
R2’ values were significantly higher overall in female AD samples than males (P = 
0.048; Figure 5-29A-D, Table 5-13). Whilst no individual regions were significantly 
different between the genders following Holm-Sidak test for multiple comparisons, 
WM values showed the strongest difference in both R2* and R2’ relaxometry. 
Similar R1 and R2 relaxivities were observed for male and female AD subjects (R1, P 
= 0.638 and R2, P = 0.166). 
Interestingly, iron contents were significantly higher in WM tissue (P = 0.038) from 
female compared with male AD subjects when comparing WM with dGM and MCL 
(Figure 5-29E, Table 5-13). GM iron contents were similar between male and female 




Figure 5-29 Gender comparison of relaxometry and elemental iron contents in AD 
samples 
(A) R1, (B) R2, (C) R2*, (D) R2’ relaxometry values, and (E) elemental iron contents, 
from male (n = 7) and female (n = 5) subjects in GM and WM tissue, and in the MCL 
and dGM sub regions. Graphs show mean values ± SD. Significance assessed using 









Table 5-13 Relaxivities and iron content from AD MTG from male and female 
subjects 
GM R1 (s-1) R2 (s-1) R2* (s-1) R2’ (s-1) Iron (ppm) 
Male 1.05 ± 0.07 32.92 ± 1.92 41.89 ± 3.24 8.80 ± 1.70 137.1 ± 22.1 
Female 1.06 ± 0.15 33.72 ± 5.04 44.40 ± 5.44 10.73 ± 1.85 149.2 ± 29.5 
WM      
Male 1.19 ± 0.18 40.48 ± 3.79 58.38 ± 7.05 17.90 ± 4.06 190.3 ± 34.6* 
Female 1.23 ± 0.17 45.39 ± 7.09 66.48 ± 11.10 21.14 ± 4.77 246.2 ± 70.3* 
MCL      
Male 1.08 ± 0.08 34.58 ± 1.56 43.64 ± 2.93 9.05 ± 1.84 146.7 ± 20.4 
Female 1.10 ± 0.14 36.39 ± 5.94 47.74 ± 7.23 11.50 ± 2.54 167.3 ± 37.9 
dGM      
Male 1.00 ± 0.06 30.28 ± 2.37 38.92 ± 3.64 8.54 ± 1.63 124.0 ± 20.5 
Female 1.00 ± 0.15 29.66 ± 3.95 38.59 ± 4.06 9.26 ± 2.70 123.4 ± 16.7 
Values are mean ± SD. Statistical testing performed using two-way ANOVA, with 
Sidak test for multiple comparisons with a level set to P ≤ 0.05 (*) (male (n = 7) and 
female (n = 5)). Significant results highlighted blue. 
 
5.5.4. Correlation of relaxometry to iron in AD samples 
5.5.4.1. Correlation of whole tissue type ROIs 
R1, R2, R2* and R2’ measurements were significantly positively correlated with iron 
content, using all the dGM, MCL and WM tissue type values from AD samples (R1: r2 
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= 0.17, P < 0.012; R2: r2 = 0.71, P < 0.0001; R2*: r2 = 0.71, P < 0.0001; R2’: r2 = 0.57, 
P < 0.0001; Figure 5-30A-D). 
 
Figure 5-30 Whole tissue ROI correlations from AD samples 
Mean (A) R1, (B) R2, (C) R2* and (D) R2’ values correlated against iron content for 
AD tissue of all dGM, MCL and WM regions (n = 36). Correlation assessed using 
Pearson correlation with significance level set at P ≤ 0.05. 
 
5.5.4.2. Individual sample correlations 
Twenty four 5x5 pixel ROIs were placed across the elemental iron and relaxometry 
maps, (see section 5.4.4.1, Figure 5-10), with eight ROIs in each of the three tissue 
regions identified in images (dGM, MCL and WM) to evaluate the consistency of 
relaxometry correlation to iron content within individual AD samples (Table 5-14). 
The mean correlations of individual samples were strongly significant between R1 
(r2 = 0.63 ± 0.23), R2 (r2 = 0.79 ± 0.16), R2* (r2 = 0.78 ± 0.14) and R2’ (r2 = 0.62 ± 
0.19) measurements with iron content (Table 5-14). Whilst an overall significant 
difference was detected using one-way ANOVA (P = 0.038), R2 and R2* correlations 
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were only generally higher than R1 and R2’ correlations, not quite reaching 
significance, following multiple comparisons testing. 
 
Figure 5-31 Representative relaxometry and elemental iron maps showing 
placement of 24 small ROIs in AD sample 
Representative (A) R1, (B) R2, (C) R2*, (D) R2’ and (E) elemental iron maps, 
demonstrating the placement of the eight equally sized ROIs within each tissue 







Table 5-14 The r2 correlation values of relaxometry against iron content for each 
individual AD sample 
Sample R1 R2 R2* R2’ 
1 0.46 0.53 0.70 0.71 
2 0.85 0.85 0.81 0.61 
3 0.55 0.87 0.68 0.21 
4 0.50 0.86 0.85 0.77 
5 0.73 0.82 0.90 0.87 
6 0.77 0.89 0.86 0.61 
7 0.84 0.86 0.85 0.50 
8 0.72 0.90 0.87 0.74 
9 0.83 0.93 0.94 0.84 
10 0.48 0.42 0.44 0.38 
11 0.07 0.66 0.69 0.59 
12 0.72 0.84 0.75 0.61 
Mean ± SD 0.63 ± 0.23 0.79 ± 0.16 0.78 ± 0.14 0.62 ± 0.19 
Significance assessed using one-way ANOVA with Tukey’s multiple comparisons test 
to significance set at P ≤ 0.05 (n = 12). 
 
5.5.4.3. Grouped correlations of AD samples 
All of the mean relaxivity values from the 5x5 ROIs were correlated with iron 
contents together, as in section 5.4.4.4, allowing evaluation of inter-sample 
variability, as well as intra-sample variability (Figure 5-32). R1, R2, R2* and R2’ 
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demonstrate significant correlations to iron contents (R1, r2 = 0.18; R2, r2 = 0.64; 
R2*, r2 = 0.61 and R2’ r2 = 0.42; all P < 0.0001; Figure 5-32, Table 5-15 and Table 
5-17). The strongest correlation to iron content was shown by R2 and R2*, which 
were similar to each other (P = 0.222; Figure 5-32B-C). R2’ correlation with iron 
content was less than that for either R2 or R2* (both, P < 0.0001) and R1 correlation 
with iron content was substantially lower than the other three relaxometry 
measurements (R2, R2* and R2’, P < 0.0001; Figure 5-32A, summarised in Table 
5-17). Molar relaxivities for each relaxometry measurement to iron are also 
summarised in Table 5-15, as a measure of sensitivity. 
 
Figure 5-32 Correlation of relaxometry values against elemental iron content 
across all AD samples 
Graphs of (A) R1, (B) R2, (C) R2* and (D) R2’ correlation against iron content, as 
assessed using the twenty four 5x5 pixel ROIs for AD samples. Each point 
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corresponds to one ROI pairing between the relaxometry map and elemental iron 
map. Correlation assessed using Pearson correlation with significance level set at P 
≤ 0.05 (n = 288).  
 
Individual sample regression lines were, again, placed together to evaluate the 
inter-sample variability in correlations between relaxometry and iron (see section 
5.4.4.4). Wide variations in regression gradients, y-intercepts and ranges for 
relaxometry to iron contents were observed per subject, in AD tissue (Figure 5-33), 
as was observed in control samples (5.4.4.4). 
 
Figure 5-33 Variability in individual AD sample correlations for relaxometry 
measurements against elemental iron contents 
Regression lines for (A) R1, (B) R2, (C) R2* and (D) R2’ relaxometry values against 
iron content, for the 12 individual AD samples. 
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5.5.4.4. Region-specific correlations in AD tissue 
Evaluation of the 5x5 ROIs in separate WM or GM tissue demonstrated that R2, R2* 
and R2’ relaxivity values were all still positively correlated to iron contents in both 
WM (R2: r2 = 0.45,  P < 0.0001, R2*: r2 = 0.33, P < 0.0001, and R2’, r2 = 0.09, P = 
0.003; Figure 5-34B-D) and GM (R2: r2 = 0.43,  P < 0.0001, R2*: r2 = 0.44, P < 0.0001, 
and R2’, r2 = 0.13, P < 0.0001; Figure 5-34F-H). However region-specific correlations 
were substantially less than to correlations with both GM and WM ROIs together 
(Table 5-15). R1 values were not correlated within these regions (WM: r2 = 0.03, P = 
0.122, and GM: r2 = 0.02, P = 0.058; Figure 5-34A and E). 
Comparing WM to GM relaxometry correlations with iron content showed that R2 
values were similarly correlated to iron content in WM and GM (P = 0.853), 
however with different molar relaxivity (P = 0.020; summarised in Table 5-16). 
Correlation of R2* values with iron content were also similar between GM and WM 
(P = 0.255), however with different molar relaxivity (P = 0.028; Table 5-16). 
Correlation of R2’ values with iron content were similar between WM and GM (P = 
0.565) and with similar molar relaxivity (P = 0.237, Table 5-16). 
In AD WM, R2 correlated greater than R2* to iron content (P = 0.009), whilst R2’ 
values were significantly less correlated to iron than both R2 and R2* values (P < 
0.0001). AD GM provides similar correlations with iron for R2 and R2* values (P = 
0.867), and R2’ values were again significantly less correlated to iron than both R2 




Figure 5-34 Correlation of relaxometry values against elemental iron content 
across AD samples in WM or GM tissue 
Graphs showing (A-D) WM and (E-H) GM correlations to iron contents, using R1, R2, 
R2* and R2’ relaxometry assessment in AD samples. Correlation assessed using 
Pearson correlation with significance at P ≤ 0.05. Solid circles are GM ROIs (n = 192), 









Table 5-15 Summary of correlations of all regions, WM only, or GM only regions 
between relaxometry values and iron content 
Measure All regions WM only GM only 
R1 r2 0.18 0.03 0.02 
r1 (s
-1 ppm-1) 0.001 0.000 0.000 
R2 r2 0.64 0.45 0.43 
r2 (s
-1 ppm-1) 0.102 0.069 0.096 
R2* r2 0.61 0.33 0.44 
r2* (s
-1 ppm-1) 0.181 0.096 0.135 
R2’ r2 0.42 0.09 0.13 
r2’ (s
-1 ppm-1) 0.079 0.027 0.040 
Significance between correlations was assessed using Pearson and Filon’s z, with 
level set to P ≤ 0.05, and significant values summarised in Table 5-17. R1 values 
were not compared due to low correlation values and regression gradients. 
 
Table 5-16 Summary of correlation and molar relaxivity comparisons, for each 
relaxometry measurement between WM and GM in AD tissue 
Measurement r2 Molar relaxivity 
R1 - - 
R2 GM = WM GM > WM 
R2* GM = WM GM > WM 
R2’ GM = WM GM = WM 
> denotes values are significantly different, = denotes values are similar. 
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Table 5-17 Summary table of relaxometry to iron correlation comparisons in 
different tissue regions 
Region Selection Order of significance 
All ROIs (WM and GM)  R2* = R2 > R2’ > R1 
WM only R2 > R2* > R2’ > R1 
GM only R2* = R2 > R2’ > R1 
Significance between correlations was assessed using Pearson and Filon’s z, with 
level set to P ≤ 0.05. > denotes values are significantly different, = denotes values 
are similar. 
 
5.5.5. Myelin assessment in AD samples 
LFB stain was used to assess myelin content in AD MTG tissue samples, as 
performed for the control samples (see section 5.4.5). The effects of PMI, fixation 
time and age of subjects at death were evaluated first, before performing 
quantitative comparisons and correlations of relaxometry measurements and iron 
contents with myelin in the AD tissue and also in comparison between AD and 
control tissue. One male sample from the AD group had to be excluded from myelin 
assessments as there was not enough tissue remaining following SR-XRF. 
 
5.5.5.1. Effect of PMI, fixation time and subjects’ age, on myelin in AD samples 
PMI length was significantly negatively correlated to myelin in the GM (r2 = 0.43, P = 
0.011), whereas WM was not affected by PMI (P = 0.925; Figure 5-35A). 
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Furthermore, neither fixation time nor subjects’ age at death affected myelin 
content in either GM (fixation time, P = 0.583 and age, P = 0.671) or WM (fixation 
time, P = 0.417 and age, P = 0.442; Figure 5-35B-C). Separation of the GM into the 
dGM and MCL revealed similar results as that for GM, with both fixation time length 
and age demonstrating no significant correlations with myelin (fixation time: dGM, 
P = 0.558 and MCL, P = 0.590 and age: dGM, P = 0.613 and MCL, P = 0.778). 
However, myelin content was significantly negatively correlated to PMI length in 
the dGM (P = 0.001) and demonstrated a trend towards correlation in the MCL (P = 
0.052). 
 
Figure 5-35 Effect of PMI, fixation time and subjects’ age at death on myelin 
contents in AD samples 
Graphs showing myelin content against (A) PMI, (B) fixation time, and (C) subjects’ 
age at death in AD samples. Correlation was assessed using Pearson’s correlation 
with significance level set at P ≤ 0.05. * P ≤ 0.05, ** P < 0.01, *** P < 0.001 and **** 





5.5.5.2. Quantitative assessment of AD tissue myelin 
As expected, more myelin was present in WM (147.2 ± 17.6) compared to GM (95.6 
± 9.5; P < 0.0001; Figure 5-36). Similarly, WM also had greater myelin than the dGM 
(89.2 ± 9.3; P < 0.0001) and MCL (100.5 ± 10.2; P < 0.0001; Figure 5-36). Whilst the 
dGM and MCL myelin levels were similar using one-way ANOVA (P = 0.118), 
evaluation using repeated-measures one-way ANOVA, showed that the increase in 
myelin was consistently in the order, dGM < MCL < WM (P < 0.0001; Figure 5-36). 
 
Figure 5-36 Myelin content in WM and GM tissue of AD samples 
Graphs showing the mean GM and WM region LFB staining of myelin, from AD MTG 
samples. Significance was assessed using Student’s unpaired (*), or paired (#) t-test. 
Mean MCL and dGM sub regions of the GM ROIs were separately assessed with WM 
iron contents, using one-way ANOVA (*), or repeated-measures one-way ANOVA 






5.5.5.3. Gender comparison of myelin in AD samples 
Separation of myelin contents between male and female subjects demonstrated no 
significant differences in the amount of myelin between male and female subject 
samples in either GM or WM (GM: male, 91.84 ± 8.63; female, 100.04 ± 9.29 and 
WM: male, 141.96 ± 16.14; female, 153.41 ± 18.93, P = 0.115; Figure 5-37). 
Similarly, testing across the three tissue types also showed myelin to be comparable 
between males and females (dGM: male, 87.26 ± 10.54; female, 91.51 ± 7.99; MCL: 
male, 96.05 ± 7.54; female, 105.75 ± 11.07 and WM: male, 141.96 ± 16.14; female, 
153.41 ± 18.93, P = 0.066; Figure 5-37). 
 
Figure 5-37 Gender comparison of myelin content in AD tissue 
Myelin contents in the GM and WM tissue regions, as well as GM sub regions, 
separated between male (n = 6) and female (n = 5) samples. Significance assessed 
using two-way ANOVA, with Holm-Sidak test for multiple comparisons with level set 





5.5.6. Correlation of myelin against relaxometry and iron in AD tissue 
5.5.6.1. Correlation of whole tissue type ROIs 
Whole tissue mean myelin contents were correlated against all AD sample 
elemental iron and R1, R2, R2* and R2’ measurements, providing positive 
significant correlations between each assessment (iron, r2 = 0.70, P < 0.0001; R1, r2 
= 0.28, P = 0.002; R2, r2 = 0.68, P < 0.0001; R2*, r2 = 0.75, P < 0.0001 and R2’, r2 = 
0.68, P < 0.0001; Figure 5-38). Iron, R2, R2* and R2’ showed similar correlations to 
myelin, but the myelin correlation for R1 was much lower. 
 
Figure 5-38 Whole tissue ROI correlations against myelin from AD samples 
Correlation of myelin with (A) mean elemental iron content and (B) R1, (C) R2, (D) 
R2* and (E) R2’ relaxometry values for the AD samples using the dGM, MCL and 
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WM regions. Correlation assessed using Pearson correlation with significance level 
set at P ≤ 0.05 (n = 33). 
 
5.5.6.2. Individual sample correlations 
The 5x5 pixel ROI method (see section 5.4.4.1, Figure 5-10) was used again, to 
evaluate the individual sample correlations between elemental iron and 
relaxometry measurements with LFB assessment of myelin, to spatially correlate 
the variation in myelin content compared with iron or relaxometry values. Myelin 
was significantly positively correlated to iron content, R1, R2, R2* and R2’ (iron, r2 = 
0.71 ± 0.22; R1, r2 = 0.67 ± 0.19; R2, r2 = 0.76 ± 0.24; R2*, r2 = 0.83 ± 0.17 and R2’, r2 











Table 5-18 The r2 correlation values of myelin against relaxometry and iron 
content for each individual AD sample 
Sample Iron R1 R2 R2* R2’ 
1 0.84 0.79 0.88 0.92 0.73 
2 0.69 0.55 0.87 0.92 0.89 
3 0.73 0.60 0.81 0.82 0.41 
4 0.92 0.86 0.83 0.91 0.89 
5 0.86 0.77 0.93 0.96 0.89 
6 0.67 0.64 0.48 0.74 0.81 
7 0.32 0.67 0.80 0.86 0.76 
8 0.95 0.76 0.89 0.93 0.86 
9 0.87 0.78 0.88 0.83 0.61 
10 0.63 0.76 0.82 0.90 0.85 
11 0.31 0.16 0.13 0.37 0.50 
Mean ± SD 0.71 ± 0.22 0.67 ± 0.19 0.76 ± 0.24 0.83 ± 0.17 0.75 ± 0.17 
Significance assessed using one-way ANOVA with Tukey’s multiple comparisons test 
to significance set at P ≤ 0.05 (n = 11). 
 
5.5.6.3. Grouped sample correlations in AD tissue 
To assess inter- and intra- sample variability of iron and relaxometry correlations to 
myelin, all the 5x5 pixel ROIs were evaluated together for each measurement, 
showing strongly significant positive correlations for each correlation to myelin 
(iron, r2 = 0.59; R1, r2 = 0.29; R2, r2 = 0.62; R2*, r2 = 0.69; R2’, r2 = 0.57, all P < 
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0.0001; Figure 5-39 and Table 5-20). R2* values were correlated to myelin 
significantly more than iron contents or R2 and R2’ values were (iron, P = 0.005; R2, 
P = 0.016 and R2’, P < 0.0001; Table 5-20 and Table 5-21). R2, R2’ and iron contents 
showed similar correlation values with myelin as each other (R2 to R2’, P = 0.181; 
iron to R2, P = 0.325 and iron to R2’, P 0.676; Table 5-20 and Table 5-21). R1 values 
were less correlated than iron contents, or R2, R2* and R2’ values were to myelin 
(all, P < 0.0001; Table 5-21). Regression gradients of each measurement to myelin 
are summarised in Table 5-20. 
 
Figure 5-39 Correlation of relaxometry values and elemental iron contents against 
myelin across AD samples 
Graphs of (A) elemental iron, (B) R1, (C) R2, (D) R2* and (E) R2’ correlation against 
myelin content as assessed using the twenty-four 5x5 pixel ROIs for AD samples. 
Each point corresponds to one ROI pairing between the myelin image and elemental 
iron map/ relaxometry maps. Correlation assessed using Pearson correlation with 
significance level set at P ≤ 0.05 (n = 264). 
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5.5.6.4. Region-specific correlations to myelin in AD tissue 
Iron content, R2 and R2* measurements were correlated with myelin within WM 
and GM regions in AD tissue, in contrast to observations made using control tissue 
(see section 5.4.6.4) (WM: iron, r2 = 0.24; R2, r2 = 0.20 and R2*, r2 = 0.12; and GM: 
iron, r2 = 0.48; R2, r2 = 0.43 and R2*, r2 = 0.39; all P < 0.0001; summarised in Table 
5-20). All correlations were still lower than correlations observed using both GM 
and WM regions together (Table 5-20). 
Better correlations of R2 and R2* to myelin were observed in GM compared with 
WM regions (R2: correlation, P = 0.022 and regression gradient, P = 0.017; and R2*: 
correlation, P = 0.006 and regression gradient, P = 0.031; Table 5-19). Iron contents 
demonstrated better correlation to myelin in GM than in WM (P = 0.019), however 
with a similar gradient (P = 0.678; Table 5-19). 
The correlation of R2 values to myelin in AD WM was higher than for R2* values (P 
= 0.019), whilst similar iron content correlations to myelin were detected against 
both R2 (P = 0.578) and R2* values correlation to myelin (P = 0.104; Table 5-20). 
Iron contents were similar to R2 and R2* correlations in GM (R2, P = 0.442 and R2*, 
P = 0.116), and R2 values were similarly correlated to myelin as R2* (P = 0.183; 






Table 5-19 Summary of correlations and gradient comparisons, for relaxometry 
and iron measurements against myelin, between WM and GM in AD tissue 
Measurement r2 Regression gradient 
Iron GM > WM GM = WM 
R2 GM > WM GM > WM 
R2* GM > WM GM > WM 
> denotes values are significantly different, = denotes values are similar. 
 
Table 5-20 Summary of r2 correlation values for all regions, WM only, or GM only 
regions between relaxivities or iron contents, compared with myelin 
 Iron R1 R2 R2* R2’ 
All regions r2 0.59 0.29 0.62 0.69 0.57 
All regions gradients 1.50 0.00 0.19 0.36 0.17 
WM r2 0.24 0.05 0.20 0.12 0.02 
WM gradients 1.64 0.00 0.16 0.20 0.04 
GM r2 0.48 0.08 0.43 0.39 0.09 
GM gradients 1.77 0.00 0.25 0.32 0.08 
Significance between correlations was assessed using Pearson and Filon’s z, with 
level set at P ≤ 0.05. Significant values summarised in Table 5-21. R1 values were 




Table 5-21 Summary table of comparisons between relaxometry or iron content 
correlation with myelin 
Region Selection Order of significance 
All ROIs (WM and GM)  R2* > iron = R2 = R2’ > R1 
Significance between correlations was assessed using Pearson and Filon’s z, with 
level set at P ≤ 0.05. > denotes values are significantly different, = denotes values 
are similar. 
 
5.5.7. Summary of AD human MTG assessments 
 PMI and subjects’ age at death did not affect relaxometry values or iron 
contents. Longer fixation times increased R1 values across all tissue regions, 
and decreased R2’ values (see section 5.5.2, Table 5-11). R2, R2* and iron 
content were unaffected by fixation time. These were similar to control 
sample observations (see section 5.4.2). Myelin content was not affected by 
fixation time or subjects’ age at death, however GM myelin was lower with 
PMI length (see section 5.5.5.1). 
 All relaxivity values, iron contents and myelin contents in AD samples were 
higher in WM than GM (see section 5.5.3 and 5.5.5.2), as also detected in 
control samples (see section 5.4.3 and 5.4.5.3). R1, R2 and R2* relaxometry 
values and iron and myelin contents increased in the order of dGM < MCL < 
WM within each sample, whilst R2’ values did not (see section 5.5.3.1). 
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 Females demonstrated higher iron content in WM than males, with a similar 
trend detected using R2* and R2’ (see section 5.5.3.3). Myelin contents 
were similar between female and male AD samples (see section 5.5.5.3). 
 Individual samples mean correlations demonstrated that R1, R2, R2* and R2’ 
were all correlated similarly to iron within each AD sample (see section 
5.5.4.2, Table 5-14). Mean correlations of individual samples were also 
similar for R1, R2, R2*, R2’ and iron content correlations against myelin (see 
section 5.5.6.2). 
 Grouped correlations assessing inter- and intra- sample variation together 
highlighted that R2* and R2 values correlated to iron similarly, and were 
both correlated to iron better than R2’ or R1 values were. R1 correlation to 
iron was much lower than other relaxometry measurements (see section 
5.5.4.3, Table 5-17). R2* was the most specific measurement for myelin, 
correlating to myelin better than iron content, R2 or R2’ (see section 
5.5.6.3). 
 Region-specific correlations demonstrated R2 values were correlated better 
with iron content than R2* values were in WM. R2 and R2* correlated with 
iron content similarly to each other in GM (see section 5.5.4.4). 
 Whilst region-specific correlations to myelin were substantially lower than 
correlations using all the ROIs, AD samples demonstrated that iron, R2 and 
R2* correlated to myelin within WM and GM tissue. Furthermore, R2 values 
demonstrated better correlation with myelin than R2* did in WM, whilst 
iron, R2 and R2* correlations to myelin in GM were similar to each other 
(see section 5.5.6.4). 
260 
 
5.6. Comparison of Results Between Control and AD Human 
MTG 
5.6.1. Comparison of control and AD relaxometry values and iron contents 
5.6.1.1. Relaxometry values and elemental iron content comparison 
Comparing GM and WM tissue in control and AD MTG demonstrated similar R1, R2, 
R2* and R2’ relaxometry values (R1, P = 0.203; R2, P = 0.326; R2*, P = 0.572 and 
R2’, P = 0.881; Figure 5-40A-D). Iron contents were also similar (P = 0.956; Figure 
5-40E). Furthermore, relaxometry values and iron contents in dGM, MCL and WM 
tissue were also similar between control and AD samples (R1, P = 0.154; R2, P = 
0.346; R2*, P = 0.655; R2’, P = 0.706 and iron, P = 0.912; Figure 5-40). 
 
Figure 5-40 Relaxometry values and iron contents compared between control and 
AD samples 
(A) R1, (B) R2, (C) R2*, (D) R2’ relaxometry values, and (E) elemental iron contents, 
compared between control (blue) (n = 12) and AD (red) (n = 12) MTG samples. 
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Comparisons made between GM and WM tissue, and between dGM, MCL and WM. 
Significance assessed using two-way ANOVA, with Holm-Sidak test for multiple 
comparisons with level set to P ≤ 0.05. Graphs show mean values ± SD. 
 
5.6.1.2. Gender comparison between control and AD tissue 
Relaxivities and iron contents from Table 5-3 and Table 5-13 were compared to 
evaluate any differences between control and AD samples in GM or WM regions for 
each gender. Both males and females demonstrated similar relaxometry values and 
iron contents in GM regions, and within separated dGM and MCL sub regions, 
between control and AD samples. Relaxometry values and iron contents in WM 
were also similar between control and AD samples for each gender using two-way 
ANOVA (Figure 5-41). 
It can be noted however that R2 and R2* values were significantly higher in male 
control WM than in male AD WM, assessed using Student’s unpaired t-test (R2, P = 
0.039 and R2*, P = 0.038), whilst female WM was similar between control and AD 




Figure 5-41 Gender comparison of relaxometry values and elemental iron contents 
in WM between control and AD samples 
Comparison of control (blue), and AD (red), (A) R1, (B) R2, (C) R2*, (D) R2’ 
relaxometry values, and (E) elemental iron contents, in the WM from male and 
female subjects (male control (n = 7), male AD (n = 7), female control (n = 5), female 
AD (n = 5)). Significance assessed using two-way ANOVA, with Sidak test for multiple 
comparisons set at P ≤ 0.05. Graphs show mean values ± SD. 
 
5.6.2. Comparison of control and AD relaxometry to iron correlations 
5.6.2.1. Comparison of relaxometry to iron correlations between control and AD 
individual samples 
Mean correlations of individual samples were similar between control and AD 
samples using two-way ANOVA, with Sidak’s test for multiple comparisons (R1: 
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control r2 = 0.77 ± 0.12, AD r2 = 0.63 ± 0.23, P = 0.112; R2: control r2 = 0.81 ± 0.12, 
AD r2 = 0.79 ± 0.16, P = 0.986; R2*: control r2 = 0.83 ± 0.10, AD r2 = 0.78 ± 0.14, P = 
0.899 and R2’: control r2 = 0.65 ± 0.18, AD r2 = 0.62 ± 0.19, P = 0.975; comparing 
Table 5-4 with Table 5-14). 
 
5.6.2.2. Comparison of grouped control and AD correlations 
Correlation values of both R2 and R2* against iron, were similar between control 
and AD samples (Figure 5-42B-C). R1 values correlated better with iron in AD 
samples than control samples (P = 0.005; Figure 5-42A), whilst R2’ values correlated 
with iron better in control than in AD samples (P = 0.048; Figure 5-42D). Comparing 
the molar relaxivities between control and AD samples demonstrated similar values 
for r1 (P = 0.368), r2 (P = 0.318), r2* (P = 0.941) and r2’ (P = 0.317; comparing results 
from Table 5-5 and Table 5-15). Furthermore, whilst R2* correlated better than R2 
measurements with iron content in control samples, AD tissue was found to 
provide similar correlations with iron content between R2* and R2 (Table 5-23). 




Figure 5-42 Correlation of relaxometry values against elemental iron content 
across all control and AD samples 
Graphs of (A) R1, (B) R2, (C) R2* and (D) R2’ against iron content, as assessed using 
the twenty-four 5x5 pixel ROIs for all control (blue) (n = 288), and AD (red) (n = 288) 
samples. Group correlation assessed using Pearson correlation and significance 
between control and AD correlations was assessed using Fisher’s z test, with the 
level set at P ≤ 0.05. * denotes significance between control and AD correlation 
values. 
 
5.6.2.3. Comparison of control and AD region-specific correlations 
Comparison of WM relaxometry correlations to iron content (Table 5-5 and Table 
5-15) highlights R2 values as showing better correlation to iron in AD tissue than 
control (correlation, P = 0.019 and molar relaxivity, P = 0.001; Figure 5-43). R2* and 
R2’ had similar correlations to iron between control and AD tissue within WM (R2*: 
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r2 value, P = 0.870; molar relaxivity, P = 0.173 and R2’, r2 value, P = 0.249; molar 
relaxivity, P = 0.339; Figure 5-43). GM regions had similar R2, R2* and R2’ 
relaxometry correlations to iron between control and AD tissue (R2: r2 value, P = 
0.555 and molar relaxivity, P = 0.521; R2*: r2 value, P = 0.415, molar relaxivity, P = 
0.779 and R2’: r2 value, P = 0.697, molar relaxivity, P = 0.818). R1 values were not 
compared due to low correlations to iron within WM and GM regions of both 
control and AD samples. 
 
Figure 5-43 Correlation of relaxometry values against elemental iron content 
across control and AD samples in WM or GM tissue 
Graphs showing (A-D) WM and (E-H) GM correlations to iron contents, using R1, R2, 
R2* and R2’ relaxometry assessment in control (blue) and AD (red) samples (control 
GM (n = 192), AD GM (n = 192), control WM (n = 96), AD WM (n = 96)). Correlation 
assessed using Pearson correlation and significance between control and AD 
correlations was assessed using Fisher’s z test with the level set at P ≤ 0.05. * 
denotes significance between control and AD correlation values. 
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Table 5-22 Summary table of relaxometry values against iron content correlations 
and molar relaxivities for control and AD tissue in all, WM only or GM only regions 
Model Group and Region Mol. Rel. r2 P-value 
R1 vs Iron CTR GM+WM 0.001 0.05 0.0003 
R1 vs Iron AD GM+WM 0.001 0.18 < 0.0001 
R2 vs Iron CTR GM+WM 0.096 0.62 < 0.0001 
R2 vs Iron AD GM+WM 0.102 0.64 < 0.0001 
R2* vs Iron CTR GM+WM 0.182 0.68 < 0.0001 
R2* vs Iron AD GM+WM 0.181 0.61 < 0.0001 
R2’ vs Iron CTR GM+WM 0.086 0.54 < 0.0001 
R2’ vs Iron AD GM+WM 0.079 0.42 < 0.0001 
R1 vs Iron CTR WM -0.001 0.09 0.003 
R1 vs Iron AD WM 0.000 0.03 0.122 
R2 vs Iron CTR WM 0.034 0.19 < 0.0001 
R2 vs Iron AD WM 0.069 0.45 < 0.0001 
R2* vs Iron CTR WM 0.072 0.34 < 0.0001 
R2* vs Iron AD WM 0.096 0.33 < 0.0001 
R2’ vs Iron CTR WM 0.038 0.20 < 0.0001 
R2’ vs Iron AD WM 0.027 0.09 0.028 
R1 vs Iron CTR GM 0.000 0.00 0.748 
R1 vs Iron AD GM 0.001 0.02 0.058 
R2 vs Iron CTR GM 0.088 0.38 < 0.0001 
R2 vs Iron AD GM 0.096 0.43 < 0.0001 
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R2* vs Iron CTR GM 0.130 0.37 < 0.0001 
R2* vs Iron AD GM 0.135 0.44 < 0.0001 
R2’ vs Iron CTR GM 0.043 0.11 < 0.0001 
R2’ vs Iron AD GM 0.040 0.13 < 0.0001 
Mol. Rel. = Molar Relaxivity. Significant results between control and AD highlighted 
blue. 
 
Table 5-23 Summary of relaxometry to iron correlation comparisons in different 
tissue regions between control and AD tissue 
Region Selection Order of significance 
All ROIs (WM and GM) – Control R2* > R2 > R2’ > R1 
All ROIs (WM and GM) – AD R2* = R2 > R2’ > R1 
WM only – Control R2* > R2 = R2’ > R1 
WM only – AD R2 > R2* > R2’ > R1 
GM only – Control R2* = R2 > R2’ > R1 
GM only – AD R2* = R2 > R2’ > R1 
Changes in correlation significance order are highlighted in blue. 
 
5.6.3. Comparison of control and AD myelin contents 
5.6.3.1. Quantitative comparison of control and AD myelin 
WM from AD samples demonstrated less myelin compared to control samples using 
two-way ANOVA, with Sidak test for multiple comparisons (compared with GM 
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values, P = 0.041; or compared with dGM and MCL P = 0.037; Figure 5-44). Similar 
amounts of myelin were present in GM regions between control and AD samples 
(GM, P = 0.511; dGM, P = 0.430 and MCL, P = 0.623; Figure 5-44). 
 
Figure 5-44 Comparison of myelin content in WM and GM tissue of control and AD 
samples 
LFB staining of myelin in GM and WM regions, as well as in GM sub regions, 
compared between control (blue) (n = 12) and AD (red) (n = 11). Significance 
assessed using two-way ANOVA, with Sidak test for multiple comparisons, with 
levels set to P ≤ 0.05 (*). Graphs show mean values ± SD. 
 
5.6.3.2. Gender comparison of myelin in control and AD tissue 
Male samples showed significantly lower myelin content within all tissue regions 
evaluated (WM, P = 0.016; GM, P = 0.013; MCL, P = 0.013 and dGM, P = 0.021; 
Figure 5-45), between control and AD tissues. Female samples were similar 
between control and AD tissue however (WM, P = 0.991; GM, P = 0.432; MCL, P = 




Figure 5-45 Gender comparison of myelin between control and AD tissue 
(A) WM, (B) GM, (C) MCL and (D) dGM myelin contents between male and female, 
control (blue) and AD (red) samples (male control (n = 7), male AD (n = 6), female 
control (n = 5), female AD (n = 5)). Significance assessed using two-way ANOVA, 
with Sidak test for multiple comparisons, with levels set to P ≤ 0.05 (*). Graphs show 
mean values ± SD. 
 
5.6.4. Comparison of control and AD myelin correlations to relaxometry or 
iron 
5.6.4.1. Comparison of control and AD individual sample correlations 
Individual sample correlations between myelin and relaxometry values or iron 
contents, demonstrated significant differences between AD and control samples 
using two-way ANOVA (P = 0.015), although none survived Sidak multiple 
comparisons test. However, comparisons using Student’s unpaired t-test 
demonstrated that iron correlation and R1 correlations with myelin were generally 
lower in AD compared with control samples (iron, P = 0.059 and R1, P = 0.052; 
comparing Table 5-8 with Table 5-18). 
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5.6.4.2. Comparison of grouped control and AD correlations to myelin 
Iron, R1, R2, R2* and R2’ were all correlated to myelin similarly when comparing 
between control and AD tissue (iron, P = 0.700; R1, P = 0.061; R2, P = 0.851; R2*, P 
= 0.644 and R2’, P = 0.854; Figure 5-46). Comparing regression gradients between 
relaxometry or iron contents with myelin also provided similar values between 
control and AD tissue for all measurements (iron, P = 0.539; R1, P = 0.273; R2, P = 
0.246; R2*, P = 0.318 and R2’, P = 0.649; Figure 5-46, and comparing values in Table 
5-9 and Table 5-20). Furthermore, no changes in the correlation significance order 
were found between control and AD tissue, with R2* showing strongest correlation 
to myelin, ahead of iron, R2 and R2’ correlations (Table 5-24). 
The AD ROI values tended to show greater spread than the control data in 
relaxometry or iron content graphs against myelin (Figure 5-46 and Figure 5-47), 





Figure 5-46 Correlation of relaxometry values and elemental iron contents against 
myelin between control and AD samples 
Graphs of (A) elemental iron, (B) R1, (C) R2, (D) R2* and (E) R2’ correlation against 
myelin, as assessed using the twenty four 5x5 pixel ROIs for control (blue) (n = 288), 
and AD (red) (n = 264) samples. Group correlation assessed using Pearson 
correlation and assessed for significance between control and AD correlations using 





Figure 5-47 Separate GM and WM clustering in iron content and relaxometry 
correlations to myelin between control and AD tissue 
Graphs of (A) iron content and (B) R1, (C) R2, (D) R2* and (E) R2’ against myelin, in 
control (blue) samples (n = 288) and (F-J) AD (red) samples (n = 264). Solid circles are 
GM ROIs, hollow circles are WM ROIs. 
 
5.6.4.3. Comparison of control and AD region-specific correlations to myelin 
Iron contents and R2* values were correlated similarly with myelin in WM tissue, 
between control and AD (iron: r2, P = 0.685 and regression gradient, P = 0.694; and 
R2*, r2, P = 0.779 and regression gradient, P = 0.614, comparing values from Table 
5-9 and Table 5-20). R2 values correlated with myelin better in AD WM tissue, than 
control WM (r2, P = 0.027 and regression gradient, P = 0.025). In GM however, iron 
contents, R2 and R2* values were all correlated to myelin better in AD samples than 
in control samples, and had better regression gradients (all, P < 0.0001, comparing 




Table 5-24 Summary of relaxometry and iron correlation comparisons against 
myelin, between control and AD tissue 
Region Selection Order of significance 
All ROIs – control R2* > iron = R2 = R2’ > R1 
All ROIs – AD R2* > iron = R2 = R2’ > R1 
> denotes values are significantly different, = denotes values are similar. 
 
5.6.5. Summary of comparisons between control and AD human MTG 
 Similar R1, R2, R2* and R2’ relaxivity values, as well as similar elemental iron 
contents were detected between control and AD human MTG samples in 
GM and WM. These values were also similar in the MCL and dGM regions, 
between control and AD samples (see section 5.6.1.1). Myelin content 
however, was lower in AD WM than control WM. 
 No changes in relaxometry values or iron content were detected between 
control and AD samples separated by gender. However separate assessment 
of R2 and R2* values demonstrated higher values in the WM from control 
males compared with AD males, whilst female R2 and R2* values were still 
similar (see section 5.6.1.2). Further evaluation of myelin contents identified 
that control male samples had higher myelin contents than AD male 
samples, within all the tissue regions evaluated (see section 5.6.3). 
 Mean correlations of relaxometry to iron content in individual samples were 
similar between control and AD (see section 5.6.2.1), however mean 
correlations of individual samples when assessing all the relaxometry and 
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iron correlations with myelin were lower in AD tissue compared with 
controls (see section 5.6.4.1). 
 Grouped correlations demonstrated better R1 correlations to iron, and 
lower R2’ correlations to iron in AD samples than controls. Furthermore, 
whilst R2* correlated better with iron content than R2 did in control 
samples, these were similar in AD tissue (see section 5.6.2.2; Table 5-23). 
 Grouped correlations of relaxometry and iron content with myelin were 
similar between control and AD samples, however a difference in the spread 
of ROI values seems to be apparent, with greater spreading of WM ROI 
values in AD samples, compared with more clustered control WM ROI values 
(see section 5.6.4.2). 
 Region-specific correlations demonstrated that R2 values were better 
correlated to iron content in AD WM tissue than control WM tissue, whilst 
all other correlations and molar relaxivities were similar in WM and GM (see 
section 5.6.2.3, Table 5-22). Furthermore, whilst R2 values demonstrated 
lower correlation to iron content than R2* values did in control WM, R2 
values became better correlated to iron content than R2* did in AD WM 
(see section 5.6.2.3, Table 5-23). 
 Region-specific correlations demonstrated that R2 values were correlated 
with myelin better in AD WM tissue, than control WM. In GM, iron contents, 
R2 and R2* values were all better correlated to myelin in AD compared with 





This chapter shows that WM regions consistently demonstrated greater levels of 
iron and myelin, and had higher R1, R2, R2* and R2’ relaxometry values than GM 
tissue. Similar iron content, as well as R1, R2, R2* and R2’ relaxometry values were 
obtained between control and AD tissues. Higher iron contents were detected in 
female AD WM, compared with male AD WM, and this can be attributed to myelin 
breakdown in the male AD WM tissue compared with control males. Whilst R1, R2, 
R2* and R2’ all correlated strongly to iron within individual samples, inter-sample 
variability was especially high for R1. R2 and R2* relaxometry were able to detect 
changes in iron content within WM or GM regions for both control and AD tissue, 
however R2 values were better correlated to AD WM iron contents than control 
WM iron contents, potentially due to a breakdown in myelin content within WM of 
AD samples. 
 
5.7.1. Post-mortem tissue factors 
PMI and subjects’ age at death did not affect R1, R2, R2* or R2’ relaxivity values, or 
iron content, of control or AD human tissue samples (Table 5-1 and Table 5-11). 
Fixation time of samples however, influenced R1 values across all tissue regions in 
both control and AD tissue and demonstrated some effects on R2 and R2’ values 





Whilst certain MR techniques, such as 1H-MRS, have been used for the detection of 
the biochemical or metabolic changes that occur early on in post mortem samples, 
(Petroff et al., 1988, Ith et al., 2002, Scheurer et al., 2005), inconsistent findings 
have been observed using relaxometry assessment (Fagan et al., 2008, Shepherd et 
al., 2009). The method performed by Shepherd et al. more closely resembles the 
conditions of human tissue obtained as part of this study, in which they observed 
decreasing T1 and T2 values in rat cortical samples directly immersed in fixative, at 
various PMIs (Shepherd et al., 2009). Despite the closely resembling model, our 
data demonstrates no impact of PMI length on relaxivity values in control or AD 
human brain tissue samples (Table 5-1 and Table 5-11). The discrepancies observed 
between our data and these two studies may be attributed not only to species 
differences with our assessment of human post-mortem tissue rather than rat 
cortex, but also due to our data evaluating PMI lengths of up to 100 hours, whilst 
both studies in rat only evaluated up to 24 hours PMI (Fagan et al., 2008, Shepherd 
et al., 2009). Relaxometry measurements are affected by tissue microstructure, 
water content and iron contents (Deoni, 2010), which are more likely to be affected 
by tissue degradation that can occur at longer PMIs. Given that no changes were 
detected for any relaxometry values due to PMI time here, we expect the level of 
degradation is not substantial enough to affect the environment of proton spins, 
measured through relaxometry assessment in these brain tissue samples, up to this 
length of PMI.  
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From the limited information available regarding the effects of PMI on iron content 
in control and AD human brain samples, no effect of PMI affecting iron content has 
been detected (Loeffler et al., 1995). Here, we also show that over the course of up 
to 100 hours, no effects can be observed on global iron contents within either GM 
or WM tissue types due to PMI. Whilst, these results allow validation that PMI 
length does not influence any results obtained with this study, it is important that 
PMI effect on iron content be evaluated in a specific longitudinal study to validate 
these observations in greater detail. 
 
5.7.1.2. Fixation time 
Fixation of human tissue samples has been extensively explored, demonstrating 
decreasing T1 and T2 values (therefore increasing R1 and R2) during the fixation 
process (Tovi and Ericsson, 1992, Blamire et al., 1999, Dawe et al., 2009). T1 values 
of brain GM and WM became similar, with fixation reducing the contrast between 
them (Tovi and Ericsson, 1992). For this reason PD weighted images have been 
suggested for use with post-mortem samples to enhance GM to WM contrast (Tovi 
and Ericsson, 1992, Blamire et al., 1999). T2 values also decrease with fixation 
although the decline is not as great as that for T1 (Tovi and Ericsson, 1992, Blamire 
et al., 1999). Recently, a systematic study was performed showing that not only do 
T2 values vary with fixation time, but they also depend on the depth of the brain 
regions, with T2 values changing less rapidly in deep brain structures, reflecting the 
time taken for fixative to reach deeper brain regions (Dawe et al., 2009). With these 
studies primarily focussed on evaluating the changes in relaxometry values 
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throughout the fixation process, the time points evaluated only range up to a 
maximum of 6 months post-mortem. Here, we find that prolonged fixation, beyond 
6 months, and up to 33 months, of both control and AD samples in formalin 
continues to affect relaxometry measurements. The results showing that R1 values 
continue to increase in both control and AD WM and GM tissue are in agreement 
with the previously described, shorter length studies. The increase in R2 values 
within control GM is also in agreement with previous studies, however it was found 
that WM tissue did not continue to change at these prolonged fixation times. In AD 
samples, R2’ values decreased in WM and GM tissue from AD samples, whilst R2 
values showed no changes in any tissue regions. Fixation can affect relaxometry 
measurement of tissues due to the cross linking of proteins increasing tissue 
rigidity, and leading to a reduction in the mobility of water protons impacting on 
the T1 and T2 values (Dawe et al., 2009). This discrepancy in R2 and R2’ between 
control and AD tissue highlights that disease specific differences may be occurring 
with prolonged formalin fixation, with neurodegeneration playing varying roles on 
prolonged protein cross linking, compared with normal tissue. It should also be 
noted that all brain samples were sliced into thin sections prior to formalin fixation 
at the brain bank, and so it would be expected that tissue depth would play no role 
on the degree of fixation of samples, as has been documented by others (Dawe et 
al., 2009). 
These results may impact work requiring the use of human post-mortem tissue 
from brain banks however, which tend to have more readily-available formalin fixed 
tissue for assessment, than fresh or frozen tissue. Therefore, care should be taken 
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to ensure that samples obtained are also fixation time matched when carrying out 
post-mortem MRI studies, to compare between groups. 
Formalin fixation demonstrated no effects on iron content over short-term fixation 
here, in agreement with previous studies (Bush et al., 1995, Chua-anusorn et al., 
1997, Gellein et al., 2008). The degree of iron leaching during storage in formalin is 
likely to be determined by the strength and mode of binding of iron to proteins, as 
well as length of time in fixative (Gellein et al., 2008). Recently however, evidence 
has been shown that highlights decreased iron content following 4-6 years fixation 
(Schrag et al., 2010). As no significant iron leaching has been demonstrated up to 18 
months fixation (Gellein et al., 2008), samples with fixation times greater than this 
have been excluded from subsequent group analyses. 
 
5.7.1.3. Subjects’ age at death 
Much of the literature surrounding age of subject death on relaxometry values has 
involved evaluation of changes between young, adult and aged populations (Pujol 
et al., 1992, Schenker et al., 1993, Saito et al., 2009). These relaxometry 
assessments predominantly evaluate changes in R2 and R2* in different brain areas 
demonstrating increases in R2 and R2* between young and adult subjects, with 
both relaxation rates reaching a plateau at around 40 years of age (Pujol et al., 
1992, Schenker et al., 1993, Saito et al., 2009). T1 values demonstrate inconsistent 
results with age, with some studies showing no change with age, whilst others 
shown an increase in certain brain regions (Breger et al., 1991, Steen et al., 1995, 
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Ogg and Steen, 1998, Saito et al., 2009).  Similar observations for iron content have 
been detected as for T2 and T2* relaxometry, with an increase in iron from young, 
until levels plateau at around 40 years of age (Hallgren and Sourander, 1958). Given 
that all the samples obtained for this thesis were from an aged population (60-95 
years), it is unsurprising that no changes in any relaxometry values, or iron 
contents, are observed as a factor of age of subject, as the population has been 
sampled from the plateaus of relaxation times and iron contents for both control 
and AD subjects’ samples. 
 
5.7.2. Relaxometry values and elemental iron content assessments 
The relaxometry values of medial temporal gyrus observed in this study are 
comparable to previously published literature using post-mortem formalin fixed 
human tissue (Dawe et al., 2009, Antharam et al., 2012) (Table 5-25). R1 values 
were comparable to both in vivo and frozen temporal cortex GM and WM values, 
within both control and AD samples. In line with the effects of fixation on 
relaxometry values in brain tissue, R2, R2* and R2’ values detected here were 
slightly higher than those from studies performed using in vivo or fresh/ frozen 
brain tissue (see section 5.7.1.2 and Table 5-25) (Gelman et al., 1999, House et al., 
2006, House et al., 2007, Langkammer et al., 2010, House et al., 2012). R2 values 
measured here were approximately 30% greater than post mortem temporal cortex 
at similar field strength. The higher R2 values measured are thus due to the fixation 
of samples, and also due to the higher field strength used here, in comparison to 
other studies (Table 5-25). The R2* values measured were also comparable to other 
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studies using fixed tissue at similar field strength (Stuber et al., 2014), however one 
study demonstrated slightly lower R2* values (Fukunaga et al., 2010) (Table 5-25). 
This study however only performed measurements in one sample. Iron contents 
measured in this study were extremely comparable to previous literature in the 
same brain regions from both fixed and non-fixed post-mortem human tissue (Bush 
et al., 1995, Deibel et al., 1996, Leite et al., 2008, Ramos et al., 2014) (Table 5-25). 
This was the case for both control and AD samples. Furthermore, wet weight iron 
contents converted into dry weights by using dry-to-wet weight ratios (House et al., 
2007), also provided iron contents of similar value to that observed here (Table 





Table 5-25 Comparison of cortical relaxometry and iron content measurements within literature 





R1  Control Temporal cortex GM 1.10 ± 0.25 12 Fixed 7 T This study 
(s-1)  Temporal cortex WM 1.31 ± 0.26 12 Fixed 7 T This study 
 Control Cortex GM 0.72 ± 0.02 108 In vivo 1.5 T (Ogg and Steen, 1998) 
  Frontal cortex WM 1.35 ± 0.02 112 In vivo 1.5 T (Ogg and Steen, 1998) 
 Control Temporal Cortex GM 0.90 ± 0.05 ** 5 Frozen 1.4 T (House et al., 2008) 
  Temporal Cortex WM 1.55 ± 0.05 ** 4 Frozen 1.4 T (House et al., 2008) 
 Control Hippocampus CA4-DG 0.76 ± 0.01 3 Unfixed 14.1 T (Antharam et al., 2012) 
 AD Temporal cortex GM 1.05 ± 0.10 12 Fixed 7 T This study 
  Temporal cortex WM 1.21 ± 0.17 12 Fixed 7 T This study 
 AD Temporal Cortex GM 1.05 ± 0.15 ** 5 Frozen 1.4 T (House et al., 2008) 
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  Temporal Cortex WM 1.50 ± 0.10 ** 5 Frozen 1.4 T (House et al., 2008) 
 AD Hippocampus CA4-DG 0.66 ± 0.06 5 Unfixed 14.1 T (Antharam et al., 2012) 
R2  Control Temporal cortex GM 33.42 ± 2.31 12 Fixed 7 T This study 
(s-1)  Temporal cortex WM 44.64 ± 3.75 12 Fixed 7 T This study 
 Control Cortex GM 11.24 ± 0.88 5 P-M 2.35 T (Brooks et al., 1989) 
  White Matter WM 13.07 ± 1.88 5 P-M 2.35 T (Brooks et al., 1989) 
 Control Cortex GM 23.67 ± 1.62 5 P-M 8.5 T (Brooks et al., 1989) 
  White Matter WM 27.84 ± 3.85 5 P-M 8.5 T (Brooks et al., 1989) 
 Control Prefrontal cortex GM+WM 14.4 ± 1.8 6 In vivo 3 T (Gelman et al., 1999) 
  Frontal WM WM 18.0 ± 1.2 6 In vivo 3 T (Gelman et al., 1999) 
 Control Temporal cortex GM 12.0 ** 11 In vivo 1.5 T (House et al., 2006) 
  Temporal cortex WM 13.0 ** 11 In vivo 1.5 T (House et al., 2006) 
 Control Temporal Cortex GM 9.8 ± 1.0 ** 5 Frozen 1.4 T (House et al., 2008) 
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  Temporal Cortex WM 16.5 ± 1.5 ** 4 Frozen 1.4 T (House et al., 2008) 
 Control Hemisphere - 26.90 ± 2.93 5 Fixed 3 T (Dawe et al., 2009) 
 Control Hippocampus CA4-DG 28.2 ± 2.8 3 Unfixed 14.1 T (Antharam et al., 2012) 
 AD Temporal cortex GM 33.25 ± 3.38 12 Fixed 7 T This study 
  Temporal cortex WM 42.53 ± 5.70 12 Fixed 7 T This study 
 Severe MCI Temporal cortex GM 12.9 ** 11 In vivo 1.5 T (House et al., 2006) 
  Temporal cortex WM 11.9 ** 11 In vivo 1.5 T (House et al., 2006) 
 AD Temporal Cortex GM 11.0 ± 0.5 ** 5 Frozen 1.4 T (House et al., 2008) 
  Temporal Cortex WM 15.0 ± 1.0 ** 5 Frozen 1.4 T (House et al., 2008) 
 AD Hippocampus CA4-DG 35.1 ± 3.8 5 Unfixed 14.1 T (Antharam et al., 2012) 
R2*  Control Temporal cortex GM 42.38 ± 3.98 12 Fixed 7 T This study 
(s-1)  Temporal cortex WM 64.39 ± 6.16 12 Fixed 7 T This study 
 Control Cortex GM 26.5 1 Fixed 7 T (Fukunaga et al., 2010) 
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  Cortex WM 46.0 1 Fixed 7 T (Fukunaga et al., 2010) 
 Control Temporal cortex WM 26 ± 3 36 P-M 3 T (Langkammer et al., 2010) 
 Control Hippocampus CA4-DG 42.7 ± 4.7 3 Unfixed 14.1 T (Antharam et al., 2012) 
 AD Temporal cortex GM 42.94 ± 4.26 12 Fixed 7 T This study 
  Temporal cortex WM 61.75 ± 9.45 12 Fixed 7 T This study 
 AD Hippocampus CA4-DG 44.8 ± 2.6 5 Unfixed 14.1 T (Antharam et al., 2012) 
R2’  Control Temporal cortex GM 8.82 ± 2.59 12 Fixed 7 T This study 
(s-1)  Temporal cortex WM 19.74 ± 3.60 12 Fixed 7 T This study 
 Control Prefrontal cortex GM+WM 3.4 ± 1.1 6 In vivo 3 T (Gelman et al., 1999) 
  Frontal WM WM 3.9 ± 1.2 6 In vivo 3 T (Gelman et al., 1999) 
 AD Temporal cortex GM 9.60 ± 1.95 12 Fixed 7 T This study 
  Temporal cortex WM 19.25 ± 4.48 12 Fixed 7 T This study 
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Iron Control Temporal cortex GM 133.2 ± 20.4 12 Fixed SR-XRF This study 
(µg/g dry wt)  Temporal cortex WM 223.9 ± 55.2 12 Fixed SR-XRF This study 
 Control Temporal cortex GM+WM 135.5 ‡ 47 P-M Colorimetry (Hallgren and Sourander, 
1958) 
 Control Temporal cortex GM 222 ± 54.6 5 P-M ICP-ES (Bush et al., 1995) 
  Temporal cortex WM 245 ± 85.9 5 P-M ICP-ES (Bush et al., 1995) 
 Control Temporal cortex GM+WM 266 ± 23.2 * 11 Frozen INAA (Deibel et al., 1996) 
 Control Temporal cortex GM 242.0 ‡ 1 Frozen GFAAS (House et al., 2007) 
  Temporal cortex WM 280.1 ‡ 1 Frozen GFAAS (House et al., 2007) 
 Control Frontal cortex GM+WM 224.0 ± 41.5 21 Frozen NAA (Leite et al., 2008) 
 Control Temporal cortex WM 163.7 ‡ 36 Fixed ICP-MS (Langkammer et al., 2010) 
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 Control Temporal cortex GM+WM 280 # 719 Frozen GFAAS (House et al., 2012) 
 Control Temporal cortex GM+WM 287 ± 65 42 Frozen GFAAS (Ramos et al., 2014) 
 AD Temporal cortex GM 142.1 ± 25.0 12 Fixed SR-XRF This study 
  Temporal cortex WM 213.6 ± 57.3 12 Fixed SR-XRF This study 
 AD Temporal cortex GM+WM 269 ± 37.9 * 10 Frozen INAA (Deibel et al., 1996) 
 AD Temporal cortex GM 251.0 ‡ 2 Frozen GFAAS (House et al., 2007) 
  Temporal cortex WM 183.2 ‡ 3 Frozen GFAAS (House et al., 2007) 
 Dementia Frontal cortex GM+WM 235.7 ± 41.2 21 Frozen NAA (Leite et al., 2008) 
GM denotes Grey Matter, WM denotes White Matter, P-M denotes samples taken post-mortem, wt denotes weight, INAA denotes instrumental 
neutron activation analysis, ICP-ES denotes inductively coupled plasma emission spectroscopy, ICP-MS denotes inductively coupled plasma mass 
spectroscopy, GFAAS denotes graphite furnace atomic absorption spectrometry, SR-XRF denotes synchrotron radiation X-ray fluorescence. 
* denotes conversion of SEM to SD, # denotes median value used, ** denotes approximate values given due to results presented as figures in 
the relevant references, ‡ denotes iron values converted from wet weight to dry weight using dry to wet weight ratios from (House et al., 2007). 
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5.7.2.1. WM compared with GM in control and AD tissue 
Using these MTG samples, both control and AD WM tissue were consistently found 
to hold greater iron contents than GM tissue, which were similarly detectable using 
R1, R2, R2* and R2’ relaxometry assessment. This has also been shown in studies 
that evaluated cortical GM iron content or relaxometry values, compared to cortical 
WM values (House et al., 2008, Fukunaga et al., 2010, Stuber et al., 2014). 
Furthermore, given the close similarities in tissue architecture detected between 
elemental iron and relaxometry maps, and the consistency of quantitative 
differences between WM and GM regions, it seems that iron content must be 
impacting on relaxometry measurements, at least to some extent. The detection of 
iron in this study was sensitive enough to investigate microstructural differences 
within the MTG, with identification of specific cortical layers, namely layers IV-V, 
within the GM (referred to as MCL). Identification of these cortical layers was also 
possible using high resolution R1, R2 and R2* relaxometry, again indicating that 
detection of these regions may be based on their iron contents. Indeed, assessment 
of this region separately provided relaxivity values increasing in the consistent 
order of dGM < MCL < WM using R1, R2 and R2* relaxometry, as was also observed 
for iron contents. It can be noted however that whilst R2 and R2* demonstrated 
similar differences as iron contents using unpaired statistical assessment between 
GM and WM regions, R1 values were generally less sensitive to this difference, only 
detecting differences consistently using paired statistics in both control and AD 
tissue. This may be due to lower reliability of R1 values for iron detection, as shown 
by the lower correlations of R1 to iron contents (see section 5.7.3.2). Furthermore, 
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R2’ values did not demonstrate this same consistent change between tissue types, 
with an inability to distinguish between the dGM and MCL. This may also be due to 
the lower correlations observed between R2’ and iron content than R2 or R2* 
relaxometry correlations to iron content (see section 5.7.3.2) or due to fewer 
effects from magnetic inhomogeneities within the MCL impacting R2’ 
measurement. 
Both the WM and MCL layers have been identified previously within the MTG using 
Perls’ staining for iron and were found to contain cortical layers with greater levels 
of myelination (van Duijn et al., 2013). With myelinated regions heavily populated 
with oligodendrocytes, the higher iron content observed in regions that contain 
greater numbers of oligodendrocytes is expected, given these cells contain the 
greatest amount of iron compared with other cell types in the brain (Connor et al., 
1990). However, given the differences in tissue microstructure and water content in 
myelin-rich WM regions compared with GM (House et al., 2008), myelin itself has 
been shown to affect relaxometry values (Gelman et al., 2001, Rooney et al., 2007). 
Therefore it is important to consider changes in myelin content and iron content 
together, to understand the relaxometry observations in greater detail (see section 
5.7.4). 
Finally, it was determined that similar iron contents, as well as in R1, R2, R2* and 
R2’ relaxometry values were detected between control and AD tissue, in all WM 
and GM regions. Whilst other studies have also shown similar iron contents 
between controls and AD tissue (Hallgren and Sourander, 1960, Jellinger et al., 
1990, Magaki et al., 2007, Schrag et al., 2011), this work does however contradict 
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the hypothesis of increased iron content holding causal roles during 
neurodegeneration in AD (Goodman, 1953, Connor et al., 1992a, Connor et al., 
1992b, Loeffler et al., 1995, Deibel et al., 1996, House et al., 2008, Smith et al., 
2010). Histochemical approaches showing increased stainable iron have been used 
in many of these positive cases (Goodman, 1953, Connor et al., 1992a, Smith et al., 
2010), however whilst these techniques provide excellent assessment of iron 
localisation, their quantitative interpretation can be complex (Meguro et al., 2007) 
(see section 1.5.1). Furthermore, quantitative studies evaluating iron content in 
various brain regions have been performed in low sample numbers, with ten AD 
samples used in one study (Deibel et al., 1996), whilst only five AD samples were 
used in another, of which two were specified as probable AD (House et al., 2008). 
Finally, other previous studies have normalised iron content to protein content, 
demonstrating differences between AD and control in the frontal cortex (Loeffler et 
al., 1995). Since protein content was also found to change during AD in that study, 
the results may be due to changes in protein content rather than solely changes in 
iron content (Loeffler et al., 1995). 
Similar iron contents have been detected in the hippocampus (Magaki et al., 2007) 
and in cortical regions (Religa et al., 2006) of AD subjects to control, supporting our 
elemental iron findings in the MTG. Furthermore, similar iron levels in CSF were 
found between control, MCI and AD patients (Lavados et al., 2008). It should be 
noted, however, that these studies were also performed with low sample numbers. 
Studies also exist highlighting the use of histochemical assessment of iron to show 
291 
 
no overall iron content changes between control and AD tissue (Hallgren and 
Sourander, 1960, Jellinger et al., 1990). 
Alongside these similar iron contents observed between control and AD, we also 
found similar values using relaxometry measurements for these groups. These 
observations are also similar to some previous studies (Antharam et al., 2012), 
whilst providing contradictory evidence to others (Schenck et al., 2006, Qin et al., 
2011). Given that T1 and T2 changes in the brain with ageing closely match the 
profile of iron content changes with ageing, these measurements have been used 
as surrogate measurements for iron in vivo (Hallgren and Sourander, 1958, 
Schenker et al., 1993, Ogg and Steen, 1998). Furthermore, strong correlations 
between relaxometry measurements and iron contents in the brain have been 
shown (Langkammer et al., 2010) (also see chapter 4 and discussed in greater detail 
in section 5.7.3). Based on this premise, T2-weighted imaging highlighted iron 
deposition in AD subjects’ hippocampus compared with controls (Schenck et al., 
2006), and increased R2’ values were identified in both MCI and AD patients’ 
hippocampus, caudate, putamen and parietal cortex (Qin et al., 2011). More 
interesting are the correlations between relaxometry measurement changes to 
cognitive scores in both AD and even in normal healthy ageing (Pujol et al., 1992, 
Qin et al., 2011, Rodrigue et al., 2012). Furthermore, increased ferritin iron in the 
caudate, globus pallidus and putamen from AD patients has been identified using 
approaches such as FDRI (Bartzokis et al., 1994b, Bartzokis et al., 2000). However, 
with all of these studies based in clinical populations, it is difficult to confirm that a 
change in iron content is truly being detected using these relaxometry 
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measurements. Finally, support for iron detection using relaxometry measurements 
has also been provided through studies evaluating the accumulation of iron in 
amyloid plaques, with loss of T2 and T2* specific to regions of Perls staining with 
amyloid deposition in animal models (Chamberlain et al., 2009, Dhenain et al., 
2009, Wengenack et al., 2011) or in human plaques (Meadowcroft et al., 2009). 
However, given that these accumulations of iron provide clearly detectable foci by 
MRI, these observations are less relevant for global iron content changes being 
evaluated here. In support of the results shown here, R2 and R2* values were found 
to be similar between the hippocampus of AD compared with control subjects, 
despite detectably strong correlations with iron content also evaluated using SR-
XRF (Antharam et al., 2012). 
 
Taken altogether, these results satisfied the objectives to perform quantitative R1, 
R2, R2* and R2’ relaxometry using control and AD human MTG. These were then 
subsequently compared between control and AD, showing similar relaxometry 
values and iron contents in each tissue region assessed (see section 5.2). These 
results, along with others’, may imply that changes in the distribution or forms of 
iron are being detected within brain tissue, as opposed to global iron content 
increase, with many studies demonstrating iron to have increased redox activity 
potential in AD pathology using histochemical or colorimetric approaches (Smith et 
al., 1997, Magaki et al., 2007, Lavados et al., 2008, Smith et al., 2010). Indeed, this 
hypothesis may be supported due to the various pathological forms of iron being 
detected at greater levels within AD tissue compared with control, such as 
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magnetite (Collingwood et al., 2005, Pankhurst et al., 2008) and hemosiderin 
(Quintana et al., 2006). In this case, altered forms of iron during pathology may play 
a greater impact on relaxometry values, (as shown in chapter 4), however no 
evidence for this has been detected in the samples assessed here. 
 
5.7.2.2. Gender comparison 
Gender differences are rarely taken into account when measuring iron content or 
relaxivity values in post-mortem studies. However, we found no differences 
between control male and female subjects here, based on either of the iron content 
or relaxometry assessments, within WM or GM of the MTG. This is in line with iron 
estimation performed using phase imaging (Xu et al., 2008) showing no discernible 
differences in brain iron, however others have detected lower female ferritin iron 
than in males using FDRI (Bartzokis et al., 2007a). More recently, whilst no overall 
differences in iron content were detected between genders, a difference in the 
correlation of age and iron was detected, whereby male subjects showed a gradual 
increase in iron content with age, whilst females did not (Ramos et al., 2014). This 
matches our data for overall iron content similarities between the genders, 
however no age-related correlations were observed in our results (see section 
5.7.1.3). 
Whilst control samples showed similar iron contents, R2* and R2’ values between 
the genders, AD tissue demonstrated higher iron contents in female subjects’ WM 
compared with males’ WM, which seems to be mirrored with a trend towards 
294 
 
significance for R2* and R2’ values. Further evaluation demonstrated that male AD 
samples had generally lower WM R2 and R2* values compared with male control 
WM tissue. These findings may be explained by a breakdown in myelin content in 
WM tissue from AD samples, which was specifically found to occur in males’, but 
not females’ samples (see section 5.7.4). 
 
Iron therefore seems to affect relaxivity, most specifically R2 and R2*, in human 
post-mortem tissue. However, greater understanding of the specificity and 
sensitivity can be gained following correlation assessments between iron and 
relaxometry values (see section 5.7.3). 
 
5.7.3. Correlation of iron to relaxometry 
5.7.3.1. Individual samples 
Most studies correlating quantitative iron contents to MR relaxometry 
measurements either involve in vivo clinical assessments correlated to previous iron 
contents established in literature (Ogg and Steen, 1998, House et al., 2010, Qin et 
al., 2011),  or performing bulk analysis quantification of whole tissue regions for 
iron content and correlating this against averaged tissue relaxivities (House et al., 
2008, Langkammer et al., 2010). Whilst these approaches provide important 
information regarding the overall regional correlations between iron and 
relaxometry, they do not allow for a full, specific and spatial assessment of 
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correlations between samples, or within regions, to fully understand the impact 
that iron may have on relaxivity changes within the brain (see section 1.6.5.1).  
To spatially assess the correlation of iron content against relaxometry (see 
objectives in section 5.2), we employed a technique using 24 small 5x5 pixel ROIs 
placed across the GM and WM regions for each sample. These generally 
demonstrated strong, positive correlations for both control and AD tissue using R1, 
R2, R2* and R2’ relaxometry measurements compared with iron content, as 
demonstrated by the mean correlation values across samples. Using this approach, 
R2’ values were found to be correlated to iron contents worse than R1, R2 or R2* 
correlated to iron, in control samples. This result was unexpected given that R2’ 
contains information on magnetic inhomogeneities, and should theoretically 
provide greater sensitivity for iron (Ordidge et al., 1994, Haacke et al., 2005). 
However, R2’ maps demonstrated greater noise across maps, as indicated by the 
larger error bars in the representative single sample correlations compared with 
either R2 or R2* (Figure 5-12D). The reason for greater noise in R2’ maps compared 
with the other relaxometry measurements is likely to be due to accumulation of 
error across pixels following the subtraction of R2 from R2* maps. To account for 
this in the future, acquisition of higher SNR data of both R2 and R2* maps should 
provide enhanced R2’ maps for correlation against iron. The caveat to this, 
however, would be much longer scan times for each sample with a greater number 
of averages per scan. Relaxivities in AD tissue were all correlated with iron similarly, 
using the mean correlations of individual samples. Furthermore, comparison 
between control and AD correlations showed similar values detected for each 
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relaxometry measurement against iron, indicating that correlations within 
individual samples do not change during AD pathology. 
 
5.7.3.2. Grouped and region-specific correlations 
In order to assess both intra- and inter- sample variations in iron content 
correlations to relaxometry, all the individual 24 ROIs of each sample were pooled 
and correlated with iron, rather than using the mean of each samples’ correlation. 
With this approach, R1 demonstrated extremely low correlation in both control and 
AD tissues (Table 5-22). This observation is in contradiction to the R1 correlations to 
iron observed in individual samples and likely indicates that other factors other 
than iron content have a great effect on R1 values across individual samples. 
Indeed, fixation time length was found to provide a significant effect on R1 values 
here, potentially impacting on the overall correlation with iron across multiple 
samples (Tovi and Ericsson, 1992, Blamire et al., 1999). Similarly, given that fixation 
of samples involves protein cross-linking affecting water availability, differences in 
water content may also substantially effect R1 correlation to iron across multiple 
samples. However, water content was not measured within our study and so 
cannot be confirmed as an influencing factor. 
R2 and R2* demonstrated strongest correlations to iron content in both control and 
AD tissues, however whilst R2* correlation to iron was higher than that for R2 
correlation in control samples, the R2* correlation seems to be less in AD tissue. 
This leads to an equal correlation for both R2* and R2 to iron content in AD 
297 
 
samples. This may indicate that neurodegeneration in the AD tissue affects R2* 
correlation to iron. Molar relaxivities were similar between control and AD tissue, 
indicating that each relaxometry assessments’ sensitivity to iron seems to be 
consistent in both control and AD samples.  
Statistical analyses using linear regression and correlation were performed in order 
to draw comparisons to other studies. Comparison of our correlation values to 
others highlights agreement with combined GM and WM regions. The correlation 
values between R2 and iron from this study were r2 = 0.62 in control and r2 = 0.64 in 
AD, which are similar to that found using ICP-MS to compare against iron contents 
in the normal brain (r2 = 0.67) (Langkammer et al., 2010). These values are also 
similar to correlations found between R2 and iron content in control (r2 = 0.64) and 
AD (r2 = 0.63) tissue, following quantification of iron using AAS (House et al., 2007). 
Using R2* correlation to iron, this study showed r2 = 0.68 in control and 0.61 in AD, 
whereas a correlation value of r2 = 0.90 was identified in the study of normal brains 
with ICP-MS (Langkammer et al., 2010). The better correlation of iron to R2* 
observed in the latter study could be due to the bulk assessment of iron content 
from a number of different tissue regions, ranging from white matter, putamen, 
caudate and the globus pallidus, providing enhanced sampling of iron contents for 
comparability with relaxometry measurements. The samples acquired as part of the 
study here were substantially smaller, containing only WM and GM tissue from the 




From molar relaxivity values, this study demonstrated r2 = 0.096 s
-1ppm-1 and r2* = 
0.182 s-1ppm-1 in controls, and r2 = 0.102 s
-1ppm-1 and r2* = 0.181 s
-1ppm-1 in AD 
(Table 5-22). Using ICP-MS assessment of iron in control samples, R2 and R2* values 
provided r2 = 0.04 s
-1ppm-1 and r2* = 0.27 s
-1ppm-1 at 3T (Langkammer et al., 2010). 
At 4.7T, R2 values correlated to iron with r2 = 0.104 s
-1ppm-1 in control and r2 = 
0.095 s-1ppm-1 in AD using GM and WM regions for assessment (House et al., 2007). 
The values obtained in this study are relatively consistent to values obtained 
previously (House et al., 2007, Langkammer et al., 2010), with discrepancies 
potentially attributed to different field strengths used. These values allow the 
provision for predicting R2 or R2* values (R2PRED or R2*PRED) (House et al., 2007), 
with a known iron content, [Fe], where, 
R2PRED or R2*PRED = A[Fe] + B  (Eq.1) 
From the measurements taken within this work across both GM and WM regions, 
the following relationships can be outlined: 
Control R2PRED = 0.096[Fe] + 21.30 
Control R2*PRED = 0.182[Fe] + 19.25 
AD R2PRED = 0.102[Fe] + 19.38 
AD R2*PRED = 0.181[Fe] + 18.36 
These relationships may also be used to evaluate the iron content present in the 




The additional advantage with the approach taken here using 24 small ROIs is the 
potential to correlate relaxometry measurements to iron contents within regions, 
e.g. within the WM and GM tissue separately. In all cases of regional iron to 
relaxometry correlations, correlation values were substantially lower within regions 
compared with across regions. As the correlations were better with ROIs including 
both WM and GM, the correlations to iron appear to be predominantly driven by 
the larger differences in iron concentration between the WM and GM from each 
sample. Hence, MR relaxometry measures seem to be relatively insensitive to small 
changes in iron concentrations, given the lower correlation values when considering 
solely WM or GM ROIs. This is supported by the finding that an iron content change 
of 55 µg g-1 wet tissue is required to provide correlative changes in MRI relaxometry 
values (House et al., 2007). 
Control GM provided greater R2 correlation to iron than in WM and showed greater 
molar relaxivity. R2* values between GM and WM were correlated to iron similarly, 
but demonstrated greater sensitivity with higher molar relaxivity in GM than WM 
(Table 5-6). These observations were similar in AD tissue, apart from R2 values also 
correlating to iron similarly between GM and WM, but still with greater sensitivity 
(Table 5-16). Altogether, these assessments show that R2 and R2* may show 
greater sensitivity for iron in GM than in WM, as had also been shown prior to this 
study using bulk assessment across multiple samples (House et al., 2008, 
Langkammer et al., 2010). R2’ values however showed similar correlations and 
similar molar relaxivity to iron in both GM and WM tissue in both control and AD 
tissue, perhaps indicating that R2’ is in fact a good measure of iron specifically, 
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irrespective of tissue types. However, the greater levels of noise in these particular 
maps have led to higher error and therefore correlation to iron to be worse overall. 
Interestingly, a change in the regional correlations is detected between control and 
AD, whereby R2 values became better correlated, and with better molar relaxivity 
in AD WM tissue than in control WM. R2 became better correlated to iron content 
than R2* in AD WM tissue. GM regions were similar for both R2 and R2* 
correlations. This signifies again, that neurodegeneration seems to affect R2 and 
R2* correlation to iron, and more specifically within WM regions (see section 5.7.4). 
 
Altogether, the results support iron shortening of T2 and T2* relaxation and 
therefore enhanced R2 and R2* values, by enhancing transverse relaxation of 
proton spins, as well as providing a source of magnetic field inhomogeneities. 
However, the degree of correlation and sensitivity of relaxometry values to iron 
seems to also depend substantially on the myelin content within the region (see 
section 5.7.4). 
 
5.7.4. Myelin content assessment 
Luxol fast blue staining of myelin content provides images demonstrating very 
similar cortical architecture as that observed in both elemental iron and MR images, 
for control and AD samples. Not only were the images qualitatively similar, but 
through quantitative assessment of the WM and GM tissue types in the control 
MTG samples, greater myelin was detected in WM than GM, as was also observed 
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for elemental iron content and R1, R2, R2* and R2’ relaxometry measurements. 
Assessment of the cortical layers corresponding to the MCL and dGM also provide a 
consistent increase in myelin content within each sample, in the order of dGM < 
MCL < WM, similar to elemental iron and relaxometry values.  
Myelin is produced by oligodendrocytes that create a sheath around long neuronal 
axons, speeding up axonal transduction of electrical stimuli across brain regions. 
Due to the high metabolic demand on oligodendrocytes for maintenance of these 
myelin sheaths, as well as the necessity of many of the enzymes involved in myelin 
production requiring iron cores, these cells have high iron content (Connor and 
Menzies, 1996, Todorich et al., 2009). The data acquired here supports this concept 
in which WM regions hold significantly higher iron content than GM regions due to 
the presence of iron in myelin within WM. The finding that different cortical layers, 
such as layers IV and V (MCL) contain greater levels of both myelin and iron than 
dGM layers (van Duijn et al., 2013) also substantiates the observations made in 
comparison to WM, whereby iron content was significantly higher in myelin rich 
regions. 
Female samples demonstrated lower myelin contents than males in control post-
mortem human MTG, however none of the tissue regions assessed were 
significantly different individually. This highlights that control populations may 
demonstrate altered levels of myelin by gender in aged populations and should be 
further explored. In AD tissue however, this difference between male and female 
samples did not exist. By comparing between control and AD tissue directly, lower 
myelin content in the WM regions of AD subjects was identified compared with 
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WM from controls. Separate evaluation of genders between control and AD 
demonstrated that male AD subjects had less myelin than male control samples, 
whilst myelin content in females was similar between control and AD. Given that 
myelin lipids and iron content can affect relaxivities in the same way (Rooney et al., 
2007), the findings demonstrating myelin loss in AD supports the results above (see 
section 5.7.2.2), in which R2 and R2* values in male AD WM were generally lower 
than male control WM. Therefore, a breakdown in myelin within WM regions 
detected using LFB staining may be driving subtle changes in R2 and R2* 
relaxometry values, especially in samples from male subjects, to provide the 
differences observed here. Furthermore, as iron content and myelin are strongly 
linked due to the presence of iron in oligodendrocytes, the breakdown of myelin in 
male AD WM may be driving the higher iron contents observed in female AD WM 
compared with male AD WM. 
GM myelin was also decreased in male AD samples compared with male control 
samples, as observed for WM regions, whilst female samples remained similar 
between control and AD. The specific reason for lower GM myelin content detected 
in AD male samples in this study may be due to the global loss of myelin within 
tissue, therefore providing less myelin within the GM as well as in WM. In addition, 
greater neurodegeneration within AD tissue leads to greater axonal loss, which may 
provide less myelin staining in the GM. Furthermore, similar trends were detected 
between control and AD tissue relaxometry values, with a general lowering of GM 
values in male AD than male control, whilst providing similar female values, 
therefore supporting the findings observed with myelin content (Figure 5-41). The 
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extent and nature of myelin loss within GM requires further investigation beyond 
that performed in this study, especially given that PMI length also correlated with 
myelin loss within AD GM. This observation could be explained due to greater 
atrophy in these AD samples following death of the patient, however given that the 
main findings of myelin loss linked to relaxometry changes appeared in the WM, 
the overall conclusions can be retained. 
A number of studies support our observation of myelin loss within the MTG of AD 
patients (Brun and Englund, 1986, Rose et al., 2000, Bozzali et al., 2002). In vivo 
diffusion based imaging studies have demonstrated WM loss in AD subjects and 
correlations to worsening cognition (Rose et al., 2000, Bozzali et al., 2002). 
Similarly, some of these changes in the temporal lobe have been identified even at 
the earliest stages of AD pathology (Huang et al., 2007). Furthermore, post-mortem 
assessments have demonstrated WM loss in temporal lobe regions using LFB 
staining for myelin (Brun and Englund, 1986), and the loss of WM has been 
suggested to be due to vascular lining breakdown during AD (Scheltens et al., 1995). 
 
5.7.5. Correlation against myelin 
In order to understand the effects of myelination on MRI-iron correlations to a 
greater degree, relaxometry values and iron contents were also correlated with 
myelin content spatially, using similarly placed 5x5 pixel ROIs across each sample 
image (see objectives section 5.2). The mean correlations of individual samples 
demonstrated that iron content and all relaxometry values were strongly correlated 
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to myelin in both control and AD tissue (Table 5-8 and Table 5-18). The correlation 
of iron with myelin is expected, due to the presence of iron in oligodendrocytes, 
and its requirement for myelin synthesis and maintenance (Connor et al., 1990, 
Connor and Menzies, 1996, Todorich et al., 2009). The correlation of relaxometry 
values to myelin has also been established previously, with studies demonstrating 
T1 correlation to myelin (Mottershead et al., 2003). However, T1 correlation to 
myelin has been suggested to be indirect, and predominantly due to magnetisation 
transfer effects (Schmierer et al., 2004). Furthermore, R1 was used as a surrogate 
for myelin content in an attempt to quantify iron and myelin from relaxometry 
maps of human cortical samples (Stuber et al., 2014). More recently, methods using 
multi-echo T2 acquisition for evaluating the myelin water fraction specifically, have 
demonstrated strong correlations with myelin (Laule et al., 2006).  
Whilst the mean relaxometry and iron correlations to myelin in individual samples 
were high in controls, R2’ demonstrated lower mean correlations to myelin, than 
R2, R2* and iron content did. The basis for this is, again, likely to be due to the 
greater noise in R2’ calculation (see section 5.7.3.1). Interestingly, lower 
relaxometry and iron content correlations with myelin were observed in AD 
samples, compared with controls (see section 5.6.4.1), likely to be as a result of WM 
myelin breakdown in AD pathology. 
The grouped correlations demonstrated that R2* was the most specific and 
sensitive measurement for myelin in both control and AD samples, and all 
relaxometry and iron correlations with myelin were similar between the two 
sample groups (Table 5-9 and Table 5-20, Figure 5-21 and Figure 5-39). 
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The measurements obtained within this work can, again, allow the provision for 
predicting R2* values or even iron content (R2*PRED or [Fe]PRED), with an 
understanding of myelin content, [Myelin], where, 
R2*PRED or [Fe]PRED = C[Myelin] + D  (Eq.2) 
Using both GM and WM regions, the relationships provided are: 
Control R2*PRED = 0.340[Myelin] + 7.33 
AD R2*PRED = 0.360[Myelin] + 7.71 
Control [Fe]PRED = 1.39[Myelin] – 6.73 
AD [Fe]PRED = 1.50[Myelin] + 2.64 
Given that relaxometry assessments are impacted by both iron and myelin 
contents, the equations described for iron (Eq.1) and myelin (Eq.2) can be 
combined to provide an overall relationship for R2 or R2* relaxometry signals (Eq.3) 
(House et al., 2007, Stuber et al., 2014). The new coefficients E and F can be 
obtained through multiple regression analysis: 
R2PRED or R2*PRED = E[Fe] + F[Myelin]   (Eq.3) 
The relationship now described in Eq.3 could be used to determine the relaxometry 
signal when both iron and myelin content are known. Conversely, if an 
understanding of myelin content in a region is known, iron content could be 
evaluated following non-invasive R2 or R2* assessment and solving for [Fe]. 
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R2* correlation to myelin is likely to be due to, in part, iron presence within myelin, 
as well as a direct effect of myelin lipids on both transverse relaxation and magnetic 
field inhomogeneities. Myelin was found to provide some residual contribution to 
R2* relaxometry following iron extraction from human cortical samples (Fukunaga 
et al., 2010). More interestingly however, was that a difference in the spread of ROI 
values seems to be apparent between iron content and relaxometry value 
correlations with myelin in AD, compared with control samples (Figure 5-47). The 
control samples’ relaxometry and iron correlations to myelin seem to be driven by 
two clusters, due to clear separation between WM and GM ROI values. The AD 
samples’ relaxometry and iron correlations to myelin demonstrate greater 
spreading of ROI values, predominantly from within the WM. This is likely due to 
the myelin loss detected in WM as part of the AD pathology in these MTG samples 
(see section 5.7.4) causing partial volume effects in the tissue therefore providing a 
greater spread of ROI values. Indeed, assessment of AD WM-specific ROI values 
demonstrated enhanced R2 correlation to myelin compared with control WM ROI 
values, indicating that correlation depends mostly on tissue type in control samples, 
with very little variation within tissue types (see section 5.4.6.4). It should be noted 
however that region-specific correlations with myelin were still substantially lower 
than inclusion of both GM and WM ROI values. 
 
5.7.6. Conclusion 
Quantitative R1, R2, R2* and R2’ relaxometry was successfully performed on 
control and AD MTG and correlated against SR-XRF elemental iron mapping (see 
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section 5.2). This allowed quantified iron contents to be compared against 
relaxometry values, to support the validation of iron detection using MRI 
relaxometry. One of the main advantages with acquisition of SR-XRF elemental iron 
maps, was the potential to spatially correlate iron content with relaxometry 
measurements, and to investigate the correlations within tissue types for better 
understanding of the sensitivity of MRI relaxometry for iron (see section 5.2). 
WM tissue was found to consistently contain higher iron contents, with 
concomitantly higher relaxivity values in both control and AD samples. Similar 
relaxivities and iron contents were detected between control and AD samples, 
however a breakdown in myelin content was observed specifically in male AD 
samples compared with male control samples. This breakdown in WM myelin 
content provided an impact on the correlations of both relaxometry measurements 
with iron content, and on the correlations of relaxometry and iron contents with 
myelin. Therefore, whilst iron was clearly identified as providing substantial impact 
on relaxometry values through its effects on transverse relaxation and in generating 
magnetic field inhomogeneities, relaxometry values were also substantially affected 
by myelin content. Given that iron content demonstrates strong links with myelin 
content, the impact of myelination on iron-MRI correlations was evaluated further 
(see section 5.2) and showed that differences exist in relaxometry correlations 
between control and AD tissues. However, greater research is required to fully 
understand the effects of myelination on iron-detection using relaxometry, 
especially, in the cases of neurodegeneration, which may show altered correlations 
compared with control tissue. 
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6. Results: Direct Injection of Iron in the Mouse 
Hippocampus 
6.1. Introduction 
Iron was injected directly into the mouse hippocampus to provide a direct in vivo/ 
ex vivo model of iron accumulation. This approach allowed the assessment of non-
invasive R1, R2, R2* and R2’ relaxometry measurement for iron content detection 
and quantification, and to determine the direct toxicological effects of iron 
accumulation in the brain without interfering, detrimental, biological effects, 
commonly associated by using transgenic models of neurodegeneration. 
Initially, pilot studies were performed in order to: 
 Minimise harm and distress due to the direct injection of ferric citrate into 
the brain.  
 Assess the ability to serially measure ME R2 and MGE R2* relaxometry 
values in vivo. 
 To provide brain tissue sections for validating histological staining methods, 
prior to main study. 






6.2. Pilot Work 
6.2.1. Methods 
Two mice were injected bilaterally with 0.5 µl of 2 mM ferric citrate prior to the 
main study, to validate the injection procedures and recovery for the main study 
animals. These mice were assessed serially using in vivo ME R2 and MGE R2* 
relaxometry on days 3, 5, 9 and 17, post-surgery, followed by perfusion fixation at 
day 17. Their brains were also scanned ex vivo using SE R1, SE R2 and GE R2* 
measurement (see section 3.2.3.4) and were subsequently sectioned for validation 
of ferritin and iba-1 immunohistochemistry, and neuronal histological staining. 
 
6.2.2. Results 
6.2.2.1. Toxic effects from direct injection of ferric citrate 
Direct injection of 2 mM ferric citrate into the hippocampus was well tolerated by 
the two pilot mice. Mild seizures were observed immediately upon recovery from 
anaesthesia for both animals, however no future signs of distress, barbering or 
weight loss were observed within the period of assessment. During longitudinal 
scanning, one animal had a further minor seizure following recovery from 
anaesthesia at day 3, however no future seizures were observed either during, or 





6.2.2.2. Serial in vivo ME R2 and MGE R2* measurement 
ME R2 relaxometry (Figure 6-1A-D) demonstrated substantially lower R2 values 
within the hippocampus at day 3 (Figure 6-1A) compared with the surrounding 
brain tissue. These lower R2 values continue to be observed at day 5 (Figure 6-1B), 
although at less of a difference to the surrounding tissue than at day 3. The 
hippocampal regions show consistent R2 values at day 9 (Figure 6-1C), as would be 
expected in normal mouse brain tissue with no change in R2 values in the region, 
which continues up to day 17 (Figure 6-1D). The corresponding ex vivo ME R2 map 
is shown adjacent to the in vivo images (Figure 6-1E). This image potentially 
highlights iron-rich areas in the hippocampus, due to the higher R2 values observed, 
compared with any in vivo R2 maps (Figure 6-1A-D, arrows). 
MGE R2* relaxometry maps were heavily affected by image artefacts in vivo at days 
3, 5 and 9 (Figure 6-1F-G), however potential iron containing regions or needle 
tracts can be observed in vivo at day 17 (Figure 6-1I, arrows), which correspond 
similarly in location to higher R2* values in the ex vivo image (Figure 6-1J, arrows). 
 
Figure 6-1 Serial ME R2 and MGE R2* assessment of mice in vivo following 
injection with ferric citrate into the hippocampus 
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Representative brain images showing (A-D) serial in vivo ME R2 hippocampal maps 
at days 3, 5, 9 and 17 post surgery, and (E) the corresponding image ex vivo, for a 
pilot 2mM ferric iron injected animal prior to the main study. (F-I) Serial in vivo MGE 
R2* maps at days 3, 5, 9 and 17 post surgery, and (J) the corresponding image ex 
vivo of the same animal brain. Arrows denote potential iron-rich areas. 
 
6.2.2.3. Summary of pilot work 
From this pilot work, it was found that the injection of ferric citrate bilaterally into 
the mouse hippocampus was feasible and well tolerated, without causing major 
distress or suffering to animals. Furthermore, it was found that in vivo ME R2 values 
seem to decrease in the hippocampus following injection and return to normal by 
day 9. MGE R2* maps were heavily artefacted making in vivo R2* assessment 
difficult. Both ME R2 and MGE R2* ex vivo maps demonstrate areas of higher 
relaxivity values in the hippocampus, marking potential iron-rich areas compared 
with in vivo maps.  
 
6.3. Objectives 
The objectives for the main study of the mouse work were: 
 To quantify and correlate in vivo ME R2 and MGE R2*, and ex vivo SE R1, SE 
R2, GE R2* and R2’ values to the spatial distribution of iron content, 
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assessed using SR-XRF elemental mapping, in an animal model of iron 
overload. 
 To evaluate the direct role iron plays on neurodegeneration and 
neuroinflammation using histological and behavioural assessments. 
 
6.4. Methods 
The methods for this work can be found in section 3.2.3. Mice were injected 
bilaterally into the hippocampus with 0.5 µl ferric citrate at 2 mM or 4 mM  (n = 6/ 
group). Sodium citrate injections were used for controls (n = 6) (see section 3.2.3.2). 
Following injection, mice were left for 7 days to recover before performing a 
behaviour assessment (fear conditioning) from day 7. In vivo ME R2 and MGE R2* 
relaxometry assessments were performed at 10 days post-surgery, prior to 
perfusion fixation (see section 3.2.3.4) and brain excision (Figure 6-2). After 7 
further days of fixation, brains were also scanned ex vivo to assess SE R1, SE R2, GE 
R2* and R2’ in the hippocampus. ME R2 and MGE R2* were also evaluated for 
comparison with in vivo assessments. Brains were cryosectioned and SR-XRF 
elemental iron mapping was performed at slices corresponding to the hippocampus 
from T2W images, for comparison to MR relaxometry maps. Histological 
assessment of ferritin and iba-1, as well as haematoxylin and Nissl staining for 
neurons, was performed to evaluate the direct effects of iron accumulation on 




Figure 6-2 Outline of animal study over the 10 day period 
 
6.5. Results 
6.5.1. Animal health 
Following surgeries, mice injected with iron frequently displayed minor seizures 
within the first 60 minutes post recovery from anaesthesia, whilst it was observed 
that control animals did not. No animals displayed any future seizures, signs of 
distress, barbering or weight loss within the 10 day experimental period. 
Furthermore, no significant differences were detected between animal body 






Figure 6-3 Mean body weights throughout the experiment period for each 
injection group 
Graph showing the mean body weights during the 10 day experimental period for 
control (CTR, blue), 2 mM ferric iron (orange) and 4 mM ferric iron (red) intra-
hippocampal injected mice. Significance assessed using two-way ANOVA for group 
differences to P ≤ 0.05. Graphs show mean values ± SD. 
 
6.5.2. Comparison of relaxometry and iron contents with ferric citrate 
injection into the mouse hippocampus 
6.5.2.1. In vivo MRI relaxometry 
Hippocampal ROIs were manually drawn over the first three imaging slices 
containing the hippocampus, to specifically match the three sections that were 
acquired using SR-XRF elemental mapping from each animal. ROIs were drawn on 
T2-weighted images of each brain, and overlaid onto R1, R2, R2* and R2’ 
315 
 
relaxometry maps. Hippocampal in vivo ME R2 and MGE R2* values were similar 
between control and iron injected mice 10 days post-surgery (R2, P = 0.095 and 
R2*, P = 0.869) (Figure 6-4A-B and Figure 6-5). Mean MGE R2* values between 
animals were extremely varied, as can be seen from the size of error bars (Figure 
6-4B), likely due to large susceptibility artefacts clearly observable within and 
between the MGE R2* maps themselves (arrows and arrowheads, Figure 6-5C-D). 
Susceptibility effects around the entorhinal cortex are expected due to presence of 
the nasal cavities nearby (arrowheads, Figure 6-5C-D), however differences in 
striatal and hippocampal basal values were detected in some animals, with higher 
pixel intensities across one brain than in another (arrows, Figure 6-5C-D). 
Therefore, maps with considerably higher basal striatal and hippocampal R2* 
values, with clear susceptibility artefacts were excluded from analysis (control n = 3, 
2 mM n = 3 and 4 mM n = 5, remaining) (Figure 6-4C). Substantially less error in R2* 
assessment was observed, however R2* values were still similar between the 
control and iron injected mice (P = 0.165) (Figure 6-4C). 
 
Figure 6-4 Mean in vivo ME R2 and MGE R2* values in the hippocampus of ferric 
citrate injected mice compared with controls 
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Graphs showing in vivo hippocampal (A) ME R2 and (B) MGE R2* values from the 
hippocampi of mice measured at 10 days post injection. (C) Graph showing mean 
MGE R2* values excluding mice with substantial image artefacts (control, n = 3; 2 
mM, n = 3 and 4 mM, n = 5). Significance assessed using one-way ANOVA, with 
Tukey’s test for multiple comparisons to P ≤ 0.05. Graphs show mean values ± SD. 
 
 
Figure 6-5 Representative in vivo ME R2 and MGE R2* maps of a ferric citrate 
injected animal 
Representative in vivo images of a (A-B) ME R2 map and (C-D) MGE R2* map for a 
control and 4 mM injected mouse. Arrows highlight areas of different basal striatal 
and hippocampal R2* values between different brains; arrowheads highlight areas 






6.5.2.2. Ex vivo MRI relaxometry 
Standard, spin-echo (SE) R1 and R2, as well as gradient-echo (GE) R2* relaxometry 
assessments were performed on the mouse brains ex vivo. Furthermore, ME R2 and 
MGE R2* assessments were also performed of ex vivo tissue for comparison against 
in vivo measurements. R2’ values were calculated by subtracting SE R2 maps from 
GE R2* maps. 
Regions of higher SE R1, SE R2, GE R2* and R2’ values were observed 
predominantly within the hippocampus of iron injected mice, compared with 
control mice across three MR slices (Figure 6-6). Higher values were also found 
outside the hippocampal regions, within the cortex (Figure 6-6C). Two mice injected 
with iron (one at 2 mM and one at 4 mM) were found not to contain bilateral 
lesions by relaxometry mapping, and were therefore excluded from further 




Figure 6-6 Ex vivo SE R1, SE R2, GE R2* and R2’ images of the hippocampi from 
one control and one 4 mM ferric citrate injected mouse 
Representative images demonstrating (A) SE R1, (B) SE R2, (C) GE R2* and (D) R2’ 
relaxivity maps of a control and 4 mM injected mouse brain. Red and green ROIs 
represent left and right hippocampal regions from the control mouse brain. The 
hippocampal ROIs have been omitted from the 4 mM mouse brain so that the 




ROIs were drawn around the hippocampus in the three slices that also 
corresponded to the sections that underwent SR-XRF (Figure 6-6; see section 
6.5.2.3), for measurement of mean relaxivities and volumes of the hippocampus 
(Figure 6-7; Table 6-1). These ROIs were drawn on T2-weighted images of each 
brain, and overlaid onto R1, R2, R2* and R2’ relaxometry maps. Standard SE R1 and 
SE R2 values were significantly higher between control and treated animals (SE R1: 
control = 0.66 ± 0.05 s-1; 2 mM = 0.75 ± 0.05 s-1; 4 mM = 0.80 ± 0.04 s-1; P = 0.001, 
and SE R2: control = 24.60 ± 0.74 s-1; 2 mM = 28.35 ± 2.00 s-1; 4 mM = 29.74 ± 0.80 s-
1; P < 0.0001). No difference however, was observed between the 2 mM and 4 mM 
treatment groups by SE R1 and SE R2 (R1, P = 0.299 and R2, P = 0.235) following 
correction for multiple comparisons (Figure 6-7A-B). ME R2 values were also 
significantly different between control (19.98 ± 0.59 s-1), 2 mM (21.37 ± 1.49 s-1) 
and 4 mM (22.58 ± 0.90 s-1; P = 0.004), however only the 4 mM injection showed 
significantly higher relaxivity values than control (P = 0.003; Figure 6-7C). Both, GE 
and MGE R2* relaxometry values led to significantly higher R2* in the iron injected 
mice hippocampi, compared with controls (GE R2*: control = 30.24 ± 1.96 s-1; 2 mM 
= 37.44 ± 2.77 s-1; 4 mM = 40.77 ± 2.02 s-1; P < 0.0001, and MGE R2*: control = 
27.26 ± 1.14 s-1; 2 mM = 34.47 ± 3.41 s-1; 4 mM = 39.91 ± 2.82 s-1; P < 0.0001; Figure 
6-7D-E). The MGE R2* acquisition method was able to distinguish between the 2 
mM and 4 mM injections (P = 0.013), as well as comparison to control injections, 
whilst GE R2* was not able to distinguish between the two ferric citrate 
concentrations (P = 0.086; Figure 6-7D-E). Finally, R2’ relaxivity assessment showed 
significantly higher values within the hippocampus of both the 2mM and 4mM 
injection groups compared to control (R2’: control = 5.63 ± 1.28 s-1; 2 mM = 9.08 ± 
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1.44 s-1; 4 mM = 11.02 ± 1.59 s-1; P < 0.0001), however again, the 2 mM and 4 mM 
iron injections were not significantly different to each other (P = 0.119). 
 
Figure 6-7 Mean ex vivo relaxometry values in the hippocampus of control, 2 mM 
and 4 mM ferric citrate injected mice 
Graphs of the mean (A) SE R1, (B) SE R2, (C) ME R2, (D) GE R2*, (E) MGE R2* and (F) 
R2’ relaxivity values obtained in the whole hippocampal regions from each injection 
treatment. Graphs show mean values ± SD, with significance obtained using one-
way ANOVA and Tukey’s multiple comparisons correction to P ≤ 0.05 (*). 
 
To assess the iron accumulation lesions from the two iron injection treatment 
groups, ROIs were drawn around areas in the hippocampus with higher GE R2* 
values than a threshold value, based on control treated animals hippocampi (Figure 
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6-8). The lesioned areas showed similar SE R1, SE R2, GE R2* and R2’ relaxometry 
measurements between the 2 mM and 4 mM injections (R1, P = 0.714; R2, P = 
0.089; R2*, P = 0.828, and R2’, P = 0.564; Figure 6-9). 
 
Figure 6-8 Example ROIs manually drawn around the iron lesion in the 
hippocampus from a 4 mM ferric citrate injected mouse, using GE R2* and R2’ 
Representative GE R2* and R2’ images of a 4 mM iron injected brain, highlighting 






Figure 6-9 Mean relaxometry values in the iron lesion of 2 mM and 4 mM ferric 
citrate injected mice 
Graphs showing the (A) SE R1, (B) SE R2, (C) GE R2* and (D) R2’ relaxivity values 
within the iron accumulation lesions in the hippocampi of only iron injected mice, 
with significance assessed using unpaired t-test to P ≤ 0.05. 
 
6.5.2.3. XRF elemental mapping 
Qualitatively, SR-XRF elemental iron maps showed regions of higher intensities, 
predominantly within the hippocampus of iron injected mice, indicating higher iron 
contents, compared with control mice across three slices corresponding to MR 
(Figure 6-10). As highlighted in some relaxometry maps (Figure 6-6), regions of 
increased iron content were also found outside the hippocampal regions, within the 
cortex (Figure 6-10B). 
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Significantly higher iron levels were observed in the hippocampus in iron injected 
animals compared to controls (control = 14.22 ± 1.18 ppm, 2 mM = 30.50 ± 5.36 
ppm, 4 mM = 44.58 ± 7.74 ppm, P = 0.002) and significant differences were 
detected between all three treatment groups to each other (CTR to 2 mM, P = 
0.025; CTR to 4 mM, P = 0.001 and 2 mM to 4 mM, P = 0.045; Figure 6-11A, Table 
6-1). Hippocampal iron lesions were also measured, showing similar iron contents 
in both the 2 mM and 4 mM treatments (2 mM = 63.18 ± 4.70 ppm and 4 mM = 
73.78 ± 7.07 ppm, P = 0.097) (Figure 6-11B).  
 
Figure 6-10 SR-XRF elemental iron maps of the hippocampi from one control and 
one 4 mM ferric citrate injected mouse 
Representative elemental iron maps of (A) one control and (B) one 4 mM ferric 





Figure 6-11 Mean elemental iron contents in the hippocampus of control, 2 mM 
and 4 mM ferric citrate injected mice, and in the iron lesion of 2 mM and 4 mM 
injected mice 
Graphs of (A) the mean iron content obtained in the hippocampus from each 
injection treatment, with significance obtained using one-way ANOVA and Tukey’s 
multiple comparisons correction to P ≤ 0.05 (*), and (B) the mean iron content 
observed within the iron lesions of the hippocampi of only ferric citrate injected 
mice, with significance assessed using unpaired t-test to P ≤ 0.05. Graphs show 




Table 6-1 Summary of the iron content and relaxivities from the hippocampus of each treatment group 
 Iron SE R1 SE R2 ME R2 GE R2* MGE R2* R2’ 
CTR 14.22 ± 1.18 0.66 ± 0.05 24.60 ± 0.74 19.98 ± 0.59 30.24 ± 1.96 27.26 ± 1.14 5.63 ± 1.28 
2 mM 30.50 ± 5.36 a 0.75 ± 0.05 a 28.35 ± 2.00 a 21.37 ± 1.49 37.44 ± 2.77 a 34.47 ± 3.41 a 9.08 ± 1.44 a 
4 mM 44.58 ± 7.74 a,b 0.80 ± 0.04 a 29.74 ± 0.80 a 22.58 ± 0.90 a 40.77 ± 2.02 a 39.91 ± 2.82 a,b 11.02 ± 1.59 a 
P-value 0.0002 0.001 < 0.0001 0.004 < 0.0001 < 0.0001 < 0.0001 
For relaxivities, n = 6, 5 and 5 per group, for control, 2 mM and 4 mM injections respectively. For iron contents, n = 3 per group. Significance 
obtained using one-way ANOVA, with Tukey’s multiple comparisons correction to P ≤ 0.05. a denotes significance compared with controls, and b 




6.5.2.4. Iron lesion volume assessment 
Whole hippocampal ROIs had similar volumes across the three treatment groups 
(control = 15.36 ± 1.70 pixels, 2 mM = 14.29 ± 1.78 pixels and 4 mM = 14.79 ± 2.25 
pixels, P = 0.658; Figure 6-12A). The iron lesion volumes, delineated using GE R2* 
maps, were significantly higher in the 4 mM, compared to the 2 mM, treatment 
groups (2 mM = 5.48 ± 2.83 pixels and 4 mM = 9.08 ± 1.07 pixels, P = 0.029; Figure 
6-12B). Similarly, the iron lesion volumes delineated from the elemental iron maps 
were also significantly higher in the 4 mM compared with the 2 mM treatment 
groups (2 mM = 398.70 ± 50.46 pixels and 4 mM = 588.70 ± 83.94 pixels, P = 0.028; 
Figure 6-12C). 
 
Figure 6-12 Lesion volumes in the hippocampus delineated using relaxometry and 
elemental iron maps 
Graphs showing (A) mean whole hippocampal volumes obtained by T2W images, 
and mean hippocampal iron lesion volumes assessed (B) from GE R2* maps and (C) 




Total iron content in the iron lesion was calculated by: lesion mean x lesion volume. 
The same calculation was also performed for each relaxometry measurement 
(Table 6-2) for assessment of how well each measurement is able to detect total 
iron content. A 1.74-fold increase in total iron content is measured using XRF 
mapping of the three slices of hippocampus, between the 2 mM and 4 mM injected 
brains (Table 6-2). Using relaxometry assessments, R2’ was closest to total iron 
content, at 1.79-fold increase between the 2 mM to 4 mM injected brains. SE R1 
(1.65-fold), SE R2 (1.59-fold) and GE R2* (1.65-fold) also detect total iron content 
similarly with XRF mapping (Table 6-2). 
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2 mM 25140 ± 3060 4.75 ± 2.13 186.13 ± 91.17 259.21 ± 124.24 73.08 ± 33.55 
4 mM 43800 ± 9880 7.84 ± 0.82 296.44 ± 30.48 427.44 ± 51.68 131.00 ± 30.12 
Fold change 1.74 1.65 1.59 1.65 1.79 
P value 0.0002 0.017 0.033 0.023 0.021 




6.5.2.5. Summary and discussion of relaxometry and iron contents in ferric 
citrate injected into the mouse hippocampus 
Ferric citrate injections into the hippocampus were well tolerated in the main 
study, with no signs of long-term distress or suffering, and no weight loss in any of 
the groups throughout the experiment. In vivo ME R2 and MGE R2* relaxometry 
assessment demonstrated no significant differences between the hippocampus of 
each treatment group and MGE R2* maps were heavily affected with susceptibility 
artefacts, adding to error using this measurement. Ex vivo SE R1, SE R2, GE R2* and 
R2’ relaxometry all detected differences between the ferric citrate treated and 
control hippocampus, however could not differentiate between the 2 mM and 4 
mM ferric citrate injections. ME R2 measurement demonstrated less clarity 
between the treatment groups, only differentiating between the 4 mM ferric citrate 
injection and control hippocampi, whilst the MGE R2* measurement demonstrated 
comparable detection capability to the elemental iron maps, distinguishing 
between all three treatment groups in this study. 
The SE R1, SE R2, GE R2* and R2’ values were similar in the iron lesions between 
the 2 mM and 4 mM ferric citrate injections, as were the elemental iron contents. 
The iron lesion volumes however, were significantly larger with the 4 mM than with 
the 2 mM ferric citrate injections, and demonstrated a near doubling in measured 
total iron content between these two treatment groups. This was comparably 




6.5.3. Correlation of hippocampal iron and relaxometry measurements 
Qualitatively, areas of high iron content corresponded to areas of higher SE R1, SE 
R2, GE R2* and R2’ values in ex vivo samples (Figure 6-13). The precise position of 
iron lesions also corresponded to relaxivity maps at each of the three bregma 
distances evaluated within the brain. The arrows highlight areas where iron is 
detected within all the relaxometry maps compared to the elemental iron maps 
(Figure 6-13). In some cases however, iron-rich regions identified in elemental iron 
maps were only observed in R2* and R2’ maps, but not in R1 or R2 maps (Figure 




Figure 6-13 Correlation of elemental iron maps against relaxometry maps from 
the mouse hippocampus 
Representative images of the three slices from elemental iron maps, co-registered 
with the corresponding brain and slice of SE R1, SE R2, GE R2* and R2’ relaxometry 
maps. Arrows highlight iron lesions that are observable in all four relaxivity maps, 





A significant correlation was detected between all four relaxometry measurements 
and the mean iron contents using all of the whole hippocampal ROIs, with R2’ 
showing strongest correlation to iron levels (SE R1, r2 = 0.33; SE R2, r2 = 0.33; GE 
R2*, r2 = 0.58 and R2’, r2 = 0.61; all correlations, P < 0.001) (Figure 6-14). R1 and R2 
correlations to iron content were similar to each other (P = 0.985), however both R1 
and R2 correlations to iron were less than R2* correlation to iron (R2* compared 
with R1, P = 0.011 and R2* compared with R2, P = 0.001) or to R2’ correlation to 
iron (R2’ compared to R1, P = 0.017 and R2’ compared to R2, P = 0.100). R2* and 
R2’ values were similarly correlated against iron content (P = 0.456). Correlation 
gradients (or molar relaxivity) of R1, R2, R2* and R2’ values to iron were, r1 = 0.003 
s-1ppm-1, r2 = 0.086 s
-1ppm-1, r2* = 0.253 s
-1ppm-1 and r2’ = 0.168 s
-1ppm-1. 
 
Figure 6-14 Correlation of hippocampal ROIs from elemental iron maps against 
each relaxometry measurements 
Graphs showing the correlation of whole hippocampal ROIs between mean (A) SE 
R1, (B) SE R2, (C) GE R2* and (D) R2’ relaxivities, and mean iron content. Correlation 




6.5.3.1. Summary of correlation of hippocampal iron and relaxometry 
measurements 
In general, high elemental iron contents corresponded to regions of high 
relaxometry values within the hippocampus, using SE R1, SE R2, GE R2* and R2’ 
assessment. Some regions of high iron content outside the hippocampus were only 
detectable using R2* and R2’ relaxometry, highlighting that these measurements 
seem to be enhanced at iron-specific detection. Correlation of all relaxometry to 
elemental iron hippocampi values demonstrates that GE R2* and R2’ were superior 
to SE R1 and SE R2 at iron detection within the mouse hippocampus. 
 
6.5.4. Behaviour assessment 
Mice learnt the contextual fear memory test equally across the three treatment 
groups, with no significant differences between control, 2 mM or 4 mM injections 
affecting learning (P = 0.594; Figure 6-15A). Contextual memory assessment of mice 
7 days post-surgery provided no significant differences between the three groups 
(control = 72.11 ± 13.01 %, 2 mM = 60.24 ± 11.27 % and 4 mM = 56.43 ± 21.30 %, P 




Figure 6-15 Effects of ferric citrate injection on contextual memory fear 
conditioning behaviour 
Graphs showing the behavioural assessment of mice injected with ferric iron, with 
(A) percentage freezing times during the training periods, and (B) percentage 
freezing time for control, 2 mM and 4 mM injected mice during contextual memory 
assessment. 
 
6.5.5. Histological assessment of ferric citrate injection pathology 
6.5.5.1. Ferritin immunohistochemistry 
Ferritin is the iron storage protein expressed in cells, and so immunohistochemistry 
was performed to detect the storage capacity in the hippocampus upon injection 
with ferric citrate. Very few ferritin-positive cells were detected following control 
injections into the hippocampus (Figure 6-16A), with cells that were positive evenly 
spread throughout the whole hippocampus and within both the dentate gyrus (DG) 
and CA3 regions, without any clustering (Figure 6-16A-C). The 2 mM ferric citrate 
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injection into the hippocampus caused substantial increases in ferritin 
immunoreactivity 10 days post-surgery, with many more positive cells observed in 
the hippocampus, and in the DG and CA3 regions (Figure 6-16D-F). The ferritin 
positive cells were also clustered tightly to the granular neuronal layers in the DG 
and CA3 (Figure 6-16E-F). The 4 mM ferric citrate injection similarly shows 
substantially increased ferritin immunoreactivity in the hippocampus compared 
with controls, and clustering to the neuronal layers of the DG and CA3 regions, as 
detected in 2 mM injected brains (Figure 6-16G-I). 
Co-staining with haematoxylin to label cell nuclei of the ferritin stained sections, 
predominantly highlights the neuronal architecture in control injected hippocampus 
for clear definition of the DG and CA3 neuronal layers (Figure 6-16B-C). Whilst the 2 
mM ferric citrate injection allows approximate architecture delineation within the 
DG and CA3 regions (Figure 6-16E-F), 4 mM injection led to complete loss of 




Figure 6-16 Ferritin immunoreactivity in the hippocampus of one control, one 2 
mM and one 4 mM ferric citrate injected animal 
Ferritin immunoreactivity (dark brown) and haematoxylin staining (pale blue) in the 
hippocampus of (A-C) a control, (D-F) a 2 mM ferric citrate and (G-I) a 4 mM ferric 
citrate injected mouse. Boxes in the left images highlight the area selected for 
evaluation at 20X magnification in the DG and CA3 regions. 
 
6.5.5.2. Iba-1 immunohistochemistry 
Iba-1 protein is a calcium-binding adaptor protein that is found specifically in 
microglial cells in the brain (Ito et al., 1998) and frequently used as a marker for 
microglial counting and morphological assessment (Ahmed et al., 2007). Iba-1 
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positive cells were spread evenly throughout the hippocampus of control injected 
mice (Figure 6-17A), and were evenly spread throughout both the DG and CA3 
hippocampal sub-regions (Figure 6-17B-C). Furthermore, the morphology of the 
microglia was predominantly non-reactive, with few processes (Figure 6-18A). The 2 
mM ferric citrate injection led to a substantial increase in the number of Iba-1 
positive cells across the hippocampus (Figure 6-17D) and whilst being identified 
throughout the hippocampus, did show some clustering to the neuronal 
architecture of the DG and CA3 regions (Figure 6-17E-F). Morphologically, Iba-1 
positive cells demonstrated more aggressive appearance, with many processes 
exuding from the cell bodies (Figure 6-17E-F, Figure 6-18B, arrowheads). Finally, 
assessment of the 4 mM ferric citrate injected hippocampus demonstrated similar 
observations as made in the 2 mM injections, with substantially increased iba-1 
positive cell numbers throughout the hippocampus compared to controls (Figure 
6-17G), with clustering to the DG and CA3 neuronal layers (Figure 6-17H-I). 
Extremely aggressive microglial morphologies could be observed with many 
processes from each cell body as well as many overlapping cells (Figure 6-18C, 
arrowheads). Amoeboid-like morphologies seemed to also be observed within the 
granular neuronal layers in the 4 mM ferric citrate injected hippocampus. 
Nissl co-staining of sections labelled with Iba-1 allowed clear delineation of the 
neuronal cell architecture within the control injected hippocampus (Figure 6-17A), 
with both the DG and CA3 regions demonstrating healthy neuronal layers (Figure 
6-17B-C, Figure 6-18A). Whilst the 2 mM ferric citrate injection allowed the 
neuronal layers to remain discernible throughout the whole hippocampus (Figure 
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6-17D), regions of greater neuronal death could be detected with highly intensely 
stained pyknotic nuclei in the DG and CA3 regions (Figure 6-17E-F, Figure 6-18B, 
arrows). The 4 mM ferric citrate injections provided less clarity in the neuronal 
layers throughout the hippocampus (Figure 6-17G) and demonstrated a near 
complete loss of integrity in neuronal cells in the DG and CA3 regions, with no layer 
structure and many intensely stained pyknotic nuclei (Figure 6-17H-I, Figure 6-18C, 
arrows).  
 
Figure 6-17 Iba-1 immunoreactivity in the hippocampus of one control, one 2 mM 
and one 4 mM ferric citrate injected animal 
Iba-1 immunoreactivity (dark brown) and nissl staining (blue/ purple) in the 
hippocampus of (A-C) a control, (D-F) a 2 mM ferric citrate and (G-I) a 4 mM ferric 
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citrate injected mouse. Boxes in the left images highlight the area selected for 
evaluation at 20X magnification in the DG and CA3 regions. 
 
 
Figure 6-18 Microglial morphologies and pyknotic nuclei in control, 2 mM and 4 
mM ferric citrate injected hippocampus 
Microglial cells (arrowheads) show different morphologies between (A) control, (B) 
2 mM and (C) 4 mM ferric citrate injected animals. Neuronal cells (arrows) highlight 
healthy neuronal cell bodies in (A) control, compared with pyknotic cells in (B) 2 mM 
and (C) 4 mM ferric citrate injections. The 4 mM ferric citrate injection has led to 
loss of neuronal layer integrity. 
 
6.5.5.3. Correlation of histology to iron content 
Histological evaluation of ferritin, Iba-1 and neuronal cell death were compared 
alongside elemental iron maps to understand the pathology in greater detail. Mice 
injected with control solution demonstrated no regions of high iron content, 
evaluated by XRF, within the hippocampus (Figure 6-10 and Figure 6-19A). 
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Histological assessment of the adjacent slices revealed no substantial increase in 
ferritin or Iba-1 staining within the hippocampus either (Figure 6-19B-C) and the 
granular neuronal layers of the hippocampus (CA1, CA2, CA3 and DG) can be clearly 
delineated using both haematoxylin (Figure 6-19B), and more specifically, Nissl 
(Figure 6-19C) stains. In the representative hippocampal section from the 2 mM 
ferric citrate injected animals, the localisation of iron is predominantly within the 
DG and CA3 regions, with lower intensity of iron content also within the CA1 region 
(Figure 6-19D). Comparison against ferritin and Iba-1 immunohistochemistry 
demonstrates substantial positive cell staining for both markers within these same 
three regions (DG, CA3 and CA1), whilst the CA2 does not show much 
immunoreactivity (Figure 6-16E-F, Figure 6-17E-F and Figure 6-19E-F). An intense 
accumulation of iron was also observed in this sample just above the hippocampus 
(Figure 6-19D; arrow), matching a ferritin positive area in the adjacent slice (Figure 
6-19E; arrow), whilst demonstrating less staining for Iba-1 in the same area (Figure 
6-19F; arrow). Furthermore, haematoxylin and Nissl staining of neurons revealed 
damaged regions of the granular layers in the same sub-regions of hippocampus 
containing high iron, high ferritin and high Iba-1 clusters (Figure 6-19E-F). Similar to 
2 mM treatment, the 4 mM ferric citrate injected animal demonstrated a global 
increase in iron content throughout the hippocampal section (Figure 6-19G), with a 
concomitant increase in ferritin and Iba-1 staining localised to the granular layers 
from the DG, CA3, CA2 and CA1 (Figure 6-19H-I). The integrity of the granular 
neuronal layers was also substantially compromised in regions containing high iron, 
high ferritin and high Iba-1 positivity (Figure 6-19H-I). A region of high iron content 
was again observed above the hippocampus (Figure 6-19G; arrow), which again 
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demonstrated ferritin positive staining, but limited Iba-1 positive staining (Figure 
6-19H-I; arrows). Finally, it was also notable that many of the hippocampal sections 
evaluated from the 4 mM ferric citrate injections demonstrated large cavities in 
their structure (Figure 6-19I; arrowhead). 
 
Figure 6-19 Elemental iron maps compared alongside ferritin and Iba-1 
immunohistochemistry 
Representative images of the whole hippocampus comparing the (A, D, G) elemental 
iron maps with (B, E, H) ferritin and (C, F, I) Iba-1 immunohistochemistry, in control, 
2 mM and 4 mM ferric citrate injected mice. Arrows denote specific regions of iron 
content increase across each image; the arrowhead denotes a large cavity in the 






6.5.5.4. Injection site 
Further evaluation of the cortical regions where high iron content is observed 
above the hippocampus, demonstrated that these areas coincided with the 
injection site, and correlated with regions of higher ferritin and some Iba-1 staining 
than the surrounding tissue (Figure 6-20A-B; arrows). Furthermore, strong ferritin 
immunoreactivity, with low Iba-1 positive staining, can be observed within the WM 
tracts above the hippocampus of mice that show areas of high iron content at 
comparable locations (Figure 6-20B; arrowheads). 
 
Figure 6-20 Injection site of ferric citrate from mouse with high iron content 
outside the hippocampus 
Histological images of (A) ferritin/ haematoxylin and (B) Iba-1/ Nissl of a 4 mM ferric 
citrate injected mouse, demonstrating a region of increased iron content above the 
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hippocampus. Arrows denote the needle tract into the hippocampus; arrowheads 
denote regions in the WM with greater ferritin, and comparably less Iba-1 staining. 
 
6.5.5.5. Summary of histological assessment of ferric citrate injection pathology 
Greater ferritin expression was found in ferric citrate injected animals than 
controls, and clustered predominantly at the neuronal layers of the DG and CA3 
regions. Iba-1 staining was also greater in ferric citrate injected animals and again 
clustered at the DG and CA3 regions of the hippocampus. Iba-1 staining also 
demonstrated more aggressive morphologies of microglial cells (as activated, rather 
than resting morphology) than observed in controls. Nissl assessment of neurons 
specifically highlighted greater levels of neuronal cell death in ferric citrate injected 
mice than controls, with greater numbers of pyknotic nuclei and loss of the 
architectural integrity of the neuronal layers in the DG and CA3 regions. 
Furthermore, the regions with greatest ferritin and Iba-1 localisation and with 




A model system for developing and validating MRI measurements for the in vivo 
detection of iron within the brain is described here, also allowing for the 
assessment of the direct toxic effects iron may play towards neuronal cell death. 
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Much of the previous literature involving injection of iron into the brain has 
evaluated the biochemical and cellular nature of iron toxicity from unilateral 
hippocampal injections, or injections within cortical areas (Willmore et al., 1983, 
Triggs and Willmore, 1984, Sloot et al., 1994, Armstrong et al., 2001, Bishop and 
Robinson, 2001, 2003, Bostanci and Bagirici, 2007). This study is the first to perform 
bilateral injection of iron into the hippocampus, to allow evaluation of behavioural 
or cognitive deficits, and demonstrates this as a tolerable model of iron toxicity in 
mice. Animals remained free from seizures throughout the experimental period, 
and did not show changes in weight between the treatment groups. Furthermore, 
this approach allows for a novel method to validate MRI measurements for the 
evaluation of brain iron. 
 
6.6.1. Ex vivo hippocampal iron detection 
SE R1, SE R2, GE R2* and R2’ were all able to detect the change in iron content 
between ferric citrate injected, versus control injected hippocampi, however they 
were unable to distinguish between the two ferric citrate concentrations. R2* relies 
on susceptibility effects, as well as the R2 transverse relaxation of protons for iron 
detection (Langkammer et al., 2010), thus clarifying the enhanced sensitivity of R2* 
within this study. R2’ provides a measure of inhomogeneities in tissue, (Haacke et 
al., 2005), and given the strong correlation of R2’ to iron content in this model, as 
was also observed with R2* to iron, these findings highlight that susceptibility 
effects seem to be a major factor contributing to sensitivity here. 
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R1 and R2 values demonstrated lower correlations to iron content than R2* and R2’ 
values, despite all four relaxometry measurements equally capable for detecting 
iron in the ferric citrate-injected, versus control-injected mice. Iron has been 
demonstrated to play a direct role on both the longitudinal and transverse 
relaxometry measurements within tissue (Ogg and Steen, 1998, Schenck, 2003), 
due to the paramagnetic effects impacting on both R1 and R2 relaxation rates 
(Vymazal et al., 1996b). The lower correlations of iron content to R1 and R2 may be 
due to less of an impact on longitudinal and transverse relaxation, than by also 
including inhomogeneity detection, within this model. This difference was most 
apparent with regions of the cortex showing iron accumulation only detected using 
R2* and R2’ mapping, whilst they were not detected in R1 or R2 maps. 
The finding that the MGE R2* assessment was able to detect the changes in iron 
content between the two ferric citrate concentrations, comparably to elemental 
iron mapping, is likely due to this acquisition sequence demonstrating enhanced 
differences between low and high R2* values compared to the GE R2* sequence 
(see sections 4.4.3). Also, given that this sequence can be performed at 
substantially faster acquisition times than the standard GE R2* method, the 
number of averages used was greater, providing improved SNR for better detection 
of the changes between treatment groups compared with GE R2*. The ME R2 
assessment was less clear at detecting the changes in iron content than SE R2 
measurement, and again this can be explained due to the ME R2 measurement 
consistently demonstrating lower R2 values than the SE sequence, especially at 
higher R2 values (see section 4.4.3). 
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6.6.2. In vivo hippocampal iron detection 
Whilst ex vivo imaging demonstrated clear differences between injection groups, 
neither ME R2 nor MGE R2* was able to detect differences between ferric citrate 
injected and control injected animals, in vivo. The results in this study can be best 
understood using current knowledge and models of haemorrhaging in the brain, 
whereby blood leakage from vessels occurs into the brain tissue. The stages for 
clearance of a brain haemorrhage have been established, with an understanding of 
how each stage might affect MRI signals differently, especially using T1W and T2W 
imaging. Five stages can be classified using MRI, predominantly dependent on the 
forms of iron present and the localisation of these iron substances (Bradley, 1993). 
The first three stages involve the conversion of oxyhaemoglobin to 
deoxyhaemoglobin, and subsequently to methemoglobin within the red cells that 
have leaked into the brain tissue (Bradley, 1993). The ferric chloride injections 
performed as part of this study resemble the stages following these, in which the 
red cells lyse and release their contents into the brain tissue (Huang et al., 2002). 
This release of haemoglobin and iron from red cells into the brain leads to oedema, 
which involves fluid accumulation at the site of injury (Huang et al., 2002). Oedema 
can lead to a lengthening of T2, and therefore lower R2 values due to the increase 
in fluid (Kato et al., 1986) and T2W imaging has been used to evaluate oedema in 
animal models (Schneider et al., 2002, Sironi et al., 2004). ME R2 values were lower 
in the hippocampus at days 3 and 5 compared with the surrounding tissue in this 
study, as assessed from the serial in vivo acquisitions in the pilot work. The lower R2 
values observed in the hippocampi in vivo at this time may therefore be due to 
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oedema presence within the iron lesioned hippocampi post-surgery. Following this 
stage, iron is finally taken up into macrophages and stored as ferritin or 
hemosiderin, which provide a shortening of T2 values due to their paramagnetic 
nature (Bradley, 1993). Indeed, during further recovery of animals in this study, the 
in vivo ME R2 values become normal for the hippocampus at days 9 and 17 post-
surgery, likely due to a reduction of oedema during recovery, as well as an increase 
in ferritin and hemosiderin. It therefore seems that at these later stages, conflicting 
relaxometry signals may be occurring within the hippocampus in vivo, with a 
combination of low R2 values from oedema, whilst higher R2 values come from iron 
content, present as ferritin. Clearly, once brains are perfusion-fixed, excised and 
then further PFA fixed, oedema is cleared and no longer plays any role in R2 signal, 
allowing iron-rich regions to be clearly delineated ex vivo (see section 6.6.1). 
Therefore, allowing a greater recovery time post-surgery would potentially provide 
better detection of iron in vivo, once oedema has been completely reduced. 
Given that neurodegenerative diseases tend to provide some level of 
neuroinflammation that may lead to oedema during pathology (Dheen et al., 2007), 
these findings may need to be taken into consideration if comparing iron contents 
between control subjects and neurodegenerative disease patients in vivo, as there 
may be interference with observed relaxometry values.  
MGE R2* maps were unable to differentiate between iron injected and control 
animals due to large susceptibility effects in vivo, likely due to local 
inhomogeneities and from susceptibility changes between tissue, skull and air 
(Czervionke et al., 1988). 
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6.6.3. Iron accumulation in lesion 
We found that iron content, as well as R1, R2, R2* and R2’ relaxivity values, were 
identical within the iron accumulation lesions of the hippocampus between the 2 
mM and 4 mM ferric citrate injections. This implies the densities of iron within the 
lesions are comparable. However, there was a greater iron accumulation lesion 
volume for the 4 mM compared with 2 mM group. This suggests greater spreading 
of injected iron throughout the hippocampus after the 4 mM ferric citrate 
injections, which led to a near doubling of detected total iron content in the 4 mM 
compared with the 2 mM injected mice. Both of these findings are reasonable, 
given that ferritin protein is only able to store a certain number of iron atoms prior 
to saturation, reflecting the similar iron contents, as well as relaxivity values, 
between the two treatment groups (Harrison and Arosio, 1996). However, given 
that more iron was injected in the 4 mM than 2 mM treatments, the greater 
amount of iron has clearly been distributed further around the hippocampus 
leading to greater lesion volumes in the 4 mM treatment. Whilst no studies have 
evaluated this spreading of iron in the hippocampus using MRI previously, total 
damage and cytotoxicity was shown to increase in a concentration dependent 
manner using ferric citrate injections (Armstrong et al., 2001). 
The greater spreading of iron within the lesion may have occurred either through 
passive diffusion within the hippocampus, or may have been through active 
movement, given that the same volume (500 nl) of 2 mM and 4 mM ferric citrate 
was injected into the hippocampus. Iron is transported within the brain by 
transferrin and lactoferrin and is exported from cells, such as neurons, through 
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ferroportin (Moos et al., 2007). If active movement of iron was occurring within the 
hippocampus following ferric citrate injection, it would be expected that these 
proteins would be expressed at greater levels in the 4 mM ferric citrate injected 
animals, than in the 2 mM injected animals. Evaluation of both transferrin and 
ferroportin immunohistochemically gave rise to non-specific and high background 
staining in mouse tissue. Therefore, western blotting of digested hippocampal 
material could be used in subsequent studies to evaluate the changes in expression 
of these proteins following ferric citrate injection (Chen et al., 2011). 
Despite injecting twice as many iron atoms in the 4 mM treatment, compared with 
2 mM ferric citrate injections, a slightly less than doubling of total iron content was 
detected. This discrepancy is likely due to only three slices of hippocampus being 
assessed using XRF elemental mapping, rather than coverage of the whole brain 
region across 4-5 slices, due to time constraints for XRF acquisition. With a greater 
spreading of iron content in the higher treatment group, as discussed above, 
movement of some injected iron may have occurred more ventrally in the 
hippocampus than was assessed by XRF mapping. Similarly, iron may have been 
transported away from the hippocampus entirely. Therefore, total iron content may 
have been underestimated in the 4 mM group compared with the 2 mM injection 
group. These findings were comparable with the relaxometry assessments across 
the 3 slices of hippocampus, also showing a slight underestimation of relaxivities in 





6.6.4. Correlation of iron to ferritin and Iba-1 immunoreactivity 
We found that higher elemental iron contents within the hippocampus, seem to 
correspond to regions of high R1, R2, R2* and R2’ values in relaxivity maps. 
Furthermore, we have demonstrated that higher iron contents correspond to 
regions of greater ferritin and Iba-1 immunohistochemistry, as well as to regions 
with greater neuronal cell death. 
Unsurprisingly, ferritin localisation was similar to that observed for iron contents 
within the hippocampi, especially given that ferritin is the storage protein for iron 
(Harrison and Arosio, 1996) and that iron overload can directly increase ferritin 
translation (see section 1.3.3) (Theil, 1990). Furthermore, the observation that 
higher iron contents, as well as ferritin and Iba-1 staining, were predominantly 
located at the DG and CA3 regions of the hippocampus, was expected given that 
this was the physical site of injection of ferric citrate within the hippocampus. The 
appearance of iron, ferritin and Iba-1 within the CA1 regions of some mice may also 
be as a direct result from surgeries, whereby any iron leakage whilst the needle was 
removed may have occurred into this hippocampal region. 
Ferritin and Iba-1 positive cells clustering at the neuronal layers within the DG and 
CA3 highlight that microglia may be involved in mediating the effects of iron toxicity 
on neuronal cells. Microglial cells have been suggested to be the predominant cells 
in the brain responsible for iron storage, given their higher expression of L-ferritin, 
involved in storage of iron (Connor et al., 1994, Han et al., 2002). Furthermore, 
injection of iron into the rat cortex alone, led to increased expression of ferritin-
positive microglia and neuronal death at the injection site (Bishop and Robinson, 
351 
 
2001). Similarly, ferritin-positive microglia were reported following the 
intracerebral injection of blood into rabbits, along with the potential identification 
of factors that may lead to recruitment of more microglial cells to the region 
(Koeppen et al., 1995). Therefore, microglial presence surrounding neurons may 
hold relevance for mediating the iron-induced toxicity of ferric citrate in the 
hippocampus. However whether this inflammatory response is pro-survival or 
deleterious to neuronal cells is unknown from this study, as we are unable to 
specify whether neuronal degeneration preceded microglial aggregation to the 
granular layers. Whilst microglia presence may provide a means for uptake and 
storage of injected iron away from regions where it would otherwise cause toxic 
effects, microglial cells can also play a role in the clearance of cell debris, following 
necrotic cell death (Graeber, 2010). 
Microglial cells seem to show a ramified morphology in control-injected 
hippocampus, however in the 2 mM injections, these cells appear activated. Whilst 
similar morphologies to these activated microglia are also detected in the 4 mM 
ferric citrate injected mice, the presence of amoeboid microglia are also apparent, 
especially across the granular neuronal layers. These amoeboid microglia imply 
phagocytosis of cell debris may be occurring around the DG and CA3 regions, 
following ferric citrate injection at the higher concentration (Graeber, 2010). 
The expression of ferritin within the WM of certain mice that also show higher iron 
content in this area highlights that other cell types may also be responsible for 
clearance of iron in the brain, given the lower expression of Iba-1 detected. Whilst 
this has not been definitively proven in this study, it is hypothesised that 
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oligodendrocytes may be responsible for accumulating the iron in these WM areas, 
given their presence within WM for myelin synthesis, along with demonstrated 
expression of ferritin in the brain (Connor et al., 1994). 
 
6.6.5. Neuronal death 
Neuronal cell death seems to be ongoing at 10 days post-injection, based on the 
detection of pyknotic nuclei within the hippocampal sub regions (de Torres et al., 
1997). The precise mechanism surrounding neuronal cell death has not been fully 
evaluated here, however is likely to be, at least in part, due to the generation of 
ROS (Willmore et al., 1983). Furthermore, neuronal death was demonstrated using 
Fluoro-Jade labelling following ferric ammonium citrate injection into the cortex, 
and continued to 7 days post-injection (Bishop and Robinson, 2001). Given that 
neuronal cells do not seem to have stopped undergoing cell death, this may explain 
the lack of significance observed in the contextual memory task at only 10 days 
post-injection. It may therefore be conceivable that allowing a longer time post-
surgery prior to behavioural testing may allow for greater levels of neuronal cell 








In conclusion, the direct injection of iron into the mouse hippocampus provides a 
novel approach for developing and validating MRI measurements for the in vivo 
detection of iron within the brain. 
In order to quantify in vivo ME R2 and MGE R2* for iron detection (see section 6.3), 
endpoint in vivo MRI was carried out using the ferric citrate injected mice compared 
with controls. Whilst ME R2 and MGE R2* were unable to detect changes in iron 
content in the mouse brain in vivo after 10 days post injection, attention can be 
drawn to confounding factors affecting the relaxometry values in vivo. 
Furthermore, R1, R2, R2* and R2’ were then evaluated ex vivo for quantification 
and correlation of iron detection capability, compared with SR-XRF elemental iron 
assessment, as noted in objectives (see section 6.3). All relaxometry assessments 
were able to detect ferric iron injected, versus control injected hippocampus ex 
vivo, and all demonstrated strong correlation to overall iron contents. This study 
highlights R2* and R2’ as the most sensitive methods for iron detection ex vivo. 
Greater optimisation of the R2* acquisition is still required for iron detection in vivo 
however. 
Finally, using this animal model, the direct role iron plays on neuronal cell death 
and neuroinflammation could be evaluated by histological and behavioural 
assessments (see section 6.3) without the additional, detrimental phenotypes from 
transgenic approaches. Iron led to an increase in ferritin immunoreactivity and Iba-
1 microglial presence in the hippocampus, and highlighted roles for microglia in 
mediating the iron-induced toxicity of neurons, given their clustering to the 
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neuronal layers in this brain region. The applicability of this model for testing 
therapeutic interventions of iron overload may provide a future goal, along with 






The work in this thesis supports the approaches using MR relaxometry for the non-
invasive detection of iron content in brain tissue during neurodegeneration. Using a 
variety of systems, greater knowledge into the direct effects that iron plays on R1, 
R2, R2* and R2’ measurements have been gained, and greater understanding of 
iron-induced neurodegeneration has also been obtained. 
With MRI evaluation of iron content in live, biological samples complicated by the 
variety of tissue environments, unconfirmed iron contents and heterogeneous 
forms of iron found (see section 2) simple model standards were first used to 
confirm and validate the direct effect of iron content and form on R1, R2, R2* and 
R2’ (see section 4). The direct, linear relationships between iron content and R1, R2 
and R2* for both ferric and ferrous iron, as well as using ferritin bound iron, 
supports the direct evaluation of iron content using relaxometry measurement, as 
outlined in the hypotheses (see section 2). These results satisfy the main objectives 
for the thesis in understanding the basic principles of iron content detection using 
MR relaxometry. However, given that the different forms of iron clearly impact 
relaxometry values irrespective of concentration, these observations may have 
considerable effects for the use of these techniques to quantitatively assess iron 
content during neurodegeneration. 
 
Spatially correlating elemental iron content against relaxometry measurements in 
individual, as well as multiple human post-mortem samples, demonstrated that R2 
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and R2* were found to be correlated most consistently with iron, in both control 
and AD MTG. This fits the evaluations performed using iron agarose standards, 
whereby both systems demonstrate linear correlation between iron content and R2 
or R2*. The lower correlation values obtained in human post-mortem tissue 
compared with the iron agarose standards can be attributed to the presence of 
many different cell types and therefore tissue microstructures in human tissue, 
compared with the homogenous nature of the iron agarose standards. Water 
content differences between post-mortem tissue and the agarose standards may 
also have impacted correlation values. R1 values demonstrated significant 
correlations when assessing individual human post-mortem samples with iron 
content, as expected from the work using iron agarose standards. However, its use 
as a specific measure of iron seems to be severely hindered by effects from other 
influencing factors between samples. An example of this includes prolonged 
fixation time in human post-mortem tissue strongly affecting R1. 
R2’ provided a sensitive measure for iron content in the human post-mortem 
samples, whereas the iron agarose standards did not allow for quantification of iron 
content using this measurement. This can be attributed due to the agarose 
standards’ greater homogeneity than the human post-mortem samples. However, 
despite R2’ being sensitive to iron from human post-mortem tissue, the low SNR 
associated with the acquisition of this parameter here seems to have led to lower 




The results provided within this thesis using post-mortem human tissue allow far 
greater understanding of iron-sensitive MRI capabilities through correlation against 
quantitative SR-XRF evaluation of iron, rather than by comparison against non-
quantitative histological Perls’ staining. This satisfies the main aims of the thesis for 
validating iron-sensitive MRI methods during neurodegeneration (see section 2). 
Comparison of control and AD tissue provided similar iron and relaxometry values 
within both GM and WM regions, as well as separation of the GM into the separate 
cortical layers of dGM and MCL. Whilst some studies have shown changes in iron 
content or relaxation between AD and control tissue (Goodman, 1953, Deibel et al., 
1996, Schenck et al., 2006, Smith et al., 2010), our results are still in agreement 
others (Schrag et al., 2011, Antharam et al., 2012). However, a decrease in WM 
myelin was identified in male AD samples compared with male control subjects and 
this loss of myelin in WM allowed for greater sensitivity in the detection of iron 
using R2 relaxometry assessment. This highlights that myelin can strongly affect 
relaxometry values, and therefore with their estimation of iron content, as was 
hypothesised (see section 2). Future work could therefore employ the use of 
multiple regression analysis in order to provide greater understanding of the impact 
of myelin, water or other factors, on the measurement of iron using relaxometry 
assessment. 
 
Finally, by directly injecting iron into the mouse hippocampus, in vivo MRI methods 
for quantitative detection of iron could be assessed. R2 and R2* in vivo assessments 
of iron were similar in the hippocampus of control and ferric citrate injected 
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animals. This was likely due to 10 days recovery of animals only just allowing for 
reduced oedema within the injection sites, as well as large image artefacts 
hampering the R2* findings in vivo. 
Iron detection was achievable ex vivo however, using R1, R2, R2* and R2’. R2* and 
R2’ provided the strongest correlation to elemental iron. These results were 
expected, given the basis of iron content changes on relaxometry values using 
agarose standards. In mouse ex vivo tissue, R2’ provided strongest correlation to 
iron, whereas this measurement was poorer than R2 and R2* in human post-
mortem tissue and non-existent in the agarose standards. The improved R2’ 
correlation in mouse tissue may be due to the smaller ID RF coil used for the animal 
work, providing greater SNR than that obtained in the human post-mortem studies. 
Furthermore, differences in the tissue types investigated may impact the 
correlation of R2’ for iron content, with human post mortem tissue performed in 
the MTG, a cortical region with low changes in iron content, whilst the mouse 
injections were performed in the hippocampus, using greater concentrations of 
iron. 
A greater amount of iron spreading within the hippocampus was identified with 
increased ferric citrate injection concentration, whilst iron levels were saturated 
within the hippocampal iron lesion. This was attributed to ferritin saturation, with 
positive cell staining identified in similar regions of the hippocampus, as elemental 
iron was located following injection. This animal model therefore provided a very 
useful approach to validate iron-sensitive MR measurements in a controlled, in vivo, 
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system and to explore the direct effect of iron overload on neuronal cell death, 
without the detrimental effects associated with transgenic models. 
 
The results taken together from the three different systems used in this thesis are 
consistent with iron-lengthening of MRI relaxivity, and imply R2, R2* and R2’ 
relaxometry can be used to provide non-invasive, quantitative information on the 
iron content of brain tissue, during neurodegeneration. 
 
7.1. Limitations and future directions 
Whilst attempts were made to perform studies in the most systematic and 
methodical manner, there remains some limitations to the studies within this 
thesis, highlighted below. Future investigations based on the observed results are 
also outlined. 
 
7.1.1. Iron agarose standards 
With ferric iron detectable compared to ferrous iron based on their individual molar 
relaxivities in agarose standards, it would beneficial to also characterise alternative, 
pathological forms of iron using this approach, such as magnetite or hemosiderin, 
given that these forms are reportedly higher during AD (Collingwood et al., 2005, 
Quintana et al., 2006, Pankhurst et al., 2008). Furthermore, it would then be of 
interest to evaluate the application of this assay using purified iron from human 
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post-mortem control and AD brain samples, or from transgenic animal models of 
AD. This may aid our understanding of whether changes in the forms of iron from 
neurodegenerative disease samples, compared with control tissue, can be detected 
by molar relaxivity measurement. Similarly, extraction of ferritin from control and 
AD human post-mortem brain tissue followed by the subsequent comparison of 
molar relaxivities may also be of interest. These experiments should clarify whether 
any changes observed between AD and control tissue using relaxometry 
measurement in clinical environments are as a direct result from changes in iron 
content, or whether there is a change in the form of iron during AD pathology. 
 
7.1.2. Iron measurement in control and AD human MTG 
A limitation of the work using human post-mortem tissue is that many other factors 
excluding iron or myelin content may play a substantial role in relaxometry signal 
generation, which were not fully explored here. Water content, for example, can 
show major effects on relaxivity values based on the greater proportion of freely 
moving water protons within the environment. Water content has been shown by 
others to correlate with relaxometry values in control and AD post-mortem tissue, 
with differences in GM and WM (House et al., 2008). However, with all of the 
samples obtained for this study being formalin fixed, we expect that any effects of 
water content will be equalised between samples. 
Another limitation to this study was that the only iron-sensitive MRI measurements 
performed here were relaxometry evaluations, whereas many other MRI 
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approaches may also support these findings against SR-XRF elemental iron, such as 
using FDRI, QSM or MFC. It would therefore be of interest to establish how well 
these alternative approaches for iron-detection correlate to post-mortem tissue 
elemental iron in the future. Furthermore, other more general MRI approaches 
using post-mortem tissue may provide greater understanding of the overall 
physiology of AD compared with controls for evaluating against iron content, such 
as using magnetisation transfer ratio or diffusion weighted imaging.  
Limitations with the histological assessments performed in this thesis are that only 
myelin content was evaluated using luxol fast blue staining. To strengthen the 
conclusions derived here, immunohistochemical staining for myelin basic protein 
(MBP) could be performed as another marker of myelin health. Similarly, 
immunohistochemical staining of physiological changes between control and AD 
tissue may also provide greater insights into the results observed using iron-
sensitive MRI approaches, such as by staining for ferritin expression. Indeed, ferritin 
showed direct correlation to relaxometry values in the agarose standards, however 
has only demonstrated modest correlation within human post-mortem tissue by 
others (Fukunaga et al., 2010). Greater general physiological understanding into the 
relaxometry signals detected can also be gained by evaluating specific cellular 
presence, such as astrocytic or microglial presence in AD compared with controls. 
Finally, the observations of ROI clustering differences within graphs correlating iron 
with relaxometry between AD and control samples, highlights that there may be a 
change in how pixel intensities are spread within tissue regions. This may be 
especially identified in WM regions, given the observed loss of myelin during AD. 
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Therefore, texture based analysis of specific regions from human samples may 
provide a novel approach for assessment of relaxometry maps, for the clinical 
evaluation of patients with neurodegenerative diseases, such as AD. 
 
7.1.3. Direct injection of iron in the mouse hippocampus  
A clear limitation of this study is that the iron clearly present in the hippocampus 
from ex vivo assessment could not be detected in vivo. This was due to the 
injections leading to oedema in the hippocampus, producing conflicting signals by 
relaxometry assessment, and R2* imaging in vivo was heavily impacted by imaging 
artefacts. Therefore to address these issues, a longer recovery period for animals 
should be allowed prior to evaluation using iron-sensitive MRI methods, and 
greater optimisation of R2* in vivo imaging is required. Indeed, a longer recovery 
time post-injection may even allow functional behavioural deficits to be more 
clearly derived, with iron-induced neurodegeneration allowed to progress for a 
longer period. 
Furthermore, this study could only provide cross-sectional evidence for the role of 
iron during neurodegeneration with no understanding of the temporal mechanisms 
of neurodegeneration assessed. Therefore, evaluation of animals at multiple time 
points following ferric citrate injection would allow greater understanding of these 
mechanisms and the cell types responsible. Indeed, rats were followed over a 10 
day period to show increase of ferritin up to this point and a plateau in neuronal 
death (Armstrong et al., 2001). However, with this thesis study performed in mice, 
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neuronal loss may be occurring at a different rate than in rats. Double or triple 
immunohistochemistry for combinations of protein markers would also provide 
beneficial evidence in understanding mechanisms of iron-induced 
neurodegeneration using this animal model, complementing work performed by 
others showing that both ROS and oxidation products are raised immediately 
following iron injection (Willmore et al., 1983, Triggs and Willmore, 1984). 
Finally, to understand how a greater spread of iron within the lesion is observed 
following greater amounts of ferric iron injection, the expression of certain iron 
regulatory proteins, such as transferrin, transferrin receptor and ferroportin, can be 
evaluated. Given that immunohistochemical staining methods were not sufficient 
to establish the expression of these proteins in the present study, Western blot 
analysis can be utilised in a subsequent study. 
 
It should also be noted that whilst the scope of this thesis has been focussed on the 
impact of iron on MRI and in understanding the roles that iron may play during 
neurodegeneration, exploration of how other metals, such as zinc or copper, are 
affected during neurodegeneration may also be of interest in the potential for 




























List of all obtained human tissue samples; with associated gender, age at death, 
PMD, PMI, and fixation time. 
Control Samples 









A319-11 Male 74 22.5 24 13 
A114-12 Male 82 24 25 7 
A261-12 Male 63 23 51 5 
A388-12 Male 65 26 28 2 
A213-12 Male 78 24 24 6 
A127-11 Male 73 23 23 20 
A53-11 Male 77 10 11 13 
A346-10 Female 84 34 34 14 
A33-11 Male 82 47 47 14 
A130-09 Male 54 31 32 33 
A136-10 Female 89 41 65 21 
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A404-12 Female 90 83 87 13 
A329-12 Female 92 66 66 15 
A382-12 Female 85 45 51 13 
A152-13 Female 78 45 70 8 
AD Samples 









A277-12 Male 79 20 24 3 
A356-11 Female 77 42 69 12 
A206-12 Female 88 41 41 6.5 
A195-12 Female 83 20 20 6 
A220-11 Female 71 18 19 7 
A195-11 Female 78 39 67 8 
A282-10 Male 68 25 25 16 
A200-10 Female 81 23 23 20 
A216-09 Female 88 22 44 31 
A348-12 Male 75 69 98 14 
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A276-12 Male 77 43 45 16 
A3-13 Male 64 48 71 11 
A244-12 Male 75 27 68 18 
A50-13 Male 74 15.5 41 10 
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